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Thesis abstract  
 
One of the key molecular events in the transmissible spongiform 
encephalopathies or prion diseases is the conformational conversion of the cellular 
prion protein PrPC into the misfolded and pathogenic isoform, PrPSc. 
Prion diseases are fatal neurodegenerative conditions affecting humans and 
other animal species, which present with diverse clinical and neuropathological 
phenotypes. In humans, prion diseases can occur as sporadic, familial or acquired 
forms. Sporadic Creutzfeldt–Jakob disease (sCJD) accounts for the majority of cases. 
The current classification system of human prion diseases recognizes several distinct 
clinico-pathological entities including sCJD, variant Creutzfeldt-Jakob disease 
(vCJD), Gerstmann–Straussler–Scheinker syndrome, fatal familial insomnia and 
variably protease-sensitive proteinopathy. Prion protein gene (PRNP) mutations and 
polymorphisms, and PrPSc types have a profound effect on these clinico-pathological 
phenotypes. 
Prion diseases of sheep and goats, cattle, and cervids are all actual animal 
health problems and present potential risks to human health. Thus far the only known 
zoonotic prion disease is bovine spongiform encephalopathy, which has resulted in 
vCJD in humans. The recognition of new forms of prion diseases in animal and 
humans has generated increased awareness of the animal and public health risks 
associated with prion disease. However the mechanisms involved in prion 
replication, transmission, and neurodegeneration remain poorly understood. 
This thesis uses in vitro PrP conversion assays (protein misfolding cyclic 
amplification and real time quaking-induced conversion) to model different aspects 
of human prion replication: Molecular susceptibility, genetic compatibility, 
spontaneous formation and the effect of molecules that might enhance or prevent 
conversion were each investigated in order to obtain a better understanding of the 
molecular mechanism of the prion replication. I have addressed the hypothesis that 
the major determinant factors in prion disease pathogenesis (PRNP genetics, PrPSc 
types and species barriers) are intrinsic to the prion protein conversion process and 




The results shows that in vitro conversion assays used in this thesis can model 
the combined effects of different PrP type and genotypes, can replicate aspects of 
cross-species transmission potential and provide information about molecular barrier 
to zoonotic transmission, can model de novo PrPSc formation, and can assess the 
potential impact of chaperones on conversion of the human prion protein. In 
summary, this work provides evidence that the origin, propagation and transmission 







129 MM Methionine homozygote at PRNP codon 129 
129 VV Valine  homozygote at PRNP codon 129 
129 MV Methionine/Valine heterocygote at PRNP codon 129 
ACDP  Advisory committee on dangerous pathogens 
BSE or C-Type BSE Bovine spongiform encephalopathy 
Cb  Cerebellum 
CJD  Creutzfeldt-Jakob disease 
CJDE200K–129M Gentic CJD linked to a  mutation of glutamic acid (E) with 
lysine (K) at PRNP  codon  200,  methionine at the  
codon 129 
CJDV180I–129M  Gentic CJD linked to a mutation  of valine (V) to isoleucine 
(I)  at PRNP codon 180, methionine at the codon 129 
CNS  Central nervous system 
CWD  Chronic wasting disease 
D178N  Mutation at PRNP codon 178: Aspartic acid (D) to  
asparagine (N) 
E200K  Mutation at PRNP codon 200: Glutamic acid (E) to lysine (K)  
E219K  Mutation at PRNP codon 219: Glutamic acid (E) to lysine (K) 
FC  Frontal cortex 
fCJD  Familial Creutzfeldt-Jakob disease 
FFI  Fatal familial insomnia 
FSE Feline spongiform encephalopathy  
GdnHCl  Guanidine hydrochloride 
GPI  Glycosylphosphatidylinositol 
GSS Gerstmann-Straussler-Scheinker Disease 
H-type BSE High type BSE  
iCJD Iatrogenic Creutzfeldt-Jakob disease 
kDa  Kilo Dalton 
mAb  monoclonal antibody 




MM1 Subtype MM1  of sporadic CJD 
MM2  Subtype MM2  of sporadic CJD 
MV  Methionine/Valine heterozygote at PRNP codon 129 
MV1  Subtype MV1 of sporadic CJD 
MV2 Subtype  MV2 of sporadic CJD 
L-type BSE Low type BSE  
LMWH Low molecular weight heparin 
NCJDRSU  National CJD Research and Surveillance Unit 
Nor98 Atypical scrapie  
ORF  Open reading frame 
P101L  Mutation at PRNP codon 101: Proline (P) to leucine (L) 
P102L  Mutation at PRNP codon 102: Proline (P) to leucine (L) 
PBS  Phosphate buffered saline 
pH Measure of hydrogen ion concentration 
PMCA  Protein misfolding cyclic amplification 
PK  Proteinase K 
PRNP  Human prion protein gene 
prnp Non-human prion protein gene 
PrP  Prion protein, irrespective of conformations 
PrPc  Normal form of the prion protein  
PrPres  Protease-resistant prion protein 
PrPSc  Disease-associated form of prion protein. Rich in β-sheet 
structure. Conformational alternated respective to the PrPC 
PrPsen Protease sensitive  prion protein 
PVDF  Polyvinylidene fluoride 
recPrP Bacterially expressed recombinant prion protein 
recPrPres Protease resistant prion protein derived from recPrP 
RT-QuIC Real-time quaking induced conversion  
sCJD Sporadic Creutzfeldt-Jakob disease 
sFI  Sporadic fatal insomnia 
TBS  Tris buffered saline 




TME  Transmissible mink encephalopathy 
TSE  Transmissible spongiform encephalopathy 
UK  The United Kingdom 
vCJD  Variant Creutzfeldt-Jakob disease 
VPSPr  Variably protease sensitive prionopathy  
V180I  Mutation at PRNP codon 180: Valine (P) to isoleucine (L)  
V210I  Mutation at PRNP codon 210: Valine (P) to isoleucine (L)  
VV  Valine homozygote at PRNP codon 129 
VV2  Subtype VV2 of sporadic CJD 
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Transmissible spongiform encephalopathies (TSEs) are a group of fatal 
neurodegenerative conditions that affect humans and a diversity of animals. The 
diseases are accompanied by a change in the conformation of the normal prion 
protein (termed PrPC) into an abnormal form of the native protein (termed PrPSc) 
(table 1.1) (Prusiner, 1998, Prusiner, 1982).  
TSEs, particularly in humans, occur as sporadic, genetic and acquired diseases, the 
commonest of which is sporadic. TSE pathology is characterized by neurological 
dysfunction and death, gliosis and the deposition of PrPSc in the brain. TSE are (as 
the name indicates) transmissible, and the causal infectious agents are termed prions 
(Prusiner, 1982)  
 
Term  Description  
PRNP Human prion protein gene 
prnp Non-human prion protein gene 
PrP Prion protein, irrespective of conformations 
PrPC Normal form of the prion protein  
PrPSc Disease-associated form of prion protein. Rich in β-sheet 
structure. Conformational alternated respective to the PrPC  
PrPres Protease-resistant prion protein 
PrP 27-30 PrP core fragment remaining after PK digestion  
PrPsen Protease sensitive  prion protein 
recPrP Bacterially expressed recombinant prion protein  
recPrPres Protease resistant prion protein derived from recPrP 
 




1.1.1 PrPC, PrPSc and the “Prion hypothesis”  
The gene coding for the prion protein (termed PRNP) is a conserved gene in 
mammals and avian species (Lee et al., 1998, Wopfner et al., 1999). In humans it is 
located on chromosome 20 but the location may vary depending of the carrier species 
(Sparkes et al., 1986, Kretzschmar et al., 1986). It encodes a 33-35 KDa protein 
which in its native state is sensitive to proteases, soluble in non-denaturing 
detergents, rich in alpha helix content (around 40%) with a small percentage of β-
sheet (3%), and with a single disulfide bond between the residues 179 and 214 (Pan 
et al., 1993, Riek et al., 1996). In contrast, the protein in its abnormal folding state is 
rich in β-sheet structures, insoluble in detergents and partially resistant to proteases 
(Pan et al., 1993). The PrP can be found in non-glycosylated, mono-glycosylated or 
di-glycosylated forms (Haraguchi et al., 1989), predominantly inserted into the outer 
leaflet of the cell membrane through an glycosylphosphatidylinositol (GPI) anchor 
(Stahl et al., 1987). The GPI anchor can promote the association of PrPC with 
cholesterol-rich lipid rafts involved in the trafficking of the protein and in the 
conversion to PrPSc (Hooper, 2005). The normal prion protein is present in different 
organs, with high expression in the brain and lymph nodes; moderate expression in 
spleen, heart, liver and lung; and lower expression in kidney (Ning et al., 2005).  
A vigorous debate has developed in the scientific community regarding the nature of 
the infectious particles involved in TSEs. Some authors have argued that the 
infectious agent is a virion, composed of proteins plus nucleic acid molecules 
(Dickinson et al., 1968, Manuelidis, 2007). Another current claim is that the 
infectious agent is composed only of proteins, in particular the one coded by the 




these new infectious agents responsible for TSEs. He coined the term “prion” for this 
small proteinaceous infectious particle resistant to procedures that attack nucleic 
acids and is partially resistant to proteases (Prusiner, 1982). This developed into the 
“protein only hypothesis” which recognizes as the “only” infectious agent the 
misfolded form of the prion protein. Two models have been proposed to explain the 
conformational conversion of prions. The “template directed refolding” model, in 
which an exogenous misfolded prion is required to convert endogenous cellular prion 
protein to PrPSc, and the “seeded nucleation” hypothesis, in which the two prion 
forms (PrPC and PrPSc) are in thermodynamic equilibrium. According to the “seeded 
nucleation” hypothesis the infectious agent consists of a highly ordered arrangement 
of PrPSc molecules in the form of an aggregate, and the normal PrPC protein is the 
precursor of further infectious PrPSc(Aguzzi and Calella, 2009, Griffith, 1967). This 
molecular interaction was confirmed when PrPC knock-out animals were 
intracerebrally challenged with high doses of prions and they failed to develop any 
clinical signs (Bueler et al., 1993). The authors concluded that development of prion 
symptoms and pathology is strictly dependent on the presence of PrPC and that 
incubation time and disease progression are inversely related to the level of PrPC 
(Bueler et al., 1993). Furthermore, in order to evaluate the misfolding properties of 
the PrPC in association with the GPI anchor, transgenic mice expressing prion protein 
lacking the GPI showed minimal clinical manifestations, although prion inoculation 
induced the formation and deposition as amyloid plaques. These results not only 
reinforce the relevance of PrPC - crucial in the conversion process - they also suggest 
a fundamental link between the PrPC and the cell membrane for the development of 




1.1.2 Animal Prion Diseases 
Wide ranges of animal species are known to be susceptible to prion disease, 
including several associated with human food consumption. 
 
Animal species Disease 
Human consumption  
Sheep and Goats 
 
Scrapie 
Atypical scrapie (Nor98) 
 
Cattle Bovine spongiform encephalopathy (BSE) 
High type BSE (H-type BSE) 
 Low type BSE (L-type BSE) 
Deer / Elk / White-tailed deer Chronic wasting disease (CWD) 
 
Non-human consumption:  
Mink Transmissible mink encephalopathy (TME) 
Cats Feline spongiform encephalopathy (FSE) 
Nyala and Oryx Exotic ungulate encephalopathy (EUE) 
  
 
Table 1.2 Non-human TSEs associated with human food consumption. 
 
In general, all the above-mentioned TSEs share common features such as 
neurological signs, neuronal loss, astrocytosis, and amyloid formation. In the case of 
sheep and goats affected by scrapie, the animals exhibit changes in posture and 
movements (trembling, severe incoordination, stumbling and animals are unable to 
stand), skin irritation weight loss and finally death (Dickinson, 1976). The first 




Hunter N, 2007) (Hunter, 2007). Since then, the disease has been reported to be 
endemic throughout the world, except in Australia and New Zealand (Reviewed by 
Imram M, 2011) (Imran and Mahmood, 2011).  
The route by which the infectious agent is transmitted between sheep and sheep-
flocks is thought likely by the oral route (horizontal transmission) or contamination 
of the environment. Transmission studies in experimental animals have shown that 
scrapie-affected-animals can spread the disease to sheep and goats by contact of the 
offspring or other lambs with the placenta and placenta fluids (Dickinson et al., 
1974). Additional information indicates that alternative transmission routes include 
skin scarification and blood transfusion (Taylor et al., 1996, Hunter et al., 2002). It 
bears noting that polymorphic variations of the ovine PRNP gene are associated with 
susceptibility to scrapie. Current research support that variations in the amino acid 
sequence, particularly associated at positions 136, 154 and 17, have a profound effect  
on the susceptibility to scrapie (Eiden et al., 2011, Bossers et al., 1996).  
With the goal of supplementing the nutritional requirements of cattle, farmers in the 
UK started to feed them with recycled ruminant tissues (including sheep and goats 
tissues) or meat-and-bone-meal (MBM) as a source rich in proteins. The objective 
was to generate an economic impact increasing the milk and meat production. This 
“inoffensive” action brought an opposite and crushing effect, producing a financial 
catastrophe and a new disease in cattle called bovine spongiform encephalopathy or 
BSE. Although the original source of BSE is not known, one hypothesis is the 
transmission of scrapie prions (from sheep) to cattle. This hypothesis is supported by 
what is currently known about the species barrier phenomena. The species barrier 




another in a primary transmission. In practice this can be recognized by an adaptation 
of the agent to the second species, producing a shorter incubation period and uniform 
transmission properties in a secondary transmission. The ability of a prion strain to 
be transmitted to a host is affected by the differences in primary sequence of the 
prion protein between donor and host species (Hill and Collinge, 2002). In this 
regard, a prion strain is defined as an infectious isolate which can cause a distinct 
prion-disease phenotype when it is inoculated to an identical host, maintaining the 
phenotypic hallmarks (incubation time, lesion profile, etc.) upon serial transmission. 
Considering the species barrier and the strain definition, Wilesmith and colleagues 
explored a possible connection between BSE and scrapie. This epidemiological study 
revealed that MBM containing ruminant-derived proteins were linked to the farms 
from which cases of BSE were reported (Smith and Bradley, 2003, Wilesmith et al., 
1991). These results suggested a cattle-adapted scrapie like agent may have been 
responsible for BSE infection. An alternative hypothesis about the origin of BSE 
suggests that the bovine TSE may have originated spontaneously as a result of a 
genetic mutation, being later spread by the feeding of contaminated MBM to cattle. 
Cattle affected by BSE usually present behavioural changes, tremors, ataxia, and 
hyperactivity to stimuli. The incubation time of BSE in cattle is between 2 to 8 years. 
Like sheep, several polymorphisms on the PRNP gene have been described to be 
associated with the susceptibility of cattle to BSE. Atypical forms of scrapie, and 
atypical forms of BSE have also been reported, e.g. Nor98 in sheep and low type 






Chronic wasting disease or CWD is another fatal TSE. CWD affect free-range and 
wild cervids, although it was first identified in captive mule deer in Colorado 
(Williams and Young, 1980, Williams and Young, 1992). The origin of CWD is still 
unknown and whether it has a relationship to scrapie or began as a sporadic disease 
will be difficult to know. Clinical signs in deer affected by CWD include behavioural 
changes, progressive loss of weight and death at the end-stage of the disease. 
Intracranial inoculations of experimental deer CWD have shown that the incubation 
time of CWD is between 17 to 21 months, and between 15 to 25 months by oral 
exposure (Sigurdson, 2008, Williams, 2005). Epidemiological and experimental data 
have provided substantial evidence of direct (animal to animal) and indirect (pasture 
contamination) transmission of CWD (Miller et al., 2004, Mathiason et al., 2009, 
Miller and Williams, 2003).  
Transmissible mink encephalopathy (TME) and feline spongiform encephalopathy 
are very rare prion diseases. TME outbreaks have been reported in ranched mink in 
the United States of America (Wisconsin, Idaho and Minnesota); and FSE has been 
reported in domestic cats and captive wild members of the family Felidae in the UK, 
with a few cases identified in France, Australia, Ireland, and Germany. Experimental 
challenge of minks inoculated with TME showed spongiform changes in the cerebral 
cortex, with a severe vacillation in the gyri bordering, the cruciate sulcus and the 
anterior and posterior sigmoid gyrus (Liberski et al., 2009). The posterior part of the 
brain showed minimal lesions. Histopathological analysis of FSE cases revealed 
spongiform degeneration in the brain and spinal cords, with substantial variations in 




(domestic cats, cheetahs, lions, ocelots, tigers and Asian golden cats). Coincidentally, 





1.1.3 Human Prion Diseases  
Human prion diseases are a group of neurodegenerative disorder characterized by a 
rapidly progressive dementia, myoclonus, visual or cerebral impairment and 
pyramidal-extrapyramidal signs (Aguzzi et al., 2008, Ironside, 1998). Human prion 
diseases are classified according to their clinical, genetic and neuropathological 
features and fall into three aetiological groups: 
 
o Sporadic or idiopathic forms include sporadic Creutzfeldt–Jakob disease 
(sCJD), sporadic fatal insomnia (sFI) and variably protease sensitive 
prionopathy (VPSPr). 
o Acquired forms include iatrogenic (iCJD), variant Creutzfeldt–Jakob disease 
(vCJD) and kuru. 
o Familial or genetic forms include Gerstmann-Straussler-Scheinker syndrome 
(GSS), fatal familial insomnia (FFI) and familial Creutzfeldt-Jakob disease 
(fCJD). 
The most common form of CJD is the sporadic form accounting for around 85% of 
human cases and with a relative incidence of 1-2 case / million population per annum 
worldwide (Ironside, 1998, Ironside et al., 2005). The main risk factors for genetic 
CJD are mutations in the PRNP gene.  
As with animals affected by TSEs, PRNP polymorphisms appear to influence clinical 
and pathological phenotypes in the human prion diseases. The most critical 
polymorphism resides at codon 129, which may encode methionine or valine. The 
prevalence of the methionine / methionine (M/M) genotype at this codon is 39%, 




11% in the normal Caucasian population. Nevertheless, 61% of sCJD cases are M/M 
at codon 129, 21% M/V and 18% V/V (Alperovitch et al., 1999, Ironside et al., 2005)  
In 1996 Will and colleagues reported 10 unusual cases of CJD in young individuals 
with a new neuropathological profile, suggesting the appearance of a new variant of 
Creutzfeldt–Jakob disease (vCJD) in the UK, with a possible link to the earlier 
bovine spongiform encephalopathy (BSE) epidemiology (Will et al., 1996). Animal 
transmission studies reinforced this view and strongly suggested that vCJD is: (i) 
caused by the same strain of agent that has caused BSE, FSE and TSEs in exotic 
ruminants; (ii) vCJD is distinguishable from sCJD; and (iii) CJD in two dairy farmers 
is of the sCJD type and is not linked to the causative agent of BSE (Bruce et al., 
1997, Ironside, 1998). 
TSEs in humans are diagnosed based on established diagnostic criteria which 
consider (i) clinical signs and symptoms, (ii) clinical tests, and (iii) post-mortem 
neuropathological confirmation. Diagnose of TSEs in animals is different since 
numerous high through-put “rapid tests” have been used. Today, considering the 
fundamental role played by the PrP in prion pathogenesis, several approaches have 
focused in detecting or amplifying the misfolded form of the prion protein PrPSc. 
Immunology-based techniques alongside the development of specific antibodies have 
led to immunoassays such western blotting, enzyme-linked immunosorbent assay 
(ELISA), immunohistochemistry (IHC) or conformation-dependent immunoassay 
(CDI) being increasingly used for diagnose and screening of animal TSEs (Gavier-
Widen et al., 2005). On the other hand, and based on the biochemical property of 
PrPSc to convert the normal prion conformation, researchers have also focused on 




developing a new test method and also to investigate the basis of the prion 
conversion. (Jones et al., 2011). 
1.1.4 In vitro replication of prions 
Caughey and colleagues developed an in vitro system in which recombinant hamster 
PrPC, incubated with the misfolded form of the prion protein and a chaotropic agent, 
generated “new” protease-resistance material derived from the original PrPC 
(Kocisko et al., 1994). Although this represented a major development in prion 
biology, a large excess of input material (PrPSc > 50 fold) was required to perform 
the conversion of the recombinant prion protein, placing constraints on its utility. 
Subsequently and based on the nucleation and polymerization model, Soto and 
colleagues described an in vitro procedure that mimics the in vivo PrPSc conversion 
process. Using this approach it was possible to amplify minute quantities of PrPSc 
present in a sample.  
This technology, called protein misfolding cyclic amplification (PMCA), consists of 
cycles of sonication followed by incubation periods of a mixture of a normal brain 
homogenate (rich in PrPC) with a source of PrPSc in the presence of detergents 






Figure 1.1 Schematic representation of protein misfolding cyclic amplification 
(PMCA) showing the presumed mechanism of molecular conversion. A large 
excess of PrPC is incubated with minimal quantities of PrPSc followed by cycles of 
incubation and sonication. PrPSc aggregates are shown to grow, converting and 
incorporating PrPC molecules. With each cycle of sonication and incubation 
(represented by arrows) PrPSc aggregates are broken, creating further seeds. After 
several cycles of sonication and incubation most of the PrPC will have been 






The aim of the sonication is to fragment the PrPSc aggregates to increase the amount 
of seeds present in the sample without affecting their ability to act as conversion 
nuclei (Saa et al., 2005). Castilla and colleagues reported that the PrPSc generated by 
PMCA and inoculated into wild-type animals retains the biochemical and 
pathological characteristics of the original source (Castilla et al., 2008b). 
PMCA has also been used to address different questions in the field of prion 
research, such as the species barrier phenomenon. Hamster and mouse prions have 
shown major difficulties in the transmission of the infectious agent between these 
two species (Race et al., 2002). Nevertheless, Castilla and colleagues reported that 
using PrPSc from mice strains (as a seed) and PrPC from hamster as a source of 
substrate it is possible to produce an adaptation on the seeds, generating “new” 
prions after serial rounds of PMCA. Similar results were obtained using hamster 
seeds and murine substrate (Castilla et al., 2008a) 
Another example of the applicability of PMCA is the spontaneous generation of 
prions. Deleault and colleagues reported that using PMCA and minimal components 
such as native PrPC, co-purified lipid molecules and polyanions, it is possible to 
generate and propagate prions de novo (Deleault et al., 2007).  
In addition, Barria and colleagues generated prions spontaneously at a low and 
variable rate in the absence of pre-existing PrPSc using a modified version of PMCA. 
The PMCA product was infectious in wild-type hamsters, producing a new disease 
phenotype with unique clinical, neuropathological and biochemical features (Barria 





More recently, Wang and colleagues reported the spontaneous generation of 
infectious prion by PMCA using exclusively recombinant PrP (Wang et al., 2010). 
These findings provide an experimental approach for studying the origins, 





1.1.5 Aims of the Thesis 
 
This thesis aims to provide a better understanding of human prion replication 
using cell-free conversion systems. It will address the following four hypotheses: 
1. Homologous (human:human) amplification of PrPSc from different 
human prion diseases. (Chapter 3) 
Hypothesis: PMCA can faithfully amplify PrPSc from a wide range of different 
human prion diseases conserving PrPres types and respecting PRNP codon 129 
barriers.  
Human prion diseases occur as sporadic, familial or acquired forms with clinical, 
genetic and neuropathological variations in each group. Jones and colleagues 
reported that PrPSc in extracts of sCJD brain could be amplified by PMCA using 
human prion protein from transgenic mouse brains by PMCA (Jones et al., 2008). 
They further showed that the efficiency of PrPSc conversion appeared to depend on 
the sCJD subtype and the PRNP codon 129 genotype of the PrPC. However, the 
above study was limited in scope and there is a need for a more detailed 
determination of the combined effects of substrate genotype and the human prion 
disease subtype of the seed on the efficiency of PrPSc conversion.  
This thesis seeks to extend the investigation of the interaction of the PRNP codon 
129 genotype (of the substrate) and the human prion disease type of the seed. PMCA 
was used as an in vitro model of the in vivo PrPC to PrPSc conversion, hypothesised to 
be a central event in prion diseases.  
To achieve the aim, brains from different lines of humanized transgenic mice that 
differ only in their PRNP codon 129 genotypes (M/M, M/V or V/V) of the human 




overexpress the human prion protein (codon 129 genotypes M and V) served as 
sources of PrPC. Brain tissue from vCJD and sCJD patients served as source of PrPSc 
seed. The main objective was to determine, for each subtype of human prion disease, 
the substrate PRNP codon 129 genotypes that are most efficient for the amplification 
of PrPSc by PMCA. This thesis also explored the in vitro conversion properties of 
non-standard PrPSc types, such as those found in the brain in GSS, FFI and VPSPr 
cases.  
 
2. Heterologous (animal:human) amplification of PrPSc from different 
animal prion diseases. (Chapter 4) 
Hypothesis: Species barriers to prion transmission can be modelled using 
PMCA. 
After the discovery of a link between BSE and vCJD, several investigators have 
examined the potential risk of transmission from animals with others TSEs to 
humans. For the purpose of this thesis, PMCA was used to model the susceptibility 
of humans to different animal prion diseases. A panel of seeds for PMCA 
amplification were prepared from cases of vCJD, cattle BSE, H-type BSE in cattle, 
L-type BSE in cattle, sheep scrapie, atypical scrapie in sheep and chronic wasting 
disease. The panel was assessed using human brain substrates from non-CJD 
individuals, transgenic mice brain, and cell lines, with genotypes of PRNP codon 129 
being M/M and V/V. The aim was to use an in vitro method of assessing the 
propensity of human PrPC to be converted by PrPSc of a potentially zoonotic strain 





3. Spontaneous PrPSc formation using in vitro conversion systems as a 
model for sporadic CJD. (Chapter 5) 
Hypothesis: Unseeded in vitro conversion reactions can be used to explore the 
factors affecting spontaneous prion protein misfolding. 
Sporadic CJD is the most common form of human TSEs, affecting approximately 1-2 
persons per million people per year (Ironside and Head, 2008, Ironside et al., 2005). 
However, important basic questions remain about the aetiology of this disease and 
whether sporadic CJD arises in individuals as a result of a spontaneous conversion of 
PrPC to PrPSc, which then self-propagates. Different approaches have been used to 
address these questions. For example, Deleaut and colleagues and Barria and 
colleagues both explored the possibility of spontaneous generation of PrPSc in PMCA 
using minimal components (Deleault et al., 2007, Barria et al., 2009). Recently an 
interesting approach was published by Edgeworth and colleagues in which they 
showed that the incubation of metal wires with susceptible cells was sufficient to 
generate PrPSc spontaneously and produce a new disease phenotype in recipient wild-
type mice (Edgeworth et al., 2010). Using a transgenic mice model which expresses 
wild-type bank vole prion protein, Prusiner and colleagues generated the spontaneous 
conversion of the normal prion protein in a transgenic model, recapitulating several 
aspects of prion disease (Watts et al., 2012). Finally, Wang and colleagues reported 
spontaneous generation of infectious prion by PMCA using exclusively recombinant 
PrP (expressed in bacteria), purified RNA from mice liver and synthetic lipids (Wang 
et al., 2010). As an alternative approach, in this thesis, two in vitro PrP conversion 
assays – protein misfolding cyclic amplification (PMCA) and real time quaking-




the spontaneous generation of human PrPSc. PMCA is a complex cell free system 
which typically utilizes brain homogenate, glycosylated and glipiated PrP, whereas 
RT-QuIC is much more simple and assesses amyloid formation using a naked protein 
backbone. Both cell free systems can used to model fundamental aspects of prion 
replication. The aims were (i) to establish a protocol for the spontaneous generation 
of the abnormal form of the human PrP in vitro, (ii) to determine whether the 
spontaneous in vitro generated human PrPres can propagate in vitro and (iii) to 
determine whether PrPC methionine or valine at the position 129 conferred greater 
susceptibility to the spontaneous conversion. 
4. A possible role for molecular chaperones in prion protein conversion. 
(Chapter 6) 
Hypothesis: Members of the α-crystallin / small heat shock protein gene family 
affect prion protein conversion efficiency in vitro. 
The α-crystallin / small heat shock proteins are a family of proteins with differential 
constitutive tissue expression patterns and stress-inducible, chaperone-related 
functions that have been implicated in responses to neurodegeneration among other 
pathologies. The cellular prion protein (PrPC) is also thought to have a stress-related 
function which has also been associated with the autocatalytic propagation of the 
misfolding disease-associate PrPSc. In order to test for a possible role for α- crystallin 
in the conversion and propagation of the human prions, two prion conversion assays: 
PMCA and RT-QuIC were used to evaluate the activity of α-crystallin in the 
generation, conversion and propagation of human prions in vitro. The aims of this 




reaction, and (ii) evaluate if there is any effect on the formation of spontaneous 













2.1 Materials and methods  
2.1.1 Laboratory requirements in handling TSE samples 
TSE-tissue handling was carried out following the biosafety procedures described by 
the Laboratory Code of Practice of the National CJD Research & Surveillance Unit 
(NCJDRSU), Edinburg, UK. The Advisory Committee on Dangerous Pathogen 
(ACDP) classifies TSE agents in various species as hazard group 3. Following the 
recommendations suggested by the ACDP, the inactivation of the infectious agent 
was conducted by incubation of contaminated material to a solution of sodium 
hydroxide at a concentration of 2N for minimum 60 minutes.  
All tissue sampling from cases of human prion disease was performed in a Class 1 
microbiological safety cabinet. Handling of infected tissue homogenate (usually 
10%) was performed under the same conditions stated above. The preparation and 
handling of uninfected tissue (10% uninfected brain homogenate) was carried out in 
a Class 2 microbiological safety cabinet. All the experimental work conducted for the 
accomplishment of this thesis was performed in a category 3 laboratory (with 
derogations) at the NCJDRSU. 
 
2.1.2 Biological Samples 
2.1.2.1 Human and non-human brain tissue  
Human brain specimens were obtained at autopsy form UK cases referred to 
National CJD Research and Surveillance Unit with consent for research. The brain 
material was obtained by the submission of a tissue request to the NCJDRSU Brain 
and Tissue Bank committee for approval. Human brain specimens were selected 




research, (iii) neuropathological confirmation of diagnosis, (iv) samples selected 
previously for published scientific research were considered in preference to samples 
that had not previously been used, (v) CJD brain specimens that had mixtures of 
PrPSc types were excluded. Age, gender, post mortem delay, were not considered as a 
part of the selection criteria. Ethical approval for the use of these tissues was covered 
by LREC 2000/4/157 (Professor James Ironside). 
Non-human brain tissues (non-human TSE samples) were obtained by request form 
the Animal Health Veterinary Laboratory Agency TSE Archive (AHVLA), 
Weybridge, UK. A detailed list of the analysed specimens is described in Chapter 4, 
Materials and method section.   
 
2.1.2.1.1 Normal brain homogenate 
Humanized MM, MV and VV transgenic mouse and frontal cortex form non–CJD 
patient were used as a substrate for the PMCA experiments. A detailed list of the 
utilized specimens is described in each specific Chapter in the Materials and method 
section. Transgenic mouse lines were kindly provided by Professor Jean Manson and 
Dr. Rona Barron, Roslin Institute, The University of Edinburgh, UK.  
 
2.1.2.1.2 Human prion disease brain homogenate  
Brain homogenates used in this study were derived from patients with a vCJD, sCJD, 
GSS, GSS with an 8kDa PrPres fragment, FFI, VPSPr and pateints who were 
considered from a diagnosis of CJD but who were found to be suffering from a 




detailed list of the analysed specimens is described in each specific Chapter in the 




2.1.3 Solutions, reagents and buffers 
The following reagents were used for the preparation and performance of PMCA and 
Western blotting experiments. 
 Reagents /Solution/Antibodies Brand 
PMCA    
Conversion Buffer PBS 1X, 150mM NaCl, 1% Triton X-100, 
1X Protease Inhibitor 
 
 





 Triton X-100 Cat No T9284-100ML 
 
 Complete Protease Inhibitor Cocktail 
Tablets (PI) 
 
Roche, Cat No 
11836170001 
 
 EDTA 0.5M Fluka, Cat No 
100967520 




Western blotting   
 Gels Nu-PAGE 10% Invitrogen, Cat No 
NPO 301BOX 
 




 Phenylmethanesulfonyl fluoride (PMSF) 50 
mM 
 
Sigma, Cat No P7626 
 
 PVDF membrane Bio-Rad Cat No 132-
0177 
 
 Anti-Prion Protein, a.a. 109-112, clone 3F4 
 
Cat No mAb 1562 
 
 Monoclonal anti-PrP antibody 6H4         
(mAb 6H4) 
 
Prionics, Cat No 01-
010 
 
 Proteinase K 
(Solution PK 1µg/µl in water) 
 
Novagen Cat No 
71049-3 
 ECL Plus Western blotting detection 
reagents GE Healthcare 
GE Healthcare  Cat 
No RPN2132 
Table 2.1 Reagents, solution and antibodies utilized to perform PMCA and 






2.1.4.1 Preparation of PMCA Substrate (PMCA-Substrate) 
2.1.4.1.1 Preparation of normal brain homogenate  
Normal brain homogenates (humanized MM, MV and VV transgenic mice and 
frontal cortex from non–CJD patient) were prepared using the tissue grinder 
homogenate and chilled conversion buffer to obtain a final 10% weight/volume (w/v) 
solution. The homogenized tissue was centrifuged at 2000 rpm for 40 seconds in a 
refrigerated centrifuge (4ºC). After centrifugation the samples were removed 
carefully form the centrifuge and the supernatant retained. The normal brain 
homogenates or substrate was aliquoted in 1.5 ml micro-centrifuge tube frozen and 
stored at -80 until to be used.  
For the preparation of PMCA-substrate,	   independent of its origin, low molecular 
weight heparin was added at 100µg/ml. EDTA was included at 500µM in all PMCA 
reactions. Both reagents (heparin and EDTA) were incorporated to the PMCA-
substrate just before use. 
 
2.1.4.1.2 Preparation of cell PMCA substrates 
Cell PMCA substrate was prepared as described by Yokoyama and colleagues 
(Yokoyama et al., 2011). 293F cell extract (Codon 129M and V) was kindly 
provided by Professor Testsuyuki Kitamoto (Tohoku University Graduate School of 







2.1.4.2 Preparation of human and non-human prion disease brain homogenate 
(PMCA-seeds)  
For the preparation of human and non-human prion disease brain material the same 
protocol was used as for the preparation of normal brain homogenate, except that 
quick freezing was not judged to be critical.  
 
2.1.4.2.1 Determination of the PMCA-seed concentration prior to the 
amplification 
All human and non-human prion disease brain material (10% brain homogenate) 
were evaluated for the presence of PrPres. Serial dilutions of the TSE seed brain 
homogenate were used to determine the PrPres levels by Western blotting. Likewise 
to determine the PrPres signal which were faintly detected by Western blotting and 
densitometry. The final aim was to calculate the seed-dilution (PrPres) (regarding the 
10% brain homogenate) which was faintly detectable before amplification in order to 
see clearly the increased signal after PMCA. For this purpose, variations of the seed 
concentration among samples were utilized for the in vitro amplification.  
 
2.1.4.3 Preparations of serially diluted samples for PMCA 
A set of serially diluted PMCA reactions were prepared. Aliquots of normal brain 
homogenate and human and non-human prion disease brain homogenate were 
thawed by incubating in water at room temperature. PrPSc seeds (1.3µl) were 
carefully mixed with near 130.7µl PMCA substrate in 0.2ml PCR tubes to prepare a 
standard PMCA dilution of 1/100 (Figure 2.1). Serial dilutions 1/10 and 1/5 and 1/2 




PMCA dilution was taken and transferred to the second tube (d-10-2) followed by 
careful up-and-down mixture by pipetting. This process was repeated until dilution 
of interest d-10-n (Figure 2.1). 
For the non-sonicated sample (termed “Frozen” samples) 19 µl from the serially 
diluted samples was taken and frozen immediately. These samples served as non-
amplified controls. All the samples were carefully mixed and then placed in the 






Figure 2.1 Diagrams represent serial dilution of infected brain in normal brain 
homogenate.  The first dilution (1/100) contains 1 volume of 10% w/v infected brain 
homogenate (source of PrPSc, PMCA-seeds) and 99 volumes of normal brain (source 
of PrPC, PMCA-substrate); the second tube is a 10x dilution of the previous mix; the 
third tube is a 100x dilution of the first tube; etc. All tubes end up with the same final 
volume (120 µl). From each tube 19 µl are removed and kept frozen for the non-





2.1.4.4 Automatic Cyclic Amplification 
The sonication step in the PMCA technique is the key element used to increase the 
efficiency and decrease the time used in the conversion of the PrPC into the abnormal 
form of the prion protein. The following methodological parameters were used 
during the PMCA protocol: 
Machine: Sonicator S4000 
• Sonication time (Pulse ON): 20 seconds. 
• Incubation time (Pulse OFF): 29 minutes and 40 seconds. 
• Duration of PMCA reaction: 48 hours. 
• Amplitude of sonication: 85-91 
• Energy (in watts) : 280-290 
• Temperature: 37°C 
 Clear nano-pure water (200ml) was added to the microplate horn to perform the 
reaction. All samples were placed in the PMCA tube holder and dipped into the 
water checking carefully that the levels of water did not reach the tube holder. 
 
2.1.4.5 PrP Digestion  
To detect the PrPres product, proteinase K (PK) digestion was performed to remove 
the remaining PrPC from the samples followed by Western blotting. Nineteen 
microliters of each sample were incubated with 1µl of 1µg/µl Proteinase K (final 




One microliter of 50 mM PMSF was added to each reaction to inhibit PK activity. 
Samples were mixed with appropriate volumes of 4X loading buffer and centrifuged 
at 2000 rpm for 20 sec. 
 
2.1.4.6 Western blotting analysis 
Samples	  were	   boiled	   at	   100°C	   for	   10min	   and	   centrifuged	   at	   2000	   rpm	   for	   20	   sec	   to 
bring down the condensate. The samples were then loaded into the wells of a 
NuPAGE Novex 10% Bis-Tris Gel (1.0 mm, 10 well) and electrophoresed at 200V 
for 50 minutes (in NuPAGE® MES SDS Running Buffer). 
Proteins were electro-transfered to a PVDF membrane (Bio-Rad) using 800 mA 
(constant) for 1 h. Membranes were blocked with 2% milk for 1hr followed by 
incubation with specific antibodies diluted in 1X PBS with 0.05% Tween 20 (PBST) 
(3F4, 6H4 mAbs) depending on the experiment. Blots were rinsed 3 times (10 min 
each time) with 1X PBST (washing buffer). ECL Anti-mouse IgG, peroxidase-linked 
species specific F(ab')2 fragment (from sheep) was used as a secondary antibody 
diluted 1/25,000 in washing buffer and incubated for 1 h. Again blots were rinsed 3 
times for 10 min each with washing buffer to eliminate excess of secondary 
antibody. 
Membranes were developed by a luminescent peroxidase substrate ECL-Plus from 





2.1.4.7	  Densitometric Analysis 
Densitometric analyses were performed using Image Lab software version 2.01 (Bio 
Rad). All images were captured using a CCD camera and saved in TIFF format for 
further analysis. Densitometric Analysis of relative bands intensity were performed 
considering lineal range of PrP immunodetection signal by Western blotting.  
In order to evaluate the potential variability in densitometric assays and western 
blotting, serial dilutions of 10% brain homogenate (from transgenic mice expressing 
the human form of the prion protein) were performed and subjected to immunoblot 
analysis using 3F4 antibody. Densitometric analysis in three independent 
immunoblots showed minimal variability across experiments.  
 
2.1.4.7.1 PMCA normalization and quantification 
To estimate the PMCA amplification efficiency, PrPres densitometric signals (after 
PK treatment and Western blotting) were calculated using the Image Lab 
software.2.0.1. The densitometric value of the intensity of PrP immunoreactive bands 
was calculated for the samples before and after PMCA measuring an equal 
designated area (number of pixels). To obtain a better comparison among the 
samples, background subtraction was performed. The densitometric values of 
“sonicated” samples were divided by the “frozen” measures. The increase in signal 
(ratio between the detectable levels of PrPres before and after PMCA) was designated 






2.1.4.7.2 Selection criteria for PMCA seed-range dilution and densitometric 
analysis 
All PMCA-seeds were evaluated for the levels of PrPres after protease K digestion 
and Western blotting. The selection criteria used to determine the dilution utilized for 
prion amplification (and further densitometry) was based on the detection of faint 
levels of PrPres before PMCA in order to visualize a measurable increase of signal 
post amplification. For this purpose variations of the seed concentration were utilized 





 Equipment  Brand 
PMCA   
 Sonicator Misonix S4000 Part S4000 Misonix 
 Tube holder and cover for PMCA Part # 444 Misonix 
 Incubator Leec compact incubator 
 
 




   
Western blotting   
 Trans-Blot Cell With Plate Electrodes  170-3939 
 Thermoblock QBD2 
 
 Trans-Blot Electrophoretic Transfer Cell 170-3954 
 




 Densitometric Analysis, Image Lab 





Others   
 Refrigerated centrifuge Sigma 3-16K 
 Ultra low freezer So-Low Nuaire -86 ultra 
 








Homologous (human:human) amplification of PrPSc from different 









3.1.1 Overview  
Human prion diseases are a group of neurodegenerative conditions associated with 
misfolding and aggregation of the prion protein. They are classified as idiopathic, 
familial or acquired. They comprise a wide range of clinical and neuropathological 
phenotypes including Creutzfeldt–Jakob disease, Gerstmann-Straussler-Scheinker 
syndrome, and fatal familial insomnia, among others (Table 3.1).  
The conformational change of the PrPC to PrPSc is considered a key element to 
understand the molecular mechanism of the disease, and also their current 
classification. The current classification of human prion diseases relies mainly on 
international well accepted protocols, wherein the clinical signs, life-test analysis 
(magnetic resonance imaging, electroencephalography, 14-3-3 protein test), and post 
mortem confirmation, are critical parameters 
(http://www.cjd.ed.ac.uk/documents/criteria.pdf). For the familial human prion 
diseases group, the presences of mutations on the PRNP are also essential.  
For the sCJD cases, a  molecular typing subclassification was proposed by Parchi 
and colleagues which relies mainly on: (i) the polymorphic variation associated with 
the PRNP gene and (ii) the mobility and glycoform ratio of the protease-resistant 
core fraction of the PrP after proteinase K cleavage, visualized by Western blotting 








To gain a deeper understanding, the present introduction will be divided into the 
following two sections: 
1. Human prion diseases: mutations and polymorphic variations of the 
PRNP gene. 





 Disease Epidemiology 
Sporadic  
Sporadic Creutzfeldt-Jakob Disease 
(sCJD) 
 


















Fatal familial insomnia (FFI) 
 
 










Iatrogenic CJD (iCJD) 
 
Variant CJD (vCJD) 
 
Historically prevalent, 
fore tribe, New Guinea 
 
∼400  worldwide * 
 
∼200 mostly UK * 
 
Table 3.1 Incidences and worldwide cases of human prion diseases. 
Epidemiology data is presented in number of cases/million/annum and total number 













3.1.2 Human prion diseases: mutations and polymorphic variations of the PRNP 
gene 
The human prion protein gene (PRNP) is located on the short arm of chromosome 20 
and comprises two exons. The exon two contains the open reading frame which 
encodes the 253 amino acid polypeptide, which after cellular processing results in a 
protein with a molecular mass of the 35-36 kDa termed the PrPC (Oesch et al., 1985, 
Liao et al., 1986, Puckett et al., 1991). 
It has been proposed that genetic variations of the PRNP gene appears not only to 
determine the susceptibility to certain prion diseases but also determines the disease 
phenotype (Reviewed by Parch P, 2012 and Head M, 2012) (Head and Ironside, 
2012b, Head and Ironside, 2012a, Parchi and Saverioni, 2012). In this sense, the 
status of codon 129 – which has been described to encode either methionine or valine 
– has been shown to have a profound effect on the susceptibility to acquire / develop 
human prion diseases and their classification. 
In the general Caucasian population, the estimated genotype frequencies at codon 
129 are 39% methionine homozygotes (MM) versus 11% of the alternative valine 
homozygotes (VV). The remaining 50% of the population harbour the heterozygous 
methionine / valine genotype (MV). However, the genotype frequencies among 
individuals affected by prion diseases follow a different distribution, suggesting a 
correlation between codon 129 genotypes and diseases susceptibility. Specifically, 
61% of sCJD cases are M/M at codon 129, 21% M/V and 18% V/V (Alperovitch et 





3.1.2.1 Sporadic human prion diseases  
3.1.2.1.1 Sporadic Creutzfeldt-Jakob disease  
With a worldwide incidence of one to two cases per million individuals per year, 
sCJD is considered the most common form of human prion diseases, accounting for 
around 85% of all CJD cases (Ironside et al., 2005, Will et al., 1996). Typically, 
sCJD occurs in middle-aged and elderly individuals, with a peak age of onset 
between 55 to 75 years. sCJD comprises a number of diverse clinical and 
neuropathological phenotypes. In general, most of the cases exhibit a progressive 
dementia, cerebellar dysfunction including muscle incoordination, visual 
disturbances and myoclonus. At the late stages of the disease, most of the patients 
develop akinetic mutism, and are unable to respond to external stimuli (Sikorska et 
al., 2012, Sikorska and Liberski, 2012, Ironside, 1998). The majority of sCJD cases 
die within six months of onset; however, in Japan a longer median survival time has 
been reported (Kitamoto and Tateishi, 1988). 
The considerable heterogeneity of the clinical and pathological phenotypes of sCJD 
has been attributed to polymorphisms on the PRNP gene. The current molecular / 
genetic subclassification of sCJD was defined in 1999 by Parchi and colleagues 
(Parchi et al., 1999b). This classification relies on the homozygosis or heterozygosis 
at codon 129, the phenotypic heterogeneity of the pathology, and the 
physicochemical properties of PrPSc. Six subgroups were proposed: The first 
subgroup correspond to the MM1/MV1 cases, which accounted for 70% of the total 
number of cases and were previously classified as typical or classical CJD. The 
second subgroup corresponded to the VV2 cases and comprised the previous cases 




subgroup corresponded to the MV2 cases, formerly classified as Kuru plaque variant 
of sCJD. They accounted for 9% of cases. Representing 1% cases of the cases, the 
subgroup VV1 incorporated the cases described as atypical CJD. Finally, the last two 
subgroups correspond to the MM2-thalamic (MM2t) and cortical (MM2c) that 
represented 1% of the cases each. The MM2t subgroup incorporated the cases 
previously classified as the thalamic variant, which shares a similar disease 
phenotype with the genetic condition known as fatal familial insomnia. This disease 
entity is characterized pathologically by thalamic atrophy, and clinically by 
insomnia. The disease is known as sporadic fatal insomnia or sFI (Parchi et al., 
1999a, Kawasaki et al., 1997, Mastrianni et al., 1999). The MM2c subgroup, which 
is denoted mainly by a cortical pathology, did not present a prior classification 
(Table 3.2). (Parchi et al., 1999b). 
An important factor not considered in detail by Parchi’s proposed classification 
refers to the possibility of mixtures of types (type 1 and type 2) in the same 
individual. This interesting fact, although reported in 5% of the cases, was not 
considered in this classification system (Parchi et al., 1999b). Several studies have 
confirmed the existence of mixtures, particularly in sCJD in which estimates of 
incidence range between 5 to 36% of cases across all three 129 codon genotypes 
(Parchi et al., 2009, Cali et al., 2009, Head et al., 2004, Puoti et al., 1999). Western 
blotting analysis using a monoclonal antibody that specifically recognizes PrPres type 
1 identified the occurrence of PrPres type 1 in all the cases of a cohort of sCJD type 2 
(Polymenidou et al., 2005). Using a similar methodology, but an alternative 
monoclonal antibody (12B2), Yull and colleagues reported for the first time the 




detected in peripheral tissue (Yull et al., 2006). A recently revised subclassification 
of sCJD proposed the active incorporation of the co-occurrence cases (type 1 + type 
2), integrating six additional subgroups to those already described (Parchi et al., 
2009). 
An alternative human prion classification has been proposed by Collinge and 
colleagues (Collinge and Clarke, 2007, Collinge et al., 1996, Wadsworth et al., 
2003). This classification recognize three PrPres types (contrary to the two presented 
by Parchi), and also distinguish more PrPres glycoform of the three recognize by 
Parchi and colleagues. This thesis employs the subclassification proposed Parchi and 




























signs at onset 
in 40% of 
cases 
 
“Classic CJD” distribution 
of pathology; 
often prominent involvement 
of occipital 
cortex; “synaptic type” PrP 
staining; 
in addition, one-third of 
cases shows 
confluent 




in most cases 
Prominent involvement of 
subcortical, including 
brain stem nuclei; in 
neocortex, 
spongiosis is often limited to 
deep layers; 
PrP staining shows plaque-
like, focal 













(more than 2 
years) in some 
cases 
 
Similar to VV2 but with 
presence of 
amyloid-Kuru plaques in the 
cerebellum, 





2 15.6 Insomnia and 
psychomotor 
hyperactivity 
in most cases, 







Prominent atrophy of the 
thalamus and 
inferior olive (no spongiosis) 
with little 
pathology in other areas; 
spongiosis may 
be absent or focal, and PrPSc 
is detected 
in lower amount than in the 
other variants 




Large confluent vacuoles 
with perivacuolar 
PrP staining in all cortical 
layers; cerebellum 
is relatively spared 
 




Severe pathology in the 
cerebral cortex and 
striatum with sparing of 
brain stem nuclei 
and cerebellum; no large 
confluent 







Table 3.2 Classification of sCJD proposed by Parchi and colleagues (1999) 
based on the phenotypic and molecular variability of 300 sCJD patients (Parchi 





3.1.2.1.2 Variably protease-sensitive proteinopathy (VPSPr) 
Variably protease-sensitive proteinopathy is a novel human prion disease 
characterized (like other forms of prion disease) by the presence of PrPSc. 
Nevertheless the PrPSc present in these cases show a distinctive sensitivity to 
treatment with protease. Although first described only for cases having 
homozygosity for valine at codon 129 (Gambetti et al., 2008), VPSPr has now been 
identified in all three genotypes (Rodriguez-Martinez et al., 2010, Head et al., 2010, 
Giaccone et al., 2007). Western blot analysis of VPSPr brain homogenates after PK 
treatment exhibit a distinctive electrophoretic mobility of the PrP resistant fragments, 
resulting in a ladder of bands with a prominent band at 8kDa, similar to those 
detected in Gerstmann–Straussler–Scheinker syndrome. So far very little is known 
about the mechanisms involved in this disease. Further work is required to establish 






3.1.2.2 Familial human prion diseases 
Familial prion diseases, also known as genetic prion diseases, are a group of 
inherited neurodegenerative disorders associated with the presence of mutations in 
the PRNP gene. The pattern of inheritance of genetic prion diseases is autosomal 
dominant; only one copy of the mutated gene is required to develop the disease 
(Lloyd et al., 2011). A large number of mutations and polymorphisms have been 
identified underlying multiple prion disease phenotypes (Mead, 2006). Typically 
these mutations are of three types: point mutations, which lead to (i) an amino acid 
change or (ii) a premature stop codon, and (iii) insertions that alter the total number 
of octarepeats (OPRI) (Lloyd et al., 2011, Mead, 2006). Although it is not entirely 
clear how these mutations result in the production of misfolded prion protein, it has 
been proposed that they can lead to structural (i.e. conformational) changes of PrPC, 
thus predisposing the normal isoform to be more susceptible to acquire the PrPSc 
conformation. Moreover, the occurrence of mutations within critical regions in the 
PrPC greatly increases the propensity to undergo a pathogenic conversion (Legname, 
2012, Jackson et al., 2009).  
The genetic forms of human prion diseases account for 10–15% of all human prion 
incidences (Mead, 2006, Windl et al., 1999, Kovacs et al., 2005). Patients affected 
with familial prion diseases exhibit a wide spectrum of clinical phenotypes, even 
among individuals carrying the same gene mutations (Barbanti et al., 1996, Collinge 
and Palmer, 1992, Zarranz et al., 2005, Zerr et al., 1998). The heterogeneity of prion 
diseases can be attributed to several factors, although the PrP polymorphic genotype 
and the PrPSc type are considered to be the major influence (Gambetti et al., 2003). 




of the patients as either CJD, Gerstmann–Straussler–Scheinker syndrome or fatal 
familial insomnia. 
 
3.1.2 2.1 Genetic or familial Creutzfeldt-Jakob disease (gCJD) 
Genetic CJD (gCJD) is an inherited form of the Creutzfeldt-Jakob disease that was 
first recorded in 1924 by Kirchbaum (Reviewed by Gambetti P, 2003) (Gambetti et 
al., 2003). The affected family was later shown to carry an inherited form of CJD 
(Kretzschmar et al., 1995). gCJD is classified into several haplotypes based on 
pathogenic mutations and the polymorphism at the codon 129 of the PRNP gene. 
Among gCJDs, CJD with the E200K 129M haplotype (CJDE200K–129M) is the most 
common form. The mean age of onset is 58 years and the mean duration is 6 months. 
The clinical presentation of CJDE200K–129M includes cognitive and mental 
abnormalities (~80% of patients), cerebellar signs (~43%), and visual signs and 
myoclonus (both <20%) (Hsiao et al., 1991, Brown et al., 1991). During the course 
of the disease all patients experience dementia. Another example of gCJD, but with 
rare mutations is the V180I–129M haplotype (CJDV180I–129M). A total of seven cases 
have been reported worldwide, six Japanese and one American. Among the affected 
individuals four carried 129M on the normal allele and one had a second mutation on 
the other allele, M232R. The distinguishing clinical features of CJDV180I–129M are the 
long duration (1-2 years) and possible presence of Kuru plaques and plaque-like 
formations in subjects with 129M genotypes (Hitoshi et al., 1993, Kitamoto, 1994, 
Iwaski et al., 1999). As the majority of gCJD cases (>50%) have been diagnosed in 
individuals without a positive family history of the disease, the term gCJD is now 




variable, as shown by considerable intra-familial and intra-generational phenotypic 
variability (Imran and Mahmood, 2011). 
 
3.1.2.2.2 Gerstmann–Straussler–Scheinker syndrome 
Gerstmann–Straussler–Scheinker syndrome (GSS) is a rare human prion disease, 
with an incidence of 1 in 100 million per population per year (Belay, 1999). The 
syndrome was first described in 1936 in a large Austrian family, in which members 
manifested a slow and progressive cerebellar ataxia admixed with cognitive decline 
at some time in the course of the disease (Reviewed by Liberski P, 2012) (Liberski, 
2012)). A number of descriptive and eponymous titles have been described to 
analogous prion disorders; and only recently they have been recognized as a cohesive 
clinicopathological entity with a nosological classification as a TSE (Masters et al., 
1981). The clinical features of GSS are early age onset (30-40 years) and slow 
progression extended over an average period of 5 years (Liberski, 2012). The 
variation in age of the onset is associated with the P102L mutation (Piccardo et al., 
1998). Clinical symptoms include cerebellar ataxia, gait abnormalities, dementia, 
dysarthria, ocular dysmetria, infrequent myoclonus, spastic paraperesis, Parkinsonian 
signs and hyporeflexia or areflexia in the lower extremities (Belay, 1999, Liberski, 
2012, Liberski and Budka, 2004). Although the main clinical features of dementia 
associated with progressive cerebellar ataxia and / or spastic paraparesis are non-
specific, GSS patients share the characteristic neuropathological feature of 
multicentric amyloid plaques (Kovacs and Budka, 2009). 
The genetic basis of GSS was first confirmed by the association of the P102L 




mutation in GSS is the P102L substitution. This mutation is usually associated with 
the classical ‘ataxic’ GSS clinopathological profile. Other mutations in the PRNP 
gene have been described; however, they are often associated with less typical 
phenotypes (Kitamoto et al., 1993b, Hsiao et al., 1992, Kitamoto et al., 1993a). Some 
missense mutations that have been reported to co-segregate with the syndrome are: 
P102L-129M; P105L–129V; A117V–129V; Y145STOP–129M; F198S–129V; 
D202N–129V; Q212P; and Q217R–129V (Belay, 1999, Jansen et al., 2010, Kovacs 
et al., 2005).  
 
3.1.2.2.3 Fatal familial insomnia (FFI) 
Fatal familial insomnia was originally considered a thalamic dementia, and it was not 
until 1986 that it was reported as a disease afflicting five members of a large Italian 
family (Lugaresi et al., 1986). Subsequently, in 1992, FFI was proposed as a novel, 
genetically determined prion disease (Medori et al., 1992). FFI is caused by the 
effect of a mutation combined in cis: an amino acidic change from aspragine to 
aspartic acid at codon 178 (D178N); and methionine at codon 129 (129 MM) 
(Goldfarb et al., 1992). Patients with D178N and valine at codon 129 exhibit a gCJD 
phenotype (Capellari et al., 2011, Lugaresi et al., 1986, Montagna et al., 2003). 
Further analysis revealed subtle differences in the gene products of D178N–129M 
and D178N–129V, as well as more discernable differences in the glycoform ratios 
and electrophoretic mobility’s of their protease-resistant derivatives (Monari et al., 
1994). The brains of FFI patients show a characteristic degeneration largely confined 
to the part of the brain involved in the sensory perception and prioritization of 




1992, Parchi et al., 1998). The core clinical features of FFI consist of a profound 
disruption of the normal sleep-wake cycle (the main clinical hallmark), sympathetic 
over-reactivity, diverse endocrine abnormalities and markedly impaired attention 
(Montagna et al., 2003). An overview of the global occurrence of FFI indicates that 
100 cases have been reported in almost 40 families from Italy, Germany, Austria, 
Spain and the UK, among other countries (Baldin et al., 2009). Although the 
incidence among men and women was similar, the clinical phenotype of FFI is 
apparently dependant on the genotype at codon 129. Myoclonus, spatial 
disorientation and hallucinations are more frequent in patients homozygote for the 
amino acid methionine (129 MM) (Zarranz et al., 2005, Krasnianski et al., 2008). 
Whereas symptoms such as bulbar disturbances and vegetative dysfunction were 
more common in heterozygous methionine / valine FFI patients (129 MV). These 
phenotypic differences between MV and MM FFI patients may be caused by 
different rates of prion conversion (Gambetti et al., 1995). Likewise, the duration of 





3.1.2.3 Acquired human prion diseases  
Acquired prion disease results from the exposure to exogenous prions. The 
transmission of infection can occur from human to human or as a zoonosis, from an 
animal to humans. Acquired forms of human prion diseases are of importance 
because of their consequences for public health. Three different clinical phenotypes 
have been described so far: Variant Creutzfeldt–Jakob disease, Iatrogenic 
Creutzfeldt–Jakob disease and Kuru. 
 
3.1.2.3.1 Variant Creutzfeldt–Jakob disease (vCJD) 
In 1995 and early 1996 a small number of cases of CJD in unusually young 
individuals were reported. The average age at death was 29 and the clinical and 
pathological features of the patients differed from those of CJD in several ways (e.g. 
the presence of florid plaques in the brain). In April 1996 the disease was defined as 
a new variant of CJD (vCJD), and a link to the epidemic of BSE in the UK cattle was 
suggested (Will et al., 1996). Several laboratory and biological studies confirmed 
that the infectious agent responsible for vCJD was similar to the BSE agent (Bruce et 
al., 1997). Scott and colleagues performed transmission studies in wild-type human 
transgenic and bovine transgenic mice and provided compelling evidence of a causal 
link between BSE and vCJD (Scott et al., 1999). Since first reported by Will and 
colleagues in 10 patients, the majority of additional cases have been identified in the 
UK (total 177 cases) and France (~25 cases). Although the incidence of vCJD is 
declining, a small number of cases are still being identified.  
In comparison to sCJD, vCJD usually affects younger age groups (onset around 27 




are remarkably stereotyped compared to the varied clinical presentations of sCJD 
(Will et al., 1996, Ironside et al., 1996). The prominent presenting symptoms of 
vCJD are mainly psychiatric and behavioural. Neurological features can appear more 
than 6 months after the initial symptoms. As the disease progresses, signs of 
cerebellar ataxia with cognitive impairment and involuntary movement arise. The 
characteristic pathological changes observed in brains affected by vCJD are the 
formation of florid plaques, non-CNS tissue deposition of PrPSc, type 2B pattern of 
protease treated PrPSc by Western blotting, and hyperintensity of the pulvinar of the 
thalamus region seen on MRI scans (Ironside, 1998, Ironside and Head, 2004, 
Ironside et al., 1996, Will et al., 1996). 
Nearly all cases of vCJD have been PRNP 129MM individuals 
(http://www.cjd.ed.ac.uk/data.html) apart from one possible MV case (Kaski et al., 
2009). However, the accumulation of abnormal PrP has been identified in the 
appendix of three asymptomatic individuals, two of which were VV at the codon 129 
of the PRNP gene (Hilton et al., 2004a, Hilton et al., 2004b, Ironside et al., 2006). 
Animal studies have shown that different clinical phenotypes could occur in people 
(exposed to the infectious agent) with polymorphic variations at the codon 129 of the 
prion protein gene (Asante et al., 2006, Wadsworth et al., 2004).  
 
3.1.2.3.2 Iatrogenic Creutzfeldt–Jakob disease (iCJD) 
The iatrogenic form of the Creutzfeldt–Jakob disease (iCJD) is a result of accidental 
exposure of patients to prions during medical procedures. The first case iCJD was 
reported in 1974 in the recipient of a corneal graft from a donor who had died of 




iatrogenic iCJD have been reported worldwide (Hamaguchi et al., 2009). The 
mechanisms of transmission are variable and include neurosurgical instruments, 
depth electrodes, human pituitary hormones and dura mater grafts, all of which have 
involved cross-contamination with prion contaminated  material (Will, 2003). When 
transmission is intracerebral the symptoms resemble those of sCJD. As for other 
prion diseases, genetic factors play an important role in the disease phenotype of the 
disease. The number of iCJD cases has decreased over time probably due to 




Kuru ("to shake” or “tremble" in the Fore language) was first reported in 1959 
(Gajdusek and Zigas, 1959). Kuru was recognized to be endemic amongst the Fore 
tribe resident in the Eastern Highlands of New Guinea, although it was also seen in 
neighbouring tribes with whom the Fore often inter-married (Gajdusek and Zigas, 
1957, Gajdusek, 1977). The clinical presentation of Kuru is characterised by 
cerebellar ataxia with relatively preserved cognition, preceded by headaches, joint 
pains and shaking of the limbs. The mechanism of transmission was identified as 
ritualistic cannibalism practices. No children born after 1959 have been affected. 
There is no evidence for vertical transmission of the disease, despite breast feeding 
of infants by clinically affected mothers (Liberski and Brown, 2009, Liberski et al., 
2012). Since endocannibalism ceased in the late 1950s, the incidence of Kuru 
decreased dramatically. The last cases, mostly MV, appeared over 40 years after 




2006). In contraposition, given that MM genotypes at codon 129 were initially 
diagnosed in the Fore population but then suffered a reduction on its frequency over 
time, a genetic susceptibility and a shorter incubation period for the MM genotype 
was suggested (Cervenakova et al., 1998, Collinge et al., 2006, Lee et al., 2001). 
Notably, a Kuru resistant factor has been reported in people who survived the 
epidemic in Papua New Guinea - those individuals harbouring the genetic variant 





3.1.3 PrP glycosylation and conformation  
The presence of two potential N-glycosylation sites at the residues (Asn-181 and 
Asn-197 in humans and Asn-180 and Asn-196 in mice) allows PrPC to be expressed 
as three different glycoform: non-glycosylated, mono-glycosylated or di-
glycosylated (Haraguchi et al., 1989, Rudd et al., 2002, Rudd et al., 2001). These two 
glycosylation sites can be occupied by high-mannose type oligosaccharides attached 
to PrP in the endoplasmic reticulum before secretion. 
In order to determine whether or not heterogeneity of the PrPC glycoforms exist as a 
function of the brain region, DeArmon and colleagues used a two dimensional PAGE 
immunoblot and a panel of antibodies, showing differences in the relative 
concentration and isoelectric point of the PrPC as a function of the hamster brain 
region. They hypothesised that the selective targeting of neuronal cell is relative to 
the affinity PrPC / PrPSc   modulated by differences in the PrPC glycosylation 
(DeArmond et al., 1999). Differences in the proportion of glycans between PrPC and 
the PrPSc have also been reported. Purification of PrPC and PrPSc from Syrian hamster 
brain revealed a broad heterogeneity in their glycan populations between these two 
isoforms, with more than 50 different sugar chains attached. Presumably, this 
difference can be linked with a perturbation of the glycosylation machinery 
specifically associated with the galactosyl trans-ferase activity, and also glycoform 
selection (Rudd et al., 1999, Endo et al., 1989). Variation in the PrPSc glycoform 
ratio can also be observed when transmitting prions from one species to another. 
Analysis of brain stem tissue from sheep infected with scrapie and BSE showed 
variations in the relative amount of PrPres glycoform, with a higher level of 




samples derived from BSE-infected sheep compared with those derived from sheep 
with-scrapie (Thuring et al., 2004). 
A clear example where the conformation of PrPSc has been employed as potential 
markers to distinguish between different strains has come from the studies of two 
hamster-adapted-TME strains termed hyper (HY) and drowsy (DY). Experimental 
transmission of TME to Syrian golden hamsters resulted in the divergence of two 
disease phenotype characterized by hyperexcitability and cerebellar ataxia (HY), and 
progressive lethargy (DY), respectively (Bessen and Marsh, 1992b). Biochemically 
these two strains can also be distinguished. Western blot analysis of PK resistant core 
fragment confirmed a 1 to 2kDa difference in the migration of the non-glycosylated 
band, showing a lower molecular weight band associated to DY PrPSc. Protein 
sequencing experiments (after proteinase K digestion) revealed that the major N-
terminal cleave sites of DY PrPSc was positioned at least 10 amino acids residues 
further towards the C terminus prior to HY, suggesting potential conformational 
differences between these two strains (Bessen and Marsh, 1992a). In order to 
evaluate more in detail the possibility that these two isolates possess variations in the 
structure, Caughey and colleagues evaluated the conformation variability over three 
hamster adapted prion strains: HY, DY (TME-derived) and 263K (scrapie-derived). 
Fourier transform infrared spectroscopy analysis revealed post-translational 
modifications associated to DY and HY conformers which could explain the 
biochemical differences between these two isolates. Perhaps more importantly, the 
studies of HY and DY strains demonstrate that different conformers of the PrPSc are 










3.1.3.1 Molecular typing of human prion diseases  
The proteolytic degradation of the prion protein by proteinase K has been used as a 
fundamental tool to discriminate between the normal prion protein and the misfolded 
isoform. Likewise it has been used to distinguish between diverse prion strains and 
types. In the current classification of the human prion diseases, Western blotting 
analysis of the PK resistant core fragments of the PrP has allowed the distinction of 
two major prion types (type 1 and type 2), which differ in the relative molecular 
mass. (Cali et al., 2006, Gambetti et al., 2003, Parchi et al., 2012, Parchi et al., 
1999b) The results of the combined analysis (Western blotting and proteinase 
cleavage) indicated that type 1 has a main cleavage site at glycine 82 thereby 
producing a N-terminal truncated fragment of about 21kDa, whereas type 2 is 
predominantly truncated at serine 97, generating a N-terminal truncated fragment of 
about 19kDa (Parchi et al., 2000b, Parchi et al., 2000a). Types 1 and 2 have intact C-
termini in their protease-resistant core; however, in certain prion pathologies the 
presence of small fragments of about 8kDa fragments have been described. These 
fragments correspond to the central region of PrPres post-truncation of the N and C-
termini by proteinase K. These PrPres fragments have been mainly described in some 
forms of GSS and in VPSPr (Zou et al., 2010, Parchi et al., 1997, Piccardo et al., 
1998, Piccardo et al., 2001, Head et al., 2010, Head et al., 2013). As well as the 
electrophoretic mobility, the glycosylation ratios of the di, mono and non-
glycosylated PrPres play a role structuring the actual classification of PrPres types. A 
glycoform ratio characterised by diglycosylated PrPres is designated by the suffix B. 
In contrast, the suffix A denotes a higher proportion of the monoglycosylated form. 




expense of the non-glycosylated band they are designated with the suffix A/B (Parchi 
et al., 1997, Head, 2013, Head and Ironside, 2012b, Head and Ironside, 2012a). 
Figure 3.1 shows a schematic representation of the PrPres profile of several human 







Figure 3.1 Schematic diagram of the spectrum of PrPres fragments observed in 





3.1.4 PMCA and human prion replication 
PMCA has been proven to be a very useful technique to investigate several aspect of 
the human prion replication. Jones and colleagues reported that PrPSc in extracts of 
sCJD could be amplified by PMCA using PrPC from transgenic mouse brains by 
PMCA (Jones et al., 2008). They further showed that the efficiency of PrPSc 
conversion appeared to depend on the sCJD subtype and the PRNP codon 129 
genotype of the PrPC. However, the study was limited in scope and there is a need for 
a more accurate and detailed determination of the combined effects of substrate 
genotype and the human prion disease subtype of the seed on the efficiency of PrPSc 
conversion.  
This chapter seeks to extend the investigation of the interaction of the PRNP codon 
129 genotype (of the substrate) and the human prion disease type of the seed. PMCA 
was used as an in vitro model of the in vivo PrPC to PrPSc conversion, hypothesised to 
be a central event in prion diseases. To achieve the aim, brains from three lines of 
humanized transgenic mice that differ only in the PRNP codon 129 genotypes (M/M, 
M/V or V/V) of the human prion protein, non-CJD human brain (of each genotype) 
and transfected 293F cells, served as sources of PrPC. Brain tissue from vCJD, sCJD 
and atypical forms of human prion diseases served as source of PrPSc seed. The main 
objective was to determine for each subtype of human prion disease, substrate PRNP 
codon 129 genotypes that are compatibles and most efficient for the amplification of 
PrPSc by PMCA. Also, this chapter explores the in vitro conversion properties of 







3.2 Material and methods: 
3.2.1 Biological Samples 
3.2.1.1 Human brain tissue  
Human brain specimens were obtained at autopsy form UK cases referred to the 
National CJD Research and Surveillance Unit with consent for research. Selection 
criteria and ethical approval are described in General Material and Methods, section 
2.1.2.1. 
 
3.2.1.1.1 Human normal brain homogenate 
Frontal cortex form non–CJD patient were used as a substrate for the PMCA 
experiments. A detailed list of the utilized non-CJD specimens is described in table 
3.7. 
 
3.2.1.1.2 Human prion disease brain homogenate  
Brain homogenates used in this study were derived from patients with: sCJD, VPSPr, 
FFI, GSS, GSS with 8kDa fragment and vCJD. Detailed lists of the analysed PrPSc 
samples are shown in the following tables (Tables 3.3, 3.4, 3.5 and 3.6).  
 
3.2.1.2 Humanized transgenic mouse brain tissue 
The entire brain form inbred humanized transgenic mouse lines expressing the 
human from of the prion protein MM, MV and VV at the PRNP codon 129 (Bishop 






3.2.1.3 Human cells lines  
Transfected human 293F cells, overexpressing a chimeric mouse-human prion 
protein (methionine or valine at the position codon 129 of the prion protein gene) 
were obtained by supressing the endogenous PrP protein expression with RNAi 
Subsequently, 293F cell were transfected with PIRESneo3-cDNA-quemier-PNRP 
expression vector. Cells were transfected and were grown by cell culture (Yokoyama 
et al., 2011).  
 
3.2.2 Methods 
3.2.2.1 Preparation of brain PMCA substrates 
Human Brain and transgenic mouse brain PMCA substrates were prepared exactly as 
described in General Material and Methods (Chapter 2) 
 
3.2.2.2 Preparation of cell PMCA substrates 
Cell PMCA substrates was prepared as described in General Material and Methods 
(Chapter 2) 
 
3.2.2.3 PMCA procedure 
PMCA reactions were prepared exactly as described in General Material and 
Methods (Chapter 2) 
 
3.2.2.4 Protease digestion and Western blot analysis  
Western blotting experiments were prepared exactly as described in General Material 




3.2.2.5 Densitometric Analysis 
Densitometric analyses were performed using Image Lab software version 2.01, Bio 
Rad. 
 
3.2.2.6 Data analysis 
All statistical analysis, graphs and further analysis were completed using GraphPad 














sCJD (MM1) sCJD-1 MM FC 1A 
sCJD (MM1) sCJD-2 MM FC 1A 
sCJD (MV1) sCJD-3 MV FC 1A 
sCJD (MV1) sCJD-4 MV FC 1A 
sCJD (MV1) sCJD-5 MV FC 1A 
sCJD (MV1) sCJD-6 MV FC 1A 
sCJD (MV1) sCJD-7 MV FC 1A 
sCJD (VV1) sCJD-8 VV FC 1A 
sCJD (VV2) sCJD-9 VV FC 2A 
sCJD (MM2c) sCJD-10 MM FC 2A 
sCJD MM2c) sCJD-11 MM FC 2A 
sCJD (MM2t) sCJD-12 MM FC 2A 
sCJD (MV2) sCJD-13 MV FC 2A 
sCJD (MV2) sCJD-14 MV FC 2A 
sCJD (MV2) sCJD-15 MV FC 2A 
sCJD (MV2) sCJD-16 MV FC 2A 
sCJD (MV2) sCJD-17 MV FC 2A 
sCJD (VV2) sCJD-18 VV FC 2A 
sCJD (VV2) sCJD-19 VV FC 2A 
 
Table 3.3 Genetic and PrPSc biochemical information for the sporadic CJD 















VPSPr VPSPr-1 VV FC 2A+8kDa  
 VPSPr-1 VV Cb 2A+8kDa  
 VPSPr-2 VV FC 2A+8kDa  
 VPSPr-2 VV Cb 2A  
 
Table 3.4 Genetic and PrPSc biochemical information for the variably protease-
sensitive prionopathy cases and specimens selected for in vitro prion conversion 










PRNP codon 129 
genotype 
PrPres type 
FFI FFI-1 FC D178N MM 0 
FFI FFI-2 FC D178N MM 2 
GSS GSS-1 FC P102L MM 1A 
GSS  GSS-2 FC P102L MM 1A+8kDa 
 
3.5 Genetic and PrPSc biochemical information for the familial cases and 
specimens selected for in vitro prion conversion (PrPSc source). PrPres type (0) 
















vCJD vCJD-1 MM FC 2B 
vCJD vCJD-2 MM FC 2B 
 
Table 3.6 Genetic and PrPSc biochemical information for the vCJD cases and 



















Substrate-1 MM FC 0 
Lewy body 
dementia 
Substrate-2 VV FC 0 
 
Table 3.7 Diagnostic and genetic information of non-CJD cases and specimens 
selected for substrate (PrPC source) preparation. PrPres type (0) corresponds to 






3.3 Results  
As suggested above, PMCA is an in vitro conversion technique that can be used to 
model aspects of prion replication. Modifications have been incorporated into this 
technique to analyse, for example, the convertibility of different substrates by various 
seeds; to increase the efficiency of the technique; to develop a diagnostic test or to 
explore the factors involved in prion conversion (Fujihara et al., 2009, Jones et al., 
2007, Wang et al., 2010, Yokoyama et al., 2011).  
The in vitro conversion process of PrPC to PrPSc most likely depends on the 
molecular compatibility of the two isoforms, the competence of the substrate to 
support amplification (PrPC source), the amount of seed (PrPSSc source), and the 
chemical or physical conditions employed. First, in order to determine efficiency and 
reproducibility of PMCA for human prion seeds, humanized transgenic animals and 
post mortem brain homogenate substrates were used to evaluate the in vitro 





3.3.1	   PRNP codon 129 MM post mortem human brain homogenate and 
humanized transgenic mouse brain homogenate as a substrate for in vitro 
conversion using variant CJD brain homogenate as seed 
Conversion of human PrPC was analysed using substrate derived from either 1) post 
mortem brain tissue from non-CJD patients homozygous for methionine (MM) at 
codon 129 or 2) brain tissue from transgenic mice (Tg) expressing the human form of 
the prion protein (MM at codon 129 of PRNP). In both cases normal brain 
homogenate was prepared following the protocol described in the materials and 
methods section 2.1.4. Ten percent brain homogenate from human post mortem 
tissue or transgenic animals was mixed with different volumes of a 10% brain 
homogenate made from vCJD brain specimen (source of seed) (Figure 3.2). Serial 
dilutions of the seed: 1/5, 1/10, 1/20, and 1/40 (in 10% normal brain homogenate) 
were made. Seeded, non-sonicated samples were used as a “before” PMCA control 
(termed “Frozen” sample or “F”).  After PMCA (“S” samples) and the “F” samples 
were treated with proteinase K (PK) and analysed by Western blotting (General 
Material and Methods, Chapter 2). Sonicated samples (“S” samples) showed higher 
levels of PrPres compared to frozen samples incubated with post mortem tissue 
(Figure 3.2A) or Tg mouse brain homogenate (Figure 3.2B). Densitometric analysis 
of PrPres of Western blots showed 10.2 fold amplification using non-CJD human 
brain homogenate and a 17.5 fold amplification using Tg mouse brain homogenate 
substrate (Figure 3.2A, lanes 7 and 8, Figure 3.2B, lanes 7 and 8). PrPres formation 
was consistently more efficient when vCJD PrPSc seed sample were amplified with 
brain homogenate from transgenic mice compared with post mortem human brain 





Figure 3.2 Serial dilutions of vCJD brain homogenate seed mixed with two 
different PMCA substrates: A: Post mortem tissue from non-CJD patients (MM at 
codon 129 of PRNP). B: Transgenic mice expressing the human form of the prion 
protein, homozygous for methionine (MM) at codon 129. F: Frozen samples; S: 





3.3.2 Reproducibility of PMCA for vCJD seeds 
To analysis the reproducibility of the PMCA technique, two independent sets of 
experiments were carried out (Figure 3.3A and B): 
1. To evaluate the efficiency of amplification over two times points (called 
experiment 1 and 2) serial dilutions of vCJD seeds (1/20, 1/100, 1/500, 
1/2500 and 1/100, 1/500, 1/2500, 1/12500) were mixed with 10% Tg mouse 
(MM) brain homogenate and subjected to rounds of incubation and 
sonication for 96 PMCA cycles (following the protocol described in General 
Material and Methods, Chapter 2). Densitometric analysis showed an 
amplification rate around 15.5 to 16.5 fold (Figure 3.3A, Experiment 1) 
compared with around 15.7 to 16.2 fold calculated for the samples in the 
experiment 2. The determination of the PMCA amplification rates were 
following the procedures described in the section: PMCA normalization and 
quantification in General Material and Methods, Chapter 2. (Figure 3.3A).  
2. To analyse the reproducibility between different machines, a second S-4000 
sonicator was used in parallel with similar settings applied for the experiment 
2. Sonicator B showed an amplification rate around 17 to 18 fold higher 
intensity in the sonicated samples compared with the non-sonicated samples 
(Figure 3.3B, lanes 2, 4, 6 and 8). 
These results therefore demonstrated good reproducibility for PMCA using two 






Figure 3.3 Reproducibility of PMCA for vCJD seed. A: amplification carried out 
over two times points (Experiment 1 and 2). B: To analyse reproducibility between 
independent machines, a different S-4000 sonicator was used in parallel to the 
experiment 2. The dilution 1/500 (for each experiment) was used to calculate the 
PMCA efficiency. F: Frozen samples; S: Sonicated samples; M: Molecular Marker. 





3.3.3 In vitro conversion of vCJD PrPSc using human brain homogenate, 
humanized transgenic mouse and 293F cells extract substrates  
To analyse the in vitro conversion capacities of vCJD using three different sources of 
PrPC, 10% human brain homogenate, 10% humanized transgenic, and 20% 293F 
cells extract, were seeded, with vCJD and 96 cycles of PMCA were conducted. vCJD 
seed (10% brain homogenate) was diluted 1/50 and 1/250 in all three substrates. 
After 96 cycles of PMCA, the human post mortem substrate showed increased levels 
of PrPres present in the sonicated samples compared with the equivalent non-
sonicated samples. Densitometric analysis of PrPres on Western blots showed an in 
vitro amplification of around 10 fold for the human post mortem substrate (Figure 
3.4, lanes 2 and 4). The humanized transgenic mice substrate showed higher levels of 
amplification compared with the human post mortem tissue with an amplification 
factor of around 21	  fold (Figure 3.4, lanes 6 and 8). The 293F cells extract showed an 
intermediate amplification rate with around 16 fold (Figure 3.4, lanes 10 and 12). 
Irrespective to the origin, all substrates showed an increase of signal across the serial 
dilution preformed for the seed. The transgenic mice substrate gave the highest levels 
of amplification, followed by the 293F cell substrate, in turn followed by the human 
post mortem tissue substrate. The determination of the PMCA amplification 
efficiency followed the procedures described in the section: PMCA normalization 






Figure 3.4 Amplification of vCJD PrPSc using human brain homogenate, 
humanized transgenic mice and 293F cells extract. A: PMCA seeded with serial 
dilutions of vCJD PrPSc (1/50 and 1/250 regarding the 10% brain homogenate). The 
seed was mixed with three different substrates and amplified for 96 cycles of PMCA. 
F: Frozen samples; S: Sonicated samples; M: Molecular Marker. Immunodetection 





3.3.4 In vitro conversion of sCJD PrPSc subtypes in human brain homogenate, 
humanized transgenic mice and 293F cells extract  
Six clinic-pathological subtypes of sCJD have been identified (MM1 and MV1, 
MM2-thalamic, MM2-cortical, MV2, VV1 and VV2) that correlate with the PrPres 
electrophoretic mobility / glycosylation ratios, and the polymorphic status at codon 
129 of the PRNP gene.  
In order to evaluate the ability to support in vitro amplification, brain homogenates 
from the six different subtypes of sCJD were mixed with different sources of PrPC. 
The seed and substrate compatibility (in terms polymorphic variation associated with 
codon 129: MM MV and VV) were tested for their in vitro conversion capacities.  
 
3.3.4.1 In vitro conversion of sCJD MM1, MM2c and MM2t PrPSc subtypes in 
human brain homogenate, humanized transgenic mice and 293F cells extract  
In order to determine the potential in vitro conversion capacities of sCJD MM1, 
MM2c and MM2t, three distinct sources of PrPC (all carriers of the amino acid 
methionine at codon 129 of PRNP gene) were mixed with PrPSc derived from 
sCJDMM1, MM2c and MM2t brain specimens. To evaluate the PrPSc amplification, 
serial dilutions of the seeds (10% brain homogenate) were performed. For sCJD 
MM1 and MM2c dilutions 1/10 - 1/50 were used, for sCJD MM2t, 1/3 - 1/6. 
Substrate prepared form human post mortem brain, transgenic mouse brain and 293F 
cell were utilized. After 96 PMCA cycles, sCJDMM1 amplification reactions 
showed PrPres formation on both dilutions (Figure 3.5A, lanes 2, 4, 6, 8, 10 and 12 




substrates supported the amplification of the sCJD MM1 PrPSc seeds. Densitometric 
analysis showed an amplification factor of around 4 fold using the human brain 
substrate. The transgenic mice derived substrate show an amplification factor of 
around 5 fold; follow by the 4 fold for the 293F cells extract.  
sCJD MM2t did not show an increase of signal at any of the seeding dilutions when 
incubated with human brain homogenate or humanized transgenic substrate (Figure 
3.5B, lanes 2, 4 and 6). However a small increase of signal was detected on the seed 
dilution 1/3 (Figure 3.5B, lane 8) in the cells extract substrate. This observation was 
not seen in the following dilution (Figure 3.5B, lanes 9 and 10), or in a duplicate 
experiment. These results confirmed the lack of amplification presented by sCJD 
MM2c. 
In summary, among the three homozygous methionine PrPSc subtypes analysed, only 
sCJD MM1 showed increased levels of PrPres formation by PMCA. The other two 






Figure 3.5 PMCA reaction seeded with sCJD MM1, MM2c and MM2t and 
supplemented with human brain homogenate, humanized transgenic mice and 
293F cell extract. Serial dilutions of (A) sCJD MM1 (1/10 and 1/50), (B) MM2t (1/3 
and 1/6) and (C) MM2tc (1/10 and 1/50) were incubated with three independent 
sources of PrPC: 10% human brain homogenate, 10% humanized transgenic mice and 
20% 293F extract, all codifying methionine at the codon 129 of the PRNP gene. 
PMCA reactions seeded with sCJD MM2t 1/3 and 1/6 (corresponding to the Human 
post mortem tissue substrate) were blot from the same gel and developed under the 
same exposure settings, however they do not correspond to consecutive lanes. F: 






3.3.4.2 In vitro conversion of sCJD VV1 and VV2 PrPSc subtypes in human 
brain homogenate, humanized transgenic mice and 293F cells extract  
To investigate the potential in vitro conversion of sCJD VV1 or sCJDVV2 PrPSc in 
vitro, similar experiments to those previous described with MM subtypes were 
performed. Brain homogenate from patients with sCJD VV1 and sCJDVV2 were 
serially diluted (1/3 - 1/6 or 1/20 - 1/40 respectively) in the three different sources of 
the human PrPC. Substrate prepared from human brain, transgenic mouse brain or 
293F cell extract were used. Considering the polymorphic compatibility of seed / 
substrate, all substrates were carriers of valine at codon 129 of PRNP gene. 
Reactions seeded with sCJD VV1, incubated with human brain homogenate (Figure 
3.6A, lanes 2 and 4), humanized transgenic mice (Figure 3.6A lanes 6 and 8), or the 
transfected cells (Figure 3.6A, lanes 10 and 12) did not show any increase PrPres over 
the unamplified samples. PMCA reactions seeded with sCJD VV2 in human brain 
post mortem tissue, showed increased levels of PrPres on both serial dilutions in the 
sonicated samples (Figure 3.6B, lanes 2 and 4). Densitometric analysis showed a 7 
fold increase for human post mortem brain substrate. The remaining two substrates 
also supported in vitro amplification, with amplification rates of around 11 fold for 
the transgenic mouse derived substrate (Figure 3.6B, lanes 6 and 8) and around 8 
fold for the cell cultures substrate (Figure 3.6B, lanes 10 and 12). 
Contrary to what was observed for to the in vitro conversion reactions seeded with 
sCJD MM subtypes,	  which amplified type 1 but not type 2, the homozygous valine 
sCJD subtypes supported amplification on the sCJD VV2 seeds, and failed to support 





Figure 3.6 PMCA reactions seeded with sCJD VV1, VV2 and supplemented 
with human brain homogenate, humanized transgenic mice and 293F cell 
extract. Serial dilutions of (A) sCJD VV1 (1/3 and 1/6), (B) VV2 (1/20 and 1/40) 
were incubated with three independent sources of PrPC: 10% human brain 
homogenate, 10% humanized transgenic mice and 20% 293F cell extract. All 
substrates coded for the amino acid valine at the codon 129 of the PRNP gene. 
PMCA reactions seeded with sCJD VV1 1/3 and 1/6 (corresponding to the Tg-VV 
substrate) were blot from the same gel and developed under the same exposure 
settings, however they has not correspond to consecutive lanes. F: Frozen samples; 






3.3.4.3 In vitro conversion of sCJD MV1 and MV2 PrPSc subtypes in human 
brain homogenate and humanized transgenic mice 
To evaluate the capacities of heterozygous sCJD MV seeds to propagate in PMCA, 
five sCJD MV1 and five MV2 cases were used (See details in Table 3.3 Material and 
methods, Chapter 3). Normal brain homogenate derived from human post mortem 
tissue and transgenic mice brain, both expressing the heterozygous (MV) human 
PrPC, were incubated and sonicated for 96 cycles of PMCA. sCJD MV1 and MV2 
seeds were dilution 1/12. Different sCJD MV1 seeds incubated with 10% post 
mortem human brain homogenate showed variable amplification rates. In one case 
amplification was undetectable. Low to moderate levels of amplification were 
detected to the other four cases, with an amplification factor of around 2 to 4 fold 
(Figure 3.7A, lane 2). The transgenic mice brain substrate gave similar results 
(Figure 3.7B, lane 4). 
The PMCA reactions seeded with MV2 PrPSc gave similar results to those observed 
for sCJD MV1.	   Low levels of amplification were detected, with variable 
amplification rate between 2 to nearly 4 fold, independent of the source of PrPC 
(human post mortem or transgenic mice brain substrate) (Figure 3.7B, lane 2 and 4). 
Representative blots are shown in Figure 3.7.  





Figure 3.7 In vitro conversion reaction seeded with sCJD MV1 and MV2 PrPSc 
in heterozygous PRNP codon 129 human brain homogenate and humanized 
transgenic mice substrates. Dilution of the 10% brain homogenate (1/12) from (A) 
sCJD MV1, (B) sCJD MV2 were incubated with two sources of PrPC: 10% human 
brain homogenate, 10% humanized transgenic mice. The two sources of PrPC were 
heterozygous (MV) at the codon 129 of the PRNP gene. F: Frozen samples; S: 





3.3.5 In vitro amplification properties of vCJD and sCJD: MM1, MV1, MV2, 
VV2 conversion of human PrPC of different codon 129 genotypes 
The amplification of vCJD, sCJD MM1 and VV2 will be discussed in the following 
section 3.3.5.1. The amplification of sCJD MV1 and MV2 will be discussed in the 
section 3.3.5.2. 
3.3.5.1 In vitro amplification properties of vCJD, sCJD MM1 and sCJD VV2 to 
convert the human PrPC of different codon 129 genotypes 
All of the PMCA reactions described above were performed using seeds and 
substrates matched for PRNP codon 129. In order to evaluate the in vitro conversion 
capacities of the PrPSc that previously supported the human PrPC conversion, but 
using different codon 129 genotype substrates, homogenate from vCJD, sCJD MM1 
and sCJD VV2 brain specimens were selected, diluted and amplification attempted. 
Normal human post mortem tissue and transgenic mice brain, expressing the human 
prion protein (in the three possible polymorphic forms: MM, MV, VV) were used as 
a source of PrPC. PrPSc seeds were diluted as follows: vCJD 1/100, sCJD MM1 and 
VV2 were diluted 1/40 into human post mortem brain substrate. Considering the 
highest efficiency observed for PMCA reactions (incubated with transgenic mice 
brain substrate), a higher dilution of the vCJD PrPSc seed was performed (1/1000). 
For the sCJD seeds (MM1 and VV2), the dilution 1/40 was maintained. 
After PMCA, samples incubated with homozygous (129 MM) post mortem substrate 
and seeded with vCJD, showed high levels of PrPres	  formation (Figure 3.8A, lane 2). 
Densitometric analysis of PrPres on Western blot showed an amplification rate over 




decrease in the PrPres formation was observed when the heterozygous MV or the 
homozygous VV substrates were similarly seeded (Figure 3.8A, lanes 4 and 6). 
Amplification efficiency of around 2.5 to 3.5 fold were observed for the MV and VV 
substrates respectively (Figure 3.8A). Using transgenic mice substrate, similar results 
were observed. vCJD PrPSc seeds showed in vitro conversion when incubated with 
MM substrate (Figure 3.8D, lane 2), with a decrease of conversion efficiency in MV 
and VV PMCA substrates (Figure 3.8D, lanes 4 and 6). Densitometric analyse 
demonstrated around 3 to 4 times lower PrPres formation on the samples incubated 
with the heterozygous MV substrate, with a further decrease of intensity in the VV 
PrPC substrate (Figure3.8D). 
As expected, sCJD MM1 seeds showed lower levels of in vitro conversion compared 
with vCJD seeds. The homologous (MM) seed / substrate PMCA reactions showed a 
similar amplification factor between 3 to 4 fold using the human brain (Figure 3.8B, 
lane 2), and the transgenic mice substrate (Figure 3.8E, lane 2).	  Amplification rate 
around 2 to 3 fold were observed for the MV substrate on both, the transgenic and 
human post mortem homogenate (Figure 3.8 and E, lane 4). The VV substrates 
showed amplification rate around 1.5 to 2.5 fold for the post mortem substrate, and 
the transgenic mice substrate respectively (Figure 3.8B and E, lane 6). 
The sCJD VV2 seeds resulted in PrPres formation into all three allelic substrates 
(Figure 3.8C and F, lanes 2 4 and 6), however a preference for the codon 129 (VV) 
substrate was observed (Figure 3.8C and F, lane 6). After PMCA, higher levels of 
PrPres formation were detected for the samples incubated with the VV human or 
transgenic brain substrate, with amplification rate around 6 to 10 fold respectively 




In summary, the amplification efficiency of vCJD PrPSc appears to depend upon the 
allelic compatibility at the codon 129. This was also observed for the PMCA 
reactions seeded with sCJD MM1 in which the favoured substrate was homozygous 
for methionine at position 129 in PrPC  and in samples seeded with sCJD VV2, in 












Figure 3.8 PMCA using vCJD, sCJD MM1 and sCJD VV2 subtypes to convert 
the human PrPC carrying the three different codon 129 genotypes. Dilutions of 
(A) vCJD 1/100, (B) sCJD MM1 1/40, (C) sCJD VV2 1/40 were incubated with two 
different sources of PrPC: 10% human brain homogenate, 10% humanized transgenic 
brain homogenate. The two different substrates expressed the human prion protein in 
the three possible polymorphic genotypes: MM, MV, VV. F: Frozen samples; S: 
Sonicated samples; M: Molecular Marker. Immunodetection by 3F4 mAb. 
Densitometric analyses of PrPres on Western blot were performed following the 
procedure described in General Material and Methods (Chapter 2). The graphics 
representations of the PMCA amplification efficiency were performed using 
GraphPad Prisms 6. The (Y) axis represents the amplification factor (in fold of 
amplification), the (X) axis shown the three human polymorphic substrates (codon 





3.3.5.2 In vitro amplification properties of sCJD MV1 and sCJD MV2 to convert 
the human PrPC of different codon 129 genotypes 
Previous experiments indicated that the in vitro conversion efficiency of human PrPC 
was affected by compatibility between the codon 129 status of seed and substrate. In 
order to evaluate the in vitro conversion capabilities of heterozygous (codon 129 
MV) sCJD PrPSc seeds to convert the human prion protein, sCJD MV1 and MV2 
subtype brain homogenates were used to seed PMCA reactions. Specimens from five 
sporadic CJD MV1 and five MV2 subtype cases were homogenized and diluted in 
each humanized transgenic (MM, MV, VV) substrate. After 96 cycles of PMCA, 
sCJD MV1 brain homogenate incubated with MM 129 codon substrate, showed 
conversion, with an amplification factor of around 2 to nearly 5 fold and with an 
average of 3.2 fold (Figure 3.9A). The heterozygous MV codon 129 substrate 
showed a lower amplification; with one fold less efficacy compared to the 
homozygous MM substrate. Even lower efficiency was seen in the reaction 
performed using the homozygous VV substrate (Figure 3.9A). An opposite tendency 
was observed in the samples seeded with sCJD MV2, in which the average 
amplification for the reactions incubated with 129 codon MM substrate was 2 fold 
(Figure 3.9B). Finally, the PMCA reactions incubated with substrate homozygous for 
valine (VV) at the codon 129 showed the highest levels of amplification (between 
1.7 to 8.5 fold), with an average of 4 fold, which is twice as efficient as that of the 
comparable MM substrate (Figure 3.9B).  
The results therefore indicate that at least two major effects influence the conversion 
of the human PrPC in sCJD cases: the PrPC / PrPSc polymorphic variability presented 






Figure 3.9 PMCA using sCJD MV1 and MV2 seeds to convert the human PrPC 
carrying distinct codon 129 genotypes Five (A) sCJD MV1, and five (B) sCJD 
MV2 cases were homogenized, mixed and incubated in each polymorphic substrate 
(MM, MV, VV) for 96 cycles of PMCA. Frozen samples; S: Sonicated samples; M: 
Molecular Marker. Immunodetection by 3F4 mAb. Densitometric analyses of PrPres 
on Western blot were performed following the procedure described in General 
Material and Methods (Chapter 2). The graphics are representations of the PMCA 
amplification efficiency and were performed using GraphPad Prisms 6. The (Y) axis 
represents the amplification factor (in fold amplification), the (X) axis shown the 
three polymorphic codon 129 substrates utilized for in vitro amplification: Codon 
129 MM (blue), MV (red), VV (green). The horizontal lane (-) for each group 
represents the means of value. Immunoblots presented in the figure A and B are 






3.3.6 In vitro conversion properties of other PrPSc types 
In order to test whether PrPSc from different human prion diseases are able to convert 
the normal human prion protein, genetic and idiopathic prion disease cases were 
selected to perform in vitro conversion assay. Samples form brain specimens of 
Gerstmann-Straussler-Scheinker syndrome, and its variant with ∼8kDa fragment 
PrPres fragment, fatal familial insomnia and variably protease sensitive prionopathy 
were homogenised and used as seeds in PMCA. Prior to amplification, all disease 
brain homogenates (seeds) were characterized for PrPres abundance and type.  
3.3.6.1 Characterization of human prion diseases brain homogenate  
To characterize total PrP and PrPres in the seeds used for the in vitro conversion 
reactions, tissue from: one case of GSS, one case of GSS with 8kDa fragment, two 
cases of FFI and two cases of VPSPr, were homogenized in conversion buffer, 
loaded on SDS gels, and analysed by Western blot. To confirm previously reported 
differences in PrPres type from different brain regions, tissue from frontal cortex and 
from the cerebellum in the VPSPr cases were selected (Figure 3.10A). The total PrP 
levels were evaluated in the form of bands located in the molecular mass range of 20-
40 kDa, probably corresponding to the diglycosylated full length PrP and the 
monoglycosylated PrP or N-terminally truncated diglycosylated form of the human 
prion protein. Differences in the total PrP levels were quantified by densitometric 
analysis. When the seed samples were compared with the unaffected prion diseases 
control, around 60-80% less total PrP was observed in the FFI samples (Figure 
3.10A, lanes 1 and 2). Similar levels of total PrP were observed in frontal cortex and 




lanes 5-6 and 7-8). However, clear differences were noted after to treat the samples 
with proteinase K. Near to undetectable levels of PrPres were seen in the FFI samples 
(Figure 3.10B, lanes 1 and 2), and the VPSPr frontal cortex samples (Figure 3.10B, 
lanes 6 and 8). In contrast, PrPres was more abundant in VPSPr cerebellum tissue 
(Figure 3.10B, lanes 7 and 9) and the GSS tissue (Figure 3.10B, lanes 3 and 4). GSS 
with 8kDa fragment sample, and the VPSPr frontal cortex brain homogenate showed 
the appearance of a low molecular weight band (∼8kDa) characteristic of these two 






Figure 3.10 Characterization of total PrP and PrPres in the FFI, GSS, VPSPr 
samples. (A) One µl of 10% brain homogenate for each human prion disease related 
samples (lanes 1 to 8) were loaded in parallel to an unaffected prion disease control 
(lane 9) for comparative purposes. (B) A total of 25µl of 10% brain homogenate for 
each human prion disease related sample were treated with 50µg/ml PK for one hour 
at 37ºC and analysed by Western blot. Fatal familial insomnia (FFI), Gerstmann-
Straussler-Scheinker syndrome (GSS), Gerstmann-Straussler-Scheinker syndrome 
variant with 8kDa fragment (GSS-8kDa), variably protease sensitive prionopathy 
(VPSPr), forntal cortex (FC) and Cerebellum (Cb). Low molecular weight band 





3.3.6.2 Amplification of GSS, GSS with 8kDa fragment and FFI PrPSc 
Little is known about the abilities of these non-standard PrPSc types to convert human 
PrPC in vitro. Therefore, two FFI and two GSS cases (one with 8kDa fragment) were 
used to evaluate the in vitro behaviour of PrPSc to convert human prion protein 
substrate, derived from human post mortem tissue and transgenic mouse brain, both 
MM at codon 129 (and without mutations in the PRNP coding sequence). The seeds 
were diluted 1/10 in the substrates. After 96 cycles of PMCA, the human post 
mortem tissue substrate seeded with GSS type 1 PrPres showed an increase in PrPres 
whereas the reaction seeded with GSS with 8kDa fragment did not show an increase 
in signal (Figure 3.11A, lanes 7 and 9). Repeating the same experiment, but using 
transgenic mouse substrate, gave similar results. The transgenic substrate confirmed 
the amplification of the GSS sample; however, GSS with 8kDa fragment did not 
show increased levels of PrPres (Figure 3.11B, lanes 7 and 9). Three independent 
experiments confirmed the low levels and the lack of PrPres formation detected after 
PMCA and Western blotting by GSS and GSS with 8kDa fragment seeds 
respectively. 
Unexpectedly, one of the FFI seeded samples (case 2) showed higher levels of PrPres 
formation with a clear PrPres fragments after PK treatment in reactions incubated 
with human post mortem substrate (PRNP codon 129 MM) (Figure 3.11A, lane 5). 
The amplification reaction seeded with the FFI case 1 brain homogenate did not 
show increased levels of PrPres (Figure 3.11A, lane 3). PMCA using transgenic mice 
substrate (PRNP codon 129 MM) showed a clear PrPres amplification in the reaction 




for the case 2 (Figure 3.11B, lane 5). This difference between the two FFI cases was 







Figure 3.11 PMCA reactions seeded with homogenates of FFI, GSS and GSS 
with 8kDa fragment brain tissue. PMCA reactions seeded with brain homogenate 
diluted 1/10 of FFI (2 cases), GSS and GSS with 8kDa fragment were incubated with 
human brain substrate and transgenic mouse brain substrate, both PRNP codon 129 
MM genotype and subjected to 96 cycles of amplification. VV2 brain homogenate 
(2µl) was used as a PrPres type standard reference. Fatal familial insomnia (FFI), 
Gerstmann-Straussler-Scheinker syndrome (GSS), Gerstmann-Straussler-Scheinker 
syndrome variant with 8kDa fragment (GSS-8kDa) F: Frozen samples; S: Sonicated 





3.3.6.3 Amplification of FFI-PMCA products in a second round of PMCA 
In order to determine whether the FFI-PMCA material retained or lost the ability to 
convert human PrPC, the two FFI-PMCA-products (Figure 3.11B, lanes 3 and 5), 
were diluted 1/10 in fresh transgenic mice substrate (codon 129 MM) and subjected 
to a second round of PMCA. After 96 PMCA cycles, case 1 retained the ability to 
convert fresh PrPC (Figure 3.12, lane 2). Interestingly, FFI case 2 showed clear PrPres 
formation in the sonicated sample compared to the frozen one, in contrast to what 
was observed in the first PMCA round using the same substrate (Figure 3.12, lane 6 
compared to lane 7) and (Figure 3.11B, lane 5). Several technical and biochemical 
factors might have contributed to this blocking effect. The presence of an inhibitory 
component present in the original homogenate might have been diluted in the second 
round (1/10), causing the release of the inhibition. Additional experiments are needed 
to clarify this point. More important is the observation that both FFI-PMCA products 






Figure 3.12 Conversion properties of FFI amplification products in a second 
round of PMCA. The two FFI-PMCA products (cases 1 and 2), generated from a 
previous round of amplification, were incubated with fresh transgenic mouse 
substrate expressing the human form of the prion protein homozygous for methionine 
(MM) at codon 129 and subjected to a second round of PMCA. sCJD MM1, sCJD 
VV2 and vCJD were used as a PrPres  type standard reference. F: Frozen samples; S: 






3.3.6.4 Molecular typing of the PMCA- generated FFI product 
Western blots analysis of the PrPres fragments derived from FFI specimens, have 
previously shown the presence of two major bands that correspond to the 
diglycosylated and monoglycosylated protease resistant fragment to predominate. 
The non-glycosylated band is under-represented, but has a molecular mass of 19 kDa 
(ie type 2). Two FFI cases were used to test the ability of FFI PrPSc to propagate in 
vitro, both with positive results. In order to determine the molecular type of the FFI-
PMCA generated material, three of the most common forms of human prion diseases 
were used as reference standards. sCJD MM1, sCJD VV2 and vCJD brain 
homogenate were analysed by Western blot in parallel with the FFI-PMCA products 
(Figure 3.13) . In term of electrophoretic mobility, both FFI-PMCA samples showed 
three major PrPres fragments, with an apparent molecular mass of the non-
glycosylated PrPres fragment of around 19kDa. In term of glycosylation profile, the 
diglycosylated PrPres predominated over the mono- and non-glycosylated fragments. 
In summary,	   the	  FFI-PMCA generated material showed an electrophoretic mobility 







Figure 3.13 Molecular typing of FFI-PMCA products: comparison with sCJD 
MM1, sCJDVV2 and vCJD standards. The two FFI-PMCA products (cases 1 and 
2) were treated with proteinase K (50µg/ml) and analysed by Western blotting. sCJD 
MM1 (lane 2), sCJD VV2 (lane 4) and vCJD (lane 5) were used as a PrPres type 
standard reference. F: Frozen samples; S: Sonicated samples; M: Molecular Marker. 





3.3.6.5 Comparison of the susceptibility of the FFI PrPSc and FFI-PMCA 
products to PK degradation 
A PK titration assay was performed to compare the sensitivity of PrPSc from the FFI 
(brain tissue) and that found in the PMCA products to proteolytic digestion. Similar 
quantities (19µl) of 10% brain homogenate from brain tissue of both FFI cases and 
their FFI-PMCA generated products were treated for 60 min with 50, 10, 2.5 and 
1µg/ml of PK. The protease sensitivity of PrP in brain tissue and the resultant PMCA 
product appeared to differ. PrP digestion was complete when 50 µg/ml of PK was 
used with the human tissue brain homogenate. Whereas when the same PK 
concentration was used to digest the PMCA product detectable PrPres remained 
(Figure 3.14A and B, lane 1 compared to lane 6). Whether this increase in PK 
resistance is the result of misfolding of wild-type human PrPC (as opposed to mutant 
PrP) is not clear, and requires further investigation. 





Figure 3.14 Protease resistance profile of PrPres associated with FFI brain 
homogenate and FFI-PMCA products. Aliquots of brain homogenate 10% brain 
homogenate derived from FFI cases or the amplification products seeded with the 
same material (19µl) were incubated for 60 min at 37ºC with different concentrations 
of PK (50, 10, 2.5, 1µg/ml and non PK). All samples products were detected by 
Western blotting analysis (A) Comparative protease resistance profile observed for 
the FFI case 1 and (B) for the FFI case 2. BH: brain homogenate.  M: Molecular 





3.3.6.6 In vitro conversion of VPSPr PrPSc 
Variably protease-sensitive proteinopathy (VPSPr) is a rare human prion disease 
characterized by the presence of a very particular form of PrPSc that is poorly 
resistant to proteolytic digestion. After PK treatment and Western blot analysis, 
VPSPr samples show a faint ladder of bands into the range of 18-30kDa, with a 
prominent and characteristic band of 7-8kDa. Thus far very little is known about the 
molecular mechanisms associated with the conversion of the PrPC to PrPSc in VPSPr 
patients. In order to evaluate the amplification properties of VPSPr PrPSc, two VPSPr 
cases (from which two different brain region were tested: frontal cortex and 
cerebellum) were homogenized, and incubated in human post mortem brain or 
transgenic mice substrate and subjected to 96 cycles of PMCA. Both substrates 
contained valine at codon 129 of the prion protein gene (PRNP) to match that of the 
VPSPr seeds. 
Independent of the origin of the substrate, PrPres amplification was observed in the 
samples seeded with cerebellar (Figure 3.15A and B, lanes 4 and 8), and showing a 
clear diglycosylated PrPres that was largely absent in the non-amplified samples 
(Figure 3.15A and B, lanes 3 and 7). Frontal cortex seeds did not result in obvious 
amplification (Figure 3.15A and B, lanes 2 and 6). The characteristic 8kDa band, 
present in the frontal cortex and cerebellum of case 1, and in the frontal cortex of 
case 2, did not show evident increase of PrPres signal, suggesting a lack of 






Figure 3.15 Amplification reactions using VPSPr samples. Brain homogenate 
prepared from two VPSPr cases (Cases 1 and 2) diluted 1/5 and incubated with 10% 
brain homogenate from: (A) post mortem tissue and (B) transgenic mouse 
homogenate, both expressing the human form of the prion protein homozygous for 
valine at codon 129 (VV), were subjected to 96 cycles  of PMCA. The VPSPr seeds 
were derived from two regions of the brain, frontal cortex (FC) and cerebellum (Cb). 
Amplified samples are represented by (S for sonicated) and non-amplified by (F for 










The present chapter addresses of the complexity and heterogeneity of human prion 
diseases. Mutations, polymorphic variation of the human prion protein gene, types or 
subtypes are just some aspects of the extensive variability of this multifaceted 
disease. 
The present chapter aimed to assess the ability of PrPSc of different human prion 
diseases to convert the native human PrPC in vitro to its abnormal, disease-associated 
isoform PrPSc. The main objective was to determine, for each subtype of sCJD, the 
substrate PRNP codon 129 genotypes, that are most efficient for the amplification of 
PrPres. Also this chapter explored the in vitro conversion properties of non-standard 
PrPSc types, such as those found in GSS, FFI and VPSPr cases, to propagate in vitro.  
First, the susceptibility of the human PrPC, along the efficacy and reproducibility of 
vCJD PrPSc in vitro conversion was considered.  
 
3.4.2 Susceptibility of human PrPC to be converted in vitro by vCJD, sCJD, 
GSS, FFI and VPSPr PrPSc 
3.4.2.1 In vitro conversion activity of vCJD PrPSc in PMCA 
Diverse sources of the human PrP protein can be used to mimic the in vitro 
conversion process of PrPC into PrPSc. Previously, Jones and colleagues reported the 
competence of humanized transgenic mouse brain and human post mortem brain 
tissue homogenates to act as substrates for the amplification of vCJD and sCJD PrPSc 




fold increase in vCJD PrPres was achieved by Jones and colleagues after each round 
of PMCA (Jones et al., 2009). 
 For the purpose of this thesis, the evaluation of substrates (MM at position 129) 
derived from non-CJD post mortem tissue and humanized transgenic mice, showed 
around 10 and 17 fold amplification respectively after 96 cycles of PMCA. Several 
factors may explain the difference in the amplification efficiency, including the delay 
between deaths and post mortem, cell lysis and proteinase activity, which could be 
expected to diminish the efficiency of the human brain substrate. 
Several groups have used PMCA to address a variety of questions concerning prion 
conversion (Jones et al., 2007, Saborio et al., 2001, Wang et al., 2010, Yokoyama et 
al., 2011). To evaluate the reproducibility of PMCA technique used in this thesis, 
two sets of experiment were performed to examine two variables, 1) experiment-to-
experiment variation (two independent experiments) and 2) equipment effects (two 
different Misonix S-4000 sonicators). Similar amplification levels were observed for 
two independent experiment seeded with vCJD showing around 15 and 16 fold 
amplification respectively. Variations of between 1 and 2 fold amplification were 
observed when comparing two different sonicators (Figure 3.3A and B). It should be 
noted that one of the machines had been used more than the other and anecdotal 
evidence implicates both a “running in” effect and a later time-dependent loss of 
potency applying to this equipment. Considering the relative difference in 
amplification rates, this data suggests an acceptable reproducibility of PMCA 




After evaluating the amplification of vCJD, sCJD seeds were used to assess the 
ability, compatibility and susceptibility of human PrPC to convert in vitro by different 
sCJD PrPSc subtypes.  
 
3.4.2.2 In vitro conversion activity of sCJD PrPSc subtypes in PMCA  
The most common form of CJD is the sporadic, representing around 85% of the 
disease in humans (Ironside, 1998). In order to evaluate the ability to support 
amplification, all sCJD subtypes (MM, MV1, MM2-thalamic, MM2-cortical, MV2, 
VV1 and VV2) were used as a seeds. These seeds were diluted in substrate from 
three different sources (human brain homogenate, humanized transgenic mice and 
293F cells) prior to PMCA. All three subtypes supported in vitro conversion, 
however not all seed types were found to amplify in each substrate. The reactions 
seeded with two sCJD MM1 cases showed a moderate amplification with around 4 to 
5 fold amplification after 96 cycles of PMCA. No amplifications were detected for 
the samples seeded with brain homogenate derived from one MM2t and two MM2c 
sCJD cases. Jones and colleagues reported the in vitro conversion of sCJD MM1, 
sCJD MM2c and MM2t seeds, and showed its dependence on a compatible PRNP 
codon 129 genotype of the substrate source of PrPC (Jones et al., 2008). The results 
presented in this chapter have confirmed the observations of Jones and colleagues for 
the amplification of sCJD MM1 seed, but presented some differences over the 
conversion of sCJD MM2t / MM2c seeds.  
Amplification of PrPres was detected in PMCA reactions seeded with two confirmed 
sCJD VV2 cases, with an amplification rate in the range of 6 to 11 fold. In contrast to 




VV1 failed to amplify in any of the substrates used. PMCA reactions seeded with 
five sCJD MV1 and MV2 cases showed low levels of amplification when compared 
to the MM1 or VV2 seeds. 
Although the amplification of sCJD MM1, VV2, MV1 and MV2 is in agreement 
with the results reported by Jones and colleague, the lack of amplification of sCJD 
MM2t / MM2c and VV1 PrPSc suggests certain degree of contradictions. The use of 
different amplification protocols might be part of the explanation of these 
differences. It is now well recognized that minor differences in experimental 
protocols can have dramatic effects on amplification efficiency, for example the use 
of heparin, inclusion of beads, and the power delivered by different sonicators 
(Barria et al., 2011, Deleault et al., 2007, Jones et al., 2007, Makarava et al., 2013, 
Wang et al., 2010, Yokoyama et al., 2011). The protocol used by Jones and 
colleagues (Jones et al., 2009), exhibited certain degree of differences to the PMCA 
procedure used here. The use of different PrPSc samples could account for part of this 
discrepancy. An important point to note is that the transgenic substrate (PrPC) used in 
both protocols were derived from the same strain of transgenic animals. The apparent 
lack of conversion seed in human PrPC when seeded with sCJD MM2t / MM2c and 
VV1 PrPSc were consistent using three different sources of substrates. 
According to the current subclassification of sCJD (proposed by Parchi and 
colleagues), the majority of the sCJD cases correspond to the subtypes MM1/MV1 
and VV2, accounting for 70 and 16% of the cases respectively. The remaining 






(Parchi et al., 1999b). Attempting to draw a parallel with the sCJD incidence 
reported by Parchi and colleagues, the results presented here suggest that the PrPSc 
types present in the most common sCJD subtypes have a better ability to convert in 
vitro, whereas the less common subtype has a poor amplification potential. sCJD 
MM1 presented a moderate amplification potential with around 4 to 5 fold of 
conversion. sCJD MV1 seeds instead showed low level of amplification (2 to 4 fold). 
The VV2 PrPSc seeds showed the highest level of in vitro amplification with around 
10 fold. sCJD MV2 PrPSc seeds showed little levels of PrPC conversion (2 to 4 fold), 
whereas the other three seeds (sCJD MMt, sCJD MMc and sCJD VV1) did not show 
any signs of conversion. This might be taken to suggest that the amplification 
procedure utilized over the course of this thesis reflects the distribution of sCJD 
subtypes, and also suggests that PrPSc in vitro conversion properties may correlate 
with the in vivo conversion and account in part for the aforementioned distribution. 
sCJD MM1 PrPSc seeds amplified efficiently in MM substrate, but less so in MV or 
VV PrPC containing substrates, which confirms the observation of Jones and 
colleagues. A similar result was observed for reactions seeded with sCJD VV2, 
which showed greater compatibility with the VV substrate, some amplification with 
MV, and less with MM. More interestingly, MV1 PrPSc seeds showed a trend 
towards more efficient amplification in MM substrates compared to VV substrates, 
whereas MV2 PrPSc displayed a preference for VV, rather than MM at the codon 
129. The factors that govern this molecular inclination remain unclear but could 
include the structural conformation of the PrPC / PrPSc sCJD subtypes. In terms of 
PrPC, a close similarity was found by Hosszu and colleagues on the stability and 




molecular behaviour of the two conformations is related more to later states of 
PrPC→PrPSc conversion rather than to the native state of the protein (Hosszu et al., 
2004). In terms of PrPSc, differences in the dynamic of prion propagation and 
susceptibility of conversion have been described in vivo and in vitro for all three 
codon 129 alleles (Tahiri-Alaoui et al., 2004, Lewis et al., 2006, Baskakov et al., 
2005, Head and Ironside, 2012a, Bishop et al., 2010).  
Inoculation of examples of each of the six sCJD subgroups (MM1, MM2, MV1, 
MV2, VV1 and VV2) to a panel of transgenic mice which express the three 
polymorphic form of the prion proteins (MM, MV and VV) revealed that all sCJD 
subtypes were transmissible to at least in one transgenic mice genotype, and 
according to the animal transmission properties, it was possible to discriminate four 
sCJD strains: M1 (which together correspond to the subtypes MM1 and MV1), V2 
(that corresponded to the subtypes VV2 and MV2), M2 (corresponded to MM2 
subtypes), and V1 (that corresponded to the VV1 subtypes) (Bishop et al., 2010). 
Using brain homogenate (a source of PrPC) from the same transgenic mouse strains 
employed in the above mention study, in vitro propagation experiments exhibit a 
certain degree of resemblance with this classification. The PMCA reactions seeded 
with MM1 and MV1 sCJD seeds presented similar in vitro amplification efficiency, 
within the range of 3 to 5 fold amplification (low to moderate), both seeds grouped 
as M1 in the transmission study. The M2 and V1 strains, which correspond to the 
sCJD MM2 and VV1 showed no clinical disease and very low death rate across the 
three mice lines. In vitro, these two subgroups showed a lack of in vitro conversion. 
The strain V2 showed a short incubation period over the mice line homozygous for 




MV). Similarly, PMCA reactions seeded with MV2 and VV2 exhibited moderate to 
robust amplification efficiency when the reactions possessed substrate valine 
homozygous at the codon 129, presenting also a reduction of the amplification 
potential by being incubated into the other two polymorphic substrates. These results 
support the association between codon 129 and the two forms of PrPres founded in 
the CJD cases, the type 1 and 2. Data also reinforce the observation in which type 1 
sCJD has an intrinsic bias to convert MM substrates, contrasting to type 2 which 
displays the trend toward its counterpart valine. Biochemical analysis of 41 patients 
with sCJD showed discrimination of four distinct subgroups, that fit as well with the 
strain classification previously mentioned (Uro-Coste et al., 2008).  
From a molecular perspective, the discrepancy of the in vitro conversion capacities 
observed for sCJD MM1 and MM2 to propagate in vitro could be explained by 
mechanistic and structural properties of each PrPSc subtype (Haldiman et al., 2013, 
Kabir and Safar, 2014, Kim et al., 2011, Kim et al., 2012, Safar, 2012). In vitro 
conversion studies using sCJD MM1 and MM2 revealed an inverse correlation 
between in vitro conversion efficiency and the presence of small aggregates of PrPSc 
(protease sensitive oligomers), which potentially correlate with the duration of the 
disease (Kim et al., 2012). These results could be considered as a potential 
explanation for the molecular behaviour of sCJD MM1 and MM2 in PMCA. 
However it remains to be explained why the reverse effect is observed for sCJD VV1 
and VV2 seed, which presented the highest level of amplification by the sCJD type 
2. If the presence of valine at the codon 129 has an impact on this molecular trend, it 




Overall, the results presented in this chapter confirm the ability of this in vitro 
conversion system to recapitulate aspects of prion strain replication, particularly 






3.4.2.3 In vitro conversion activity of GSS, FFI and VPSPr PrPSc in PMCA 
Soto and colleagues reported that PrPSc generated in vitro by protein misfolding 
cyclic amplification, maintains the biochemical and the biological properties of the 
original seeds. Comparison of the glycoform ratio and the electrophoretic mobility 
after PK digestion and deglycosylation between brain-derived and PMCA-generated 
PrPSc for each strains showed that the biochemical features were maintained upon in 
vitro propagation (Castilla et al., 2008b).  
To evaluate for the first time the in vitro conversion properties of non-standard PrPSc 
types such as those found in GSS, FFI and VPSPr cases, PMCA experiments were 
performed with samples from these rare human prion diseases. The GSS PrPSc did 
show an increase of PrPres formation using either normal human post mortem brain 
tissue or using humanized transgenic substrate (both methionine homozygous at 
codon 129 of PRNP). However, under the same experimental conditions GSS with 8 
kDa fragment seed did not convert. The FFI samples showed PrPres formation after 
PMCA, with a predominantly diglycosylated profile, characteristic of type 2B and 
similar to that of the seed material. PMCA products derived from FFI amplification 
exhibit PrPres formation after a second round of PMCA, thereby confirming their 
capability to propagate in vitro. Previously Soto and colleagues reported that even 
following multiple rounds of PMCA the in vitro generated PrPres has identical 
biochemical and structural properties to the original seed (Castilla et al., 2008b, 
Castilla et al., 2005). However, during the in vitro propagation of FFI samples, the 
PrPres type produced by the in vitro propagation was maintained, but the product 
acquired a higher degree of protease resistance. This may be because the 




form. Genetic prion diseases are usually heterozygous for the causative mutation and 
PrPSc contributions from both the wild-type and mutated forms of the prion protein 
are possible. Chen and colleagues examined the allelic origin of the misfolded form 
of the human prion protein in the FFI brain. They observed that the majority of PrPres 
produced in FFI cases derives from the mutated PrP isoform, with only a small 
contribution from the wild-type protein. In contrast, the genetic condition familial 
Creutzfeldt-Jakob disease, which present the same mutation (D178N) but carrying 
valine at the codon 129, seems to be constituted of both the mutated and the wild-
type misfolded isoforms (Chen et al., 1997).  
The observation presented in this chapter opens the possibility of an interesting 
interaction among the mutated FFI PrPSc recruiting wild-type PrPC to finally produce 
PrPres. To have a better understanding, PMCA and systematic evaluation of mutated 
and wild-types seed and substrates - with their respective polymorphic variations - 
(D178N mutations / M129V polymorphisms) need to be performed.  
To assess whether VPSPr PrPSc has in vitro conversion potential, 96 cycles of PMCA 
were performed. Samples prepared form frontal cortex and cerebellum form two 
VPSPr cases served as the seed. After PMCA, VPSPr PrPSc samples showed an 
increase in PrPres, but only of the higher molecular mass forms found in cerebellum 
rather than the 7-8kDa PrPres fragments found in frontal cortex and cerebellum. An 
unexpected change in the PrPres glycosylation profile was also found (when seed was 
compared with PMCA product) with the appearance of the diglycosylated form in 
cerebellar samples. There was no evident amplification for the small fragment 




It is noteworthy that the form of VPSPr PrPSc that is amplified in PMCA resembles 
that of sCJD (PrPres type 2) whereas the form of PrPSc that does not amplify in 
PMCA resembles that of GSS (PrPres with 8kDa). VPSPr has been proposed (rightly 
or wrongly) to be the sporadic form of GSS (Zou et al., 2010). Whether the different 
PrPSc forms present in VPSPr share similar capacities with PrPSc fragments founded 
in sCJD type 2 or GSS to propagate in vitro is unknown and needs to be explored. 
The results presented in this chapter showed for the first time, an experimental in 
vitro approach to trying to understand the replication of VPSPr PrPSc.  
 
Finally, the results in this chapter show that: (i) PrPSc from different human prion 
diseases have different amplification potentials in vitro, (ii) the appropriate matching 
of codon 129 seed / substrate, influence the abilities of PrPSc to convert efficiently in 
vitro (iii) mutations in the PRNP gene have an effect on the structural conformation 
of PrPSc and seems to give them differential propagation properties, (iv) in situations 
where different type are present such as VPSPr and GSS these have altered in vitro 
amplification in which the forms that are protease resistant over a greater extent of 
the protein (PrPres types 1 and 2) replicate better in vitro than those in which protease 
resistance is lower overall or is confined to the central region of the protein (8kDa 
PrPres). This implies that different conformers and glycotypes present in the brain 
might compete during replication with some environments favouring one over the 
other.  
Macro - and micro - heterogeneity of PrPSc conformers is well accepted and has been 




the impact and consequences of this phenomenon are only beginning to be 
understood.  
Whether the in vitro conversion of the different PrPSc conformations have distinctive 
amplification properties or competence is unclear and remains to be addressed. The 
kinetics of prion propagation by in vitro conversion systems could be used as a 
model in which to evaluate candidate treatment or to develop sensitive diagnostic 











Heterologous (animal:human) amplification of PrPSc from different 




4.1 Introduction  
4.1.1 Overview 
Transmissible spongiform encephalopathies have been described in humans and in a 
range of farmed, captive and free-ranging animal species, including bovine 
spongiform encephalopathy in cattle, scrapie in sheep and goats and chronic wasting 
disease in deer and elk. In humans, Creutzfeldt–Jakob disease.  
Especially following the BSE epidemic in the UK and its link to a new form of CJD 
in humans, the potential for animal prion diseases to affect humans has been 
recognized as a subject of importance. Efforts to understand zoonotic potential and 
evaluate risk have gone hand-in-hand with the development of new in vivo and in 
vitro biological models and a better understanding of prion biology. 
The increasing evidence in favor of the prion hypothesis has involved 
epidemiological, clinical and pathological research on TSEs in humans and animals. 
Increasingly sophisticated experimental models, including the use of non-human 
primates, wild-type, humanized transgenic mice and cell-free molecular conversion 
systems, have been proven very useful in the study of prions. 
 
4.1.1.1 Transgenic mice models 
Ten years after the initial development of trangenesis in animal models, a transgenic 
rodent with a single amino acid substitution (P101L) in the murine prion protein gene 
was developed. This transgenic model showed a neurodegenerative process, similar 
to that in humans affected by a corresponding P102L mutation in the PRNP gene. 




model certain aspects of prion diseases (Hsiao et al., 1990). In order to evaluate the 
association between the PRNP gene expression and the prion transmission, Bueler 
and colleagues intracerebrally inoculated PRNP knock-out mice with high doses of 
scrapie prions. The animals failed to develop any clinical signs of TSE disease, and 
showed no TSE pathology in the brain. The authors concluded that development of 
prion symptoms and pathology is strictly dependent on the presence of PrPC, and that 
incubation time and disease progression are inversely related to the levels of PrPC 
(Bueler et al., 1993).  
Transgenic models have not only been relevant to understand basic questions of 
prion replication, they have also contributed to our understanding of their 
transmission between species.  
 
4.1.1.2 In vitro Prion conversion systems  
In vitro conversion systems attempt to model the conversion mechanism of PrPC to 
the misfolded form of the prion protein. One of the first attempts was developed by 
Coughey and colleagues, in which recombinant hamster PrPC incubated with PrPSc 
and chaotropic agents generated PrPres at the expense of the normal PrP isoform after 
several hours of incubation. Based on this finding a number of in vitro conversion 
models have been developed. Protein Misfolding Cyclic Amplification (PMCA), 
quaking-induced conversion (QuIC) - and their respective variations - have been 
utilized to model several aspects of prion phenomenon, such the potential zoonotic 





4.1.2 vCJD and BSE: The first example of a zoonotic prion disease 
In 1985 the emergence of a new TSE affecting cattle was reported in the United 
Kingdom. The disease, called bovine spongiform encephalopathy or BSE eventually 
affected more than 180,000 animals in the United Kingdom with more than 70,000 
confirmed clinical cases between 1992 and 1993 (Smith and Bradley, 2003). The 
animals affected showed a slowly progressive neurological disorder affecting 
sensation, posture and movement, in which weight loss and reduced milk yield were 
observed. Affected cattle were pathologically characterized by brain stem grey mater 
vacuolisation (Ducrot et al., 2008). 
At the time it was unclear whether BSE would prove a threat to human health.  
BSE is now known to be the pathogen that causes variant CJD (vCJD) in humans, 
whereas scrapie in sheep is thought to pose little or no risk to human health. In 
retrospect, the association between these two pathologies is obvious, but at the time it 
required careful surveillance and research for the connection to be established. 
In 1996 Will and colleagues reported the identification of 10 unusual cases of CJD in 
young individuals in the UK. Active surveillance identified no obvious increase in 
the incidence of CJD in young patients in other European countries. Taking into 
account the young age at onset of the reported cases, a distinctive neuropathological 
profile, the presence of “florid” PrP plaques and the apparent absence of cases with a 
similar profile in Europe, the authors suggested that the appearance of vCJD in the 
UK was linked to the earlier BSE epidemic (Will et al., 1996). 
In order to further test the link between BSE and vCJD, non-human primates were 
intracerebral inoculated with BSE brain homogenate. All three BSE inoculated 




vCJD cases and had a neuropathology including PrPSc deposition reminiscent of that 
seen in vCJD patients. This further supported the hypothesis that BSE is the 
responsible agent for vCJD. Transmission studies in inbred mouse strains reinforced 
this view, and strongly suggested that vCJD is caused by the same strain of agent that 
caused BSE, feline spongiform encephalopathy (FSE) and TSEs in exotic ruminants 
(Ironside, 1998, Bruce et al., 1997). More compiling evidence of a link between BSE 
and vCJD was presented by Scott and colleagues who inoculated bovinized 
transgenic mice with BSE, scrapie, and vCJD. All three inocula propagated 
efficiently; reinforcing the hypothesis that vCJD is caused by the same strain of agent 
that has caused BSE (Scott et al., 1999).  
In order to study the transmissibility of vCJD, sCJD and BSE to humans, transgenic 
animals that express human PRNP valine (V) or methionine (M) at codon 129 were 
inoculated with the aforementioned prion diseases (Asante et al., 2002, Hill et al., 
1997). The transgenic mice presented evidence of transmission for all the inocula. 
However, the molecular signature of the vCJD PrPres generated by the infected 
animals carrying valine at the position 129 did not share the same electrophoretic 
mobility as the original inoculate (Hill et al., 1997) In contrast, the animals carrying 
the polymorphism methionine and inoculated with the same inoculum, conserved the 
molecular pattern as the original inoculum (Asante et al., 2002). To further evaluate 
prion transmissibility of BSE and vCJD and assess effect of codon 129 
polymorphism on human susceptibility, Bishop and colleagues produced humanized 
transgenic mice carrying three distinct genotypes at codon 129: methionine and 
valine homozygous and methionine/valine heterozygous. After inoculation with BSE 




was detected among genotypes. In terms of vCJD propagation, the MM genotype at 
codon 129 was more susceptible than MV, which in turn was more susceptible than 
VV (Bishop et al., 2006). This genotype dependant gradient of susceptibility to 
transmission was suggested by the authors to be explained by a previous study in 
which recombinant human PrP with M at position 129 was shown to be more 
efficiently converted than with 129 V by using a cell-free conversion assay 
(Raymond et al., 1997). 
In order to test whether inter-species transmission barriers could be modelled using 
PMCA, Jones and colleagues tested the ability of BSE and scrapie to convert human 
prion protein of the three major human prion protein polymorphic variants (PRNP 
codon 129 MM, MV and VV) expressed in humanized transgenic mouse brain. The 
results showed that cattle BSE effected efficient conversion of human PrP with a 
human PRNP genotypic preference similar to that of human variant CJD 
(MM>MV>VV) and that scrapie failed to convert the human substrate (Jones et al., 
2009). These results mean that PMCA can faithfully replicate aspects of cross-
species transmission potential and might provide useful additional information 
concerning the molecular barrier to zoonotic transmission. 
 
The establishment of a causative link between BSE and vCJD clearly involved 
epidemiology, clinical and neuropathological investigation, but as shown above, it 
also involved the use of carefully selected in vivo and in vitro model systems. The 
history of BSE / vCJD can be used as a paradigmatic example of how to consider 





4.1.3 Atypical TSEs 
Following the BSE epidemic in the UK, active surveillance programs for animal 
prion diseases in Europe and elsewhere led to the identification of rare atypical forms 
of prion diseases in sheep and cattle.  These included Nor98 or atypical scrapie in 
sheep (Benestad et al., 2003) and two prion diseases of cattle: bovine amyloidotic 
spongiform encephalopathy or L-type BSE (Casalone et al., 2004) and H-type BSE 
(Biacabe et al., 2004) both of which have a pathology and epidemiology distinct 
from classical or (C-type) BSE .  
 
4.1.3.1 Atypical scrapie: Nor98 
First diagnosed in Norway in 1998, Nor98 affected animals presented with 
progressive ataxia and showed vacuolar lesions and PrPSc accumulation in the 
cerebral and cerebellar distinct from classical scrapie.  Nor98 affected sheep are of 
prnp genotypes rarely affected by the classical scrapie. Molecular analysis of 
protease-resistant prion protein in the brain revealed a low Proteinase K resistance 
and the presence of a low molecular weight PrPres band hitherto not described in 
animal TSE. These features suggested the identification of a novel scrapie phenotype 
or strain (Benestad et al., 2003, Tranulis et al., 2011) 
Transmission of scrapie and atypical scrapie to a transgenic mice model that 
overexpresses the ovine prion protein of the ARQ/ARQ prnp genotype revealed 
differences in the transmission rate between these two sheep TSEs. These results 
suggested that the two forms of scrapie correspond to different strains and that the 




scrapie (Arsac et al., 2009). Wilson and colleagues reported a failure of transmission 
of Nor98 in humanized transgenic model mice, arguing a substantial transmission 
barrier between atypical scrapie and humans (Wilson et al., 2012). In agreement with 
Wilson and colleagues, recently, Wadsworth and colleagues showed that transgenic 
mouse that overexpress the human protein presented a lack of infectivity after 
challenge with ovine prions (scrapie and atypical scrapie) (Wadsworth et al., 2013). 
 
4.1.3.2 L-type BSE / H-type BSE: in vivo models  
Intracranial inoculation of cynomolgus monkeys (Macacca fasicularies) with three 
bovine strains, including C-type BSE, L-type BSE and vCJD revealed a distinctive 
pathological profile for L-type BSE.   
These animals had a shorter survival time compared with those challenged with C-
type BSE inoculated macaques, although the dose was 4 times less in terms of the 
amount of tissue compared to C-type BSE inoculum. Furthermore, PrPres was 10 fold 
more concentrated in the C-type BSE inoculum than L-type BSE material. These 
results show the susceptibility of non-human primates to L-type BSE and suggest a 
higher pathogenicity of L-type BSE compared to the C-type BSE (Comoy et al., 
2008). 
Active animal TSE surveillance programs worldwide have identified H-type BSE 
and L-type BSE in countries outside the European Union (e.g. Japan). The evaluation 
of the infectivity and the prion disease phenotype of the Japanese L-type BSE 
isolates was assessed by intracranial inoculation of cynomolgus macaques with 




The incubation periods and the duration of the disease were approximately 2/3 
shorter than those of C-type BSE, similar to the previous observations made by 
Comoy and coworkers.   This evidence suggests once again that L-type BSE may be 
more virulent than the C- type BSE in non-human primates (Ono et al., 2011).  
With the potential evidence that L-type BSE could be more virulent than C-type 
BSE, researchers have focused on quantifying the risk that L-type BSE and H-type 
BSE pose to the humans health. Beringue and colleagues reported that humanized 
PrP 129 methionine overexpressing mice were susceptible to L-type BSE, 
showing100% attack rate and shorter incubation periods compared with C-type BSE 
(Beringue et al., 2008). In contraposition, H-type BSE failed to transmit the disease. 
The authors suggested a higher theoretical risk of transmission of L-type BSE to 
humans compared to C-type BSE (Beringue et al., 2008).  
Recently, a wide range of atypical animal prion diseases were used to challenge 
humanized transgenic mice that express physiological levels of the human prion 
protein (Wilson et al., 2012). In contrast to the findings of Beringue and colleagues, a 
substantial transmission barrier between the atypical forms of BSE and humans was 
observed, given that L-type BSE and H-type BSE did not show any signs of disease 




4.1.4 Chronic wasting disease  
First recognized as a TSE in the early 1980s by Williams and colleagues(Williams 
and Young, 1980), chronic wasting disease (CWD) is a transmissible spongiform 
encephalopathy that affects North American mule deer (Odocoileus hemionus), 
white-tailed deer (Odocoileus virginianus), Rocky Mountain elk (Cervus elaphus 
nelsoni), and less frequently moose (Alces alces shirasi). After being first identified 
in Colorado and Wyoming, the disease has been identified in 15 states across USA, 
two Canadian provinces and 15 states and provinces in South Korea (Reviewed by 
Saunders S, 2012) (Saunders et al., 2012). Clinical symptoms usually presented in 
animals affected by CWD are progressive loss of weight, pronounced behavioral 
changes, excessive salivation, ataxia with head tremors.  
 
4.1.4.1 Surveillance for CWD-related disease in human 
The possibility of CWD affecting human health will be a function of exposure to the 
CWD agent (or agents) and of human susceptibility to these agents. Dose and route 
could reasonably be expected to be relevant aspects of exposure and as with other 
human prion diseases the PRNP codon 129 polymorphisms may be expected to exert 
an effect on human susceptibility to CWD. The disseminated nature of PrPSc and 
infectivity in animals infected with CWD, coupled with the popularity of deer 
hunting in CWD endemic areas, suggests the most likely form of human exposure to 
CWD infectivity is by the oral route. CJD surveillance systems in CWD affected 
countries have been alert to this possibility and have been vigilant for CJD patients 




game hunting and venison consumption. The literature contains five such cases 
(Belay et al., 2001, Anderson et al., 2007). The results of intensive investigation 
provided diagnoses of sporadic CJD, (Belay et al., 2001) familial CJD and early-
onset Alzheimer’s disease (Anderson et al., 2007) and on balance the authors 
discounted a link to CWD, but conceded the difficulties involved in coming to this 
conclusion. It is important to note however that the specific features of an animal 
prion disease need not be conserved when zoonoses occur. Neither the characteristic 
vCJD neuropathology nor the pronounced peripheral tissue involvements of vCJD 
are features of BSE in cattle. The absence of neuropathological similarities between 
CWD and any individual cases of human prion disease is not sufficient grounds to 
discount CWD as a human pathogen. Continued surveillance and epidemiology are 
required. In parallel the susceptibility of humans to the CWD agent has been 
investigated using in vivo and in vitro model systems.  
 
4.1.4.2 Transmission and bioassays in cervids 
CWD is believed to be horizontally transmitted between deer by direct contact (e.g. 
by saliva) and indirectly through pasture contamination with urine or faeces 
(Reviewed by Miller M, 2003) (Miller and Williams, 2003). The experimental 
exposure of uninfected mule deer to contaminated excreta and decomposed carcasses 
of infected animals show that CWD prions can persist in the environment for two 
years, maintaining their infectivity (Miller et al., 2004). Using bioassays in deer 
Mathiason and colleagues evaluated the presence of CWD prions in body fluids and 




transmission of the disease using repeated environmental exposure. Positive results 
were found, and blood and saliva were detected as a potential source of CWD prions. 
Additionally, the infectious agent was sufficient to transmit the disease from the 
environment (experimentally shed)  to naive deer (Mathiason et al., 2009). These 
findings reinforce the idea that there is an indirect transmission between deer.  
 
4.1.4.3 Non-human primates model 
In order to test the transmissibility of CWD to non-human primates, Marsh and 
colleagues reported the experimental challenge of two squirrel monkeys (Saimiri 
sciureus) with brain homogenate of CWD infected mule deer. The two animals were 
euthanized at 31 and 34 months post inoculation. Both animals showed a progressive 
neurological disease, detection of PrPres by Western blot and histopatological 
spongiform changes in the brain, all consistent with a TSE (Marsh et al., 2005).  
Based on the evidence that non-human primates are susceptible to CWD infection, 
Race and colleagues evaluated (i) the susceptibility of cynomolgus macaques 
(Macaca fasicularis) and squirrel monkeys to CWD infection, (ii) the different 
possible routes of inoculation (intracranial and oral), and (iii) various sources of the 
inoculum (representing wild and captive deer and elk). Intracranial inoculation of 
squirrel monkeys showed that independent of the origin, 80% of the animals 
developed signs of a spongiform encephalopathy and accumulated PrPres in the brain. 
Oral exposure with the infectious agent showed 15% of the squirrel monkeys had the 
presence of PrPSc in the brain and in peripheral tissue. In contrast, cynomolgus 




disease 70 months post inoculation. Considering the relationship of the two non-
human primates species to humans, the authors suguested a pronounced species 
barrier to CWD in humans (Race et al., 2009). 
 
4.1.4.4 Transgenic mouse models 
To model the zoonotic transmission of CWD prions to convert human prion protein, 
humanized transgenic mice codon 129 methionine lines (overexpressing the 
transgene PrP one and two fold) were inoculated with CWD elk brain homogenate. 
After approximately 700 days none of the transgenic mice showed signs of prion 
disease. The authors concluded that a substantial species barrier to transmission was 
present (Kong et al., 2005). Sandberg and colleagues confirmed this observation by 
showing that CWD fails to transmit to transgenic mice irrespective of whether the 
mice expressed (i) bovine, ovine or human PrP, (ii) the human 129 MM or 129 VV 
PrP allelic variants, or (iii) whether the CWD isolates were from mule deer, elk or 
white tailed deer (Sandberg et al., 2010, Tamguney et al., 2006). 
In order to evaluate the transmissibility of a range of animal TSEs to transgenic 
animals that express physiological levels the human prion protein, atypical scrapie, 
C-type BSE, H-type BSE, L-type BSE and CWD were used to challenge humanized 
transgenic mice constructed by gene replacement. All TSEs, including the CWD 
isolate used (derived from white tail deer infected animal), failed to produce disease 
(or signs of infection) on first experimental passage, whether the mice were 




suggesting a substantial species barrier between the atypical TSEs and humans 
(Wilson et al., 2012). 
 
4.1.4.5 In vitro conversion systems: modelling the human PrP susceptibility to 
chronic wasting disease 
One of the earliest attempts to assess molecular barriers of the human prion protein 
conversion by animal prion diseases was performed by Raymond and colleagues. 
They compared the ability of CWD, C-type BSE, sheep scrapie, and CJD brain 
homogenates to convert human prion protein that was metabolically labelled and 
purified from transfected cells (Raymond et al., 2000). A limited conversion of 
human PrP by CWD, C-type BSE and scrapie was observed, however, the model 
system was unable to discriminate between the molecular susceptibility of the two 
PRNP genotypes (PRNP 129 M or V polymorphisms) used in the conversion 
process.  These results revealed an overall substantial molecular barrier to conversion 
of PrPC by CWD, C-type BSE and sheep scrapie prions (Raymond et al., 2000). 
Using PMCA, Kurt and colleagues reported failure to support in vitro conversion of 
the human prion protein (independent of the PRNP 129 M or V polymorphisms) 
when the reaction was seeded with CWD brain homogenate (Kurt et al., 2009). In 
contrast, Barria and colleagues observed that extensive in vitro conditioning of a 
mule deer-CWD isolate by PMCA in cervid substrate (or passage in cervidised mice) 
allowed for subsequent efficient in vitro amplification in a humanized transgenic 




In this chapter, a side-by-side comparison of the zoonotic potential of a wide range of 
animal prions including BSE, atypical BSE, scrapie, atypical scrapie, and CWD 
using PMCA was conducted to develop an in vitro method of assessing the 





4.2 Material and methods: 
4.2.1 Biological samples  
4.2.1.1 Animal prion disease tissues 
Ovine, bovine and cervid frozen brain tissue from prion disease affected and 
unaffected animals were obtained by request from the Animal Health Veterinary 
Laboratory Agency TSE Archive (AHVLA, Weybridge, UK). The cases and brain 
regions supplied were selected on the basis of proven disease status and of brain 
region with an expected high PrPSc burden, characteristic of the particular prion 
disease. The prion disease status of the animals involved was determined at AHVLA 
and/or CFIA Ottawa Laboratory by neuropathology and prion protein 
immunohistochemistry. The classical scrapie specimen was of brain stem from a 
field suspect of the prnp ARQ/ARQ genotype and a brain stem specimen from an 
unaffected scrapie suspect of the same genotype was also supplied. The atypical 
scrapie specimen was of parietal cortex, also from a field suspect, but of the 
ARQ/AHQ genotype and a corresponding negative control animal specimen was also 
supplied. The classical or C-type BSE samples were of brain stem from confirmed 
positive C-type BSE suspects obtained through passive surveillance and the 
corresponding negative control specimen was similarly obtained. Both the H- and L-
type BSE specimens were of frontal cortex from successful experimental bovine 
transmissions conducted at AHVLA Weybridge. Mid-brain tissue from a confirmed 
CWD positive and control negative (unaffected) elk (both with prnp codon 132MM 
genotype) was also supplied through the AHVLA. Detailed lists of the analysed 






Species Thesis Samples ID Brain region  
BSE 
 
Bovine BSE-1 Brain stem 
BSE Bovine BSE-2 Brain stem 
 




Cervid (elk) CWD-1 Mid-brain 
Atypical scrapie Ovine Scrapie-2 Parietal cortex 
    
L-type BSE Bovine BSE-3 Frontal cortex 
    
H-type BSE Bovine BSE-4 Frontal cortex 
 
Table 4.1 TSE diagnosis, species and brain region for the animal prion disease 





Species Thesis Samples ID Brain region  
Bovine Bovine-1 Brain stem 
 
Bovine Bovine-2 Brain stem 
 
Bovine Bovine-3 Frontal cortex  
 
Ovine Ovine -1 Brain stem 
 
Ovine Ovine-2 Parietal cortex 
 
Cervid (elk) Cervid-1 Mid-brain 
 
Table 4.2 Species and brain region of unaffected TSE animal specimens selected 





4.2.1.2 Transgenic mouse brain tissue 
The entire brain form inbred humanized transgenic mouse lines expressing human 
PrPC of the PRNP codon 129 methionine (HuMM) and valine (HuVV) were used for 
substrate preparation and PMCA reactions (Bishop et al., 2006). 
 
4.2.1.3 Human cell lines 
The production of PMCA substrates from stably transfected human 293F cells is	  
described in Material and Methods Chapter 3, section 3.2.1.3 (Yokoyama et al., 
2011).  
 
4.2.1.4 Human brain tissues 
Human brain tissues (frontal cortex) were sampled from a frozen half brain collected 
at autopsy with the appropriate consent for tissue retention and research use. 
Selection criteria and ethical approval are described in General Material and 
Methods, section 2.1.2.1. The vCJD specimen was from a patient (PRNP codon 129 
MM) with definite variant CJD as defined by established criteria (General Material 
and Methods, section 2.1.2.1). The non-CJD human brain specimens used for PMCA 
substrate preparation were frontal cortex from patients with Guillain-Barre syndrome 
(PRNP codon 129 MM) and dementia with Lewy bodies (PRNP codon 129 VV). 
Ethical approval for the use of these tissues in this chapter is covered by LREC 
2000/4/157 (Professor James Ironside). Detailed lists of the non-CJD human brain 




4.2.2 Methods  
4.2.2.1 Preparation of brain PMCA substrates 
Human brain and transgenic mouse brain PMCA substrates were prepared exactly as 
described in General Material and Methods (Chapter 2) 
 
4.2.2.2 Preparation of prion disease brain PMCA seeds 
Homogenates (10% w/v) of C-type BSE, scrapie, CWD, L-type BSE, H-type BSE 
atypical scrapie and vCJD brain were prepared exactly as described in General 
Material and Methods (Chapter 2) 
 
4.2.2.3 PMCA procedure 
PMCA reactions were prepared exactly as described in General Material and 
Methods (Chapter 2) 
 
4.2.2.4. Protease digestion and Western blot analysis  
4.2.2.4.1 Western blot analysis 
Western blotting experiments were prepared exactly as described in General Material 









4.2.2.4.2 Detection of PrP total and PrPres  
After proteins were electro-transfered to a PVDF membrane, blots were blocked with 
2% milk for 1h followed by incubation with 3F4 or 6H4 antibodies exactly as 
described in General Material and Methods (Chapter 2). The monoclonal antibody 
9A2 was obtained from Central Veterinary Institute of Wageningen UR, Lelystad, 
The Netherlands (Jacobs et al., 2007).  
The antibody 6H4 recognize an epitope in the protease resistant core of human PrP, 
which is immunoreactive with amino acids 145-153 and it cross-reacts with bovine, 
ovine and cervid PrP. The antibody 3F4 also recognize the human PrP (PrPC and PrP 
27-30) presenting immunoreactivity with amino acids 109-112, but 3F4 does not 
recognize PrP from species other than human and hamster. The combination of 
protease digestion and detection by 3F4 in these experiments therefore provides a 
very sensitive method for the detection of newly formed human PrPres (Jones et al., 
2009, Jones et al., 2011, Barria et al., 2011). The antibody 9A2 reacts with human 
PrP amino acids 99-101 and cross-reacts with ovine, bovine and cervid PrP 
 
4.2.2.4.3 Western blot image analysis 
Western blot image analyses were performed using, Image Lab software version 






4.3.1 Characterisation of animal prion disease tissues 
The animal TSE brain homogenates to be used as seeds in PMCA experiments were 
first characterised for the presence of total PrP and PrPres (Figure 4.1). The presence 
of total PrP was observed in all samples in the form of two major bands in the 20-
40kDa molecular mass range, probably corresponding to full-length diglycosylated 
PrP (upper band) and N-terminally truncated diglycosylated or full length 
monoglycosylated PrP (lower band). The levels of total PrP and the electrophoretic 
pattern were broadly similar between prion disease samples and the corresponding 
negative control (unaffected) (Figure 4.1A). However, after proteinase K treatment 
(50µg/ml), clear differences were noted in the amount of PrPres contained in the TSE 
specimens (Figure 4.1B). PrPres was most abundant in classical scrapie and CWD 
samples (Figure 4.1B, lanes 3 and 4), lower levels were detected in C-, H- and L-type 
BSE samples (Figure 4.1B, lanes 1, 2, 6 and 7) and undetectable level in atypical 






Figure 4.1 Determination of total PrP and PrPres level present in the animal 
tissues. (A) To characterize the prion protein expression levels (total PrP), brain 
homogenates were analysed by Western blot. One µl of 10% brain homogenate for 
each animal prion disease samples (odd lanes) were loaded in parallel to unaffected 
animal prion disease control (even lanes) for comparative purposes. (B) Nineteen 
microliters of each 10% weight to volume homogenate was loaded in each lane. To 
detect the PrPres present into the samples, proteinase K (PK) digestion (50µg/ml) was 
performed to remove PrPC and was then analysed. (+) Samples denotes animal prion 
disease specimens and (-) the normal animal specimens. M: Molecular marker.  The 





4.3.2 Conversion of human PrP (PRNP codon 129 methionine) by animal prion 
disease samples 
The susceptibility of the human PrP (PRNP codon 129 MM) to in vitro conversion 
was evaluated by PMCA using BSE, L-type BSE, H-type BSE, scrapie, atypical 
scrapie, and CWD seeds diluted 1/3 in 10% human brain homogenate substrate. The 
vCJD seed was diluted 1/100. Western blotting analysis with mAb 3F4 showed 
formation of human PrPres in the samples seeded with BSE and vCJD. (Figure 4.2A, 
lanes 2, 4, 14 compared with lanes 1, 3 and 13). Scrapie, L-type BSE, H-type BSE 
and atypical scrapie did not show detectable human PrPres (Figure 4.2A, lanes 6, 10, 
12 and 16). However, 3F4 did detect the presence of human PrPres in the reaction 
seed with the CWD brain homogenate (Figure 4.2A, lane 8). The corresponding 
Western blot analysis using the mAb 6H4 (which detects animal PrPres in the animal 
seeds and newly formed in the human substrate) shows that amplification in the BSE 
and vCJD seeded samples is marked (Figure 4.2A and B). Repeating a similar 
experiment with the animal prion disease seeds, but using humanized transgenic 
mouse brain (PRNP codon 129 MM) as the PMCA substrate, BSE and vCJD shows a 
robust amplification and readily detectable using 3F4 antibody (Figure 4.2B, lanes 2, 
4, 14 compared with lanes 1, 3 and 13). Clear PrPres formation was detected in the 
PMCA reactions seeded with CWD (Figure 4.2B, lane 8). However, reactions seeded 
with scrapie and H-type and L-Type BSE did not show clear detectable human PrPres 










Figure 4.2 PMCA of PRNP codon 129 MM human brain homogenate and 
humanized transgenic mice brain homogenate seeded with BSE, scrapie, CWD, 
L-type BSE, H-type BSE, vCJD and atypical scrapie. PMCA reactions using 
PRNP 129 MM human brain homogenate (A) and PRNP 129 MM humanized 
transgenic mouse brain homogenate (B) were seeded TSEs brain homogenate as 
indicated. Lanes 1, 3, 5, 7, 9, 11, 13 and 15 show the samples without PMCA. 
Samples in lanes 2, 4, 6, 8, 10, 12, 14 were subjected to PMCA. Western blotting 
used the mAb 3F4 that allows for the specific detection of human PrP. To compare 
the PrPres levels present in the seeds (prior to the PMCA) mAb 6H4 was also used. F: 





4.3.3 Comparison of the conversion of codon 129 MM and codon 129 VV human 
PrP by CWD brain homogenate 
Serial dilutions (1/6, 1/12 and 1/24) of CWD brain homogenate were incubated in 
substrates prepared from human brain, transgenic mouse brain and 239F cells 
expressing human PrP with either methionine or valine at codon 129 in order to 
evaluate their ability to support amplification by PMCA. Irrespective of origin 
(human post mortem tissue brain, transgenic mouse brain, and 293F human cell line) 
all three PRNP codon 129 methionine substrates supported amplification, albeit with 
slightly different efficiencies (Figure 4.3A, B and C). Western blotting analysis using 
mAb 3F4 also indicated in vitro prion conversion in all three PRNP codon 129 valine 
PrP substrates (Figure 4.3 D, E and F), even though the level of amplification were 
lower than the allele codon 129 methionine. As a control, PMCA reactions using 
vCJD brain homogenate as a source of PrPSc (seed) were conducted using these same 
three source of substrates (human post mortem tissue brain, transgenic mouse brain, 
and 293F human cell line). The vCJD sonicated reactions showed higher levels of 
PrPres formation compared with non-sonicated samples. Similar to observed in the 
reaction seeded with CWD PrPSc, lower level of amplification were observed over 






Figure 4.3 Susceptibility of human brain, humanized transgenic mouse brain 
and 293F cell extract PrPC to in vitro conversion by CWD brain homogenate. 
PMCA seeded with serial dilutions of CWD brain homogenate (1/6, 1/12 and 1/24) 
were mixed with three different sources of substrate. (A and D): human brain 
homogenate. (B and E): transgenic mouse that express the human prion protein and 
(C and F): 293F human cell extract. The substrates contained human PrP129 MM 
(A, B and C) or PrP 129 VV (D, E and F). These same substrates were seeded with 
vCJD brain homogenate at 1/100 dilution (G). Odd numbers show the samples 
without PMCA. Even numbered lanes were subjected to PMCA. The PrP detection 
antibody was 3F4.	  F: Frozen samples; S: Sonicated samples; M: Molecular Marker. 





4.3.4 Conversion of human PrPC by CWD prior to sarkosyl precipitation	  
In order to discount the possibility that the amplification levels seem in PMCA 
reactions seeded with CWD brain homogenate depend on the presence of cervid PrPC 
in the seed, the CWD PrPSc in the seed was collected by virtue of its sodium lauroyl 
sarcosinate (sarkosyl) insolubility properties and compared with an equivalent 
volume (seed dilution) of CWD brain homogenate. The collected-insoluble CWD 
material and CWD brain homogenate were used to seed PMCA. Serial dilution of 
CWD brain homogenate (seed) were performed in PBS (1/12 and 1/24). The diluted 
CWD samples were mixed with an equal volume of sarkosyl 20% (dissolved in PBS) 
and incubated for 15 minutes (Morales et al., 2008). Samples were centrifuged at 
100000g for 1 hour and resuspended in an equivalent volume of transgenic mouse 
brain homogenate (substrate) codon 129 MM prior to amplification (100µl). After 96 
cycles of PMCA, PrPres formation was detected by 3F4 antibody (Figure 4.4, lanes 2, 
4, 6 and 8). The ability of the CWD brain specimen to seed conversion of human 
PrPC was found to be retained by this sarkosyl insoluble (PrPres enriched) preparation 
compared with the respective control (1/12 and 1/24) (Figure 4.4, lanes 6 and 8) and 
is therefore unlikely to represented cervid PrPC added to the reaction as part of the 






Figure 4.4 Partial purification of CWD PrPSc prior to the in vitro conversion. To 
confirm human PrPC in vitro conversion by cervid PrPSc, a sarkosyl insoluble CWD 
brain homogenate was prepared. The detergent insoluble sample was resuspended in 
an equivalent volume of 10% humanized transgenic mouse brain homogenate. Serial 
dilution of CWD seeds (1/12 and 1/24) were performed. Control samples were not 
fractionated by detergent insolublity. Lanes 1, 3, 5 and 7 show the samples without 
PMCA. Lanes 2, 4, 6 and 8 show the corresponding samples after PMCA. F: Frozen 






4.3.5 Relative conversion efficiency of human PrP (129 MM) by different animal 
prion disease samples 
The previous in vitro prion conversion experiments were normalised by the amount 
(weight/volume) brain homogenate used as seed rather than by the amount of PrPres 
present in the seed sample. It was therefore possible that the abundant PrPres present 
in the CWD specimen (Figure 4.2B) was responsible for the amplification by human 
PMCA substrates (Figure 4.2A and B). For this reason the PrPres present in each 
sample was estimated by densitometry and the amount of 10% brain homogenate 
from the different animal prion diseases used in the PMCA reaction was adjusted to 
give roughly equivalent amounts of PrPres seed in each PMCA reaction. The amount 
of PrPres in the atypical scrapie specimen was so low that a maximum amount of 
homogenate was used (dilution 1/2). The results of the Western blot analysis of all 
seed PrPres normalised PMCA reactions using mAb 3F4 (Figure 4.5 A) confirmed 
that amplification was a function of PrPSc / PrPC compatibility (seed / substrate) and 
not simply PrPres abundance. After 96 cycles of PMCA, BSE, vCJD showed higher 
levels of PrPres formation (Figure 4.5A, lanes 2, 4 and 14). CWD seed also supported 
the amplification of human prion protein (Figure 4.5A, lanes 8). However, scrapie, 
and atypical scrapie did not show an increase of PrPres signal by the 3F4 antibody 
(Figure 4.5A, lanes 6, 10, 12 and 16). L-type BSE, H-type BSE showed a small 
increase of signal detected on the amplified reactions. In order to assess whether this 
increase of signal corresponded to human PrPC, a second round of PMCA was 




Western blot analysis using mAb 6H4 confirmed that an equivalent amount of PrPres 
was incorporated to each reaction previous to the PMCA (Figure 4.5B, lanes 1, 3, 5, 










Figure 4.5 Relative conversion efficiency of human PrP (129 MM) by different 
animal prion disease samples. Brain homogenates from animal prion diseases were 
seeded at different volumes adjusted to give roughly equivalent amounts of seeding 
PrPres and amplified using PrP 129 MM containing human brain substrates. Human 
PrPres formation was detected by the 3F4 antibody (A) and seed and newly formed 
PrPres detected using the 6H4 antibody (B). F: Frozen samples; S: Sonicated samples; 




4.3.6 Properties of BSE, CWD and vCJD amplification products in a second 
round of PMCA 
In order to determine whether the PMCA products generated by 96 cycles of PMCA 
maintained the ability to convert human PrP carrying the amino acid methionine at 
the position 129, amplification products originally seeded with BSE, vCJD and CWD 
amplification products were normalized and serially diluted (1/3, 1/6, 1/12, 1/24) in 
fresh human brain tissue homogenate (PrP 129 MM) and subjected to a second round 
of PMCA. Densitometric analysis (Figure 4.6) showed that human-PMCA-BSE had 
an amplification factors of 9.05 fold determined for the first dilutions (Figure 4.6A, 
lanes 1 and 2). The equivalent amplification factors for CWD were 5.5 fold (Figure 
4.6B, lanes 1 and 2). As expected vCJD showed a very much higher propagation 
efficiency extending to lower seed dilutions (Figure 4.6C, lanes 1,2, 3,4, 5,6, 7,8). 
The amplification factor was calculated by densitometry measurement, dividing the 
sonicated (PMCA) value by the value determined for the sample prior to PMCA. The 
determination of the PMCA amplification factor were following the procedures 
described in the section: PMCA normalization and quantification in General Material 






Figure 4.6 Properties of BSE, CWD and vCJD amplification products in a 
second round of PMCA. (A) human-BSE, (B) human-CWD and (C) human-vCJD 
(from a previous round of PMCA) PMCA products were supplemented with fresh 
human brain homogenate and subjected to a second round of PMCA. The reactions 
were normalized by PrPres level and the product diluted (1/3, 1/6, 1/12, 1/24) in fresh 
human brain homogenate (PRNP codon 129 MM) prior to PMCA. Odd numbers 
correspond to samples without PMCA and even numbers to the reactions after 





4.3.7	  Molecular typing of the CWD-human-PMCA PrPres product  
In order to perform a molecular typing analysis of  the PrPres material derived from 
the human CWD amplification product, the electrophoretic mobility and 
glycosylation profile of CWD-human PMCA product was evaluated against PrPres 
material derived from cases of sCJD MM1, sCJD VV2 and vCJD. Western blot 
analysis of PrPres fragments produced by in vitro amplification of human post 
mortem brain homogenate (as a source of PrPC) incubated with CWD brain 
homogenate (as a source of PrPSc), showed that after incubation with 3F4 antibody 
the PrPres fragment share the electrophoretic mobility and glycosylation profile of 






Figure 4.7 Molecular typing of human-CWD-PMCA products: comparison with 
vCJD, sCJD VV2, sCJD MM1 standards. The CWD-PMCA product was treated 
with proteinase K (50µg/ml) and analysed by Western blotting. vCJD (lane 1), sCJD 
VV2 (lane 2) and vCJD (lane 4) were used as a PrPres type standard. The human 
CWD PMCA product derived from amplification in a human substrate (PRNP codon 
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Table 4.3 Comparison of the outcomes of experimental transmission and in vitro 
conversion studies of chronic wasting disease in human (PMCA substrate 
derived from human post-mortem tissue), humanized, and nonhuman primate 
model systems. Numbers in parentheses denote the stated expression levels of PrPc 
in the animal species and cell lines used. PrP, prion protein; (+), positive; (-), 
negative; PrPc, host’s normal celular PrP. Blank cells indicate that data of this 






TSEs by definition are transmissible. Through experimental investigation it has been 
shown that prion transmissibility is multifactorial and highly complex. In addition to 
infectious dose and route, a transmission barrier effect has been described to be 
involved in the transmission of this infectious agent. Although it is reasonable to 
suggest – within the context of the prion hypothesis – that the basis for a species 
barrier would be prnp sequence similarity, however, evidence indicates that this 
factor is a poor predictor of transmissibility.  A possible explanation of this is that the 
interactions between PrPC and PrPSc occurs in the form of native PrPC and misfolded 
and aggregated PrPSc conformers, nevertheless, the effect of species-specific 
sequence difference on PrPC folding are not well understood. However, there is clear 
evidence that different prion strains are associated with different PrPSc conformers 
and glycotypes which may exist as a quasi-species or molecular cloud (Collinge and 
Clarke, 2007, Makarava and Baskakov, 2013). Under such a complex scenario 
molecular compatibility might very well be hard to predict. 
With the aim of isolating and studying the molecular effects of compatibility on 
transmission barriers, Jones and colleagues conducted cell-free prion protein 
conversion experiments by PMCA using homogenates of bovine and ovine prion 
disease brain samples to seed brain homogenates containing human PrP, assessing 
the extent of conversion by detection of human protease-resistant prion protein 
(PrPres). The results indicated that samples of BSE converted the human PrPC, with a 
codon 129 preference similar to that of vCJD. Samples of classical scrapie did not  
convert human PrP. Remarkably, a sheep BSE isolate resembled BSE and vCJD in 




sequence similarity in determining what might be termed a molecular transmission 
barrier (Jones et al., 2009). 
In this chapter, the same approach was applied to study a series of emergent animal 
prion disease which may pose a risk to human health. Under the PMCA settings used 
in this thesis, L-type BSE, H-type BSE and atypical scrapie isolates fail to convert 
the human PrPC. The CWD seeds utilized did convert human PrPC, although less 
efficiently than classical BSE. These observations were confirmed normalising the in 
vitro conversion assay not only by tissue weight but also by PrPres abundance, and 
whether the PMCA substrate was derived from three sources of substrate (human 
post mortem tissue, humanized transgenic mouse or human cell line that overexpress 
the human PrPC). The conversion of human PrPC by CWD brain homogenate after 
PMCA was shown to be dependent on amino acid position at codon 129, with a more 
efficient amplification for the methionine substrate than the valine one. Furthermore, 
molecular typing of the CWD amplified products show that the PrPres material 
resemble in the most common form of human prion disease which is sporadic CJD 
MM1 type.  
Atypical scrapie PrPSc has shown a reduced PK resistance compared with the 
classical scrapie (Klingeborn et al., 2006). In the PMCA protocol used in this study, 
both seed and substrate were treated with 50µg/ml PK prior to Western blot analysis. 
This pre-treatment may have eliminated protease sensitive PrPSc associated with 
atypical scrapie. Therefore, in order to evaluate the conformational properties of the 
PMCA products derived from the amplification of human PrPC seeded with atypical 
scrapie, an alternative method such as the conformation-dependent immunoassay that 




Several attempts to determine the transmissibility of these prions disease to humans – 
thereby enabling to assessment of their zoonotic potential – have employed 
experimental challenge of non-human primates, humanized PrP transgenic mice, and 
cell-free assays showing some contradictory results. Marsh and colleagues and Ono 
and colleagues reported a successful transmission of CWD and L-type BSE to non-
human primates, with L-type BSE showing a different pathological profile and a 
shorter incubation period than C-type BSE (Marsh et al., 2005, Ono et al., 2011). 
Using a transgenic murine model, Beringue and colleagues reported that humanized 
overexpressing PrP mice carrying methionine at the position 129, were susceptible to 
L-type BSE with 100% attack rate and shorter incubation time compared with C-type 
BSE, suggesting that L-type BSE was more virulent than C-type BSE and may 
present a higher theoretical risk of transmission to humans (Beringue et al., 2008). 
Contrary to this finding, H-type BSE failed to transmit the disease in the same animal 
model. 
To assess the potential transmissibility of CWD to humans, Kong and colleagues 
challenged humanized transgenic mice models. They fail to transit CWD (from elk 
brain homogenate) to animals expressing human PrP encoding methionine at the 
position 129 (Kong et al., 2005). Sandberg  and colleagues  and Tamgüney and 
colleagues confirmed the previous report of Kong and colleagues that CWD failed to 
transmit to a transgenic mouse models, irrespective of whether the mice expressed (i) 
bovine, ovine or human PrP, (ii) the human 129 MM or 129 VV PrP allelic variants, 
or (iii) whether the CWD isolates were from mule deer, elk or white tailed deer 




In addition to the uses of in vivo models to evaluate the potential transmission of 
animal prions to the humans, in vitro conversion approaches have also been reported 
(Barria et al., 2011, Castilla et al., 2008a, Jones et al., 2009, Kurt et al., 2009). 
Raymond and colleges compared the ability of CWD, C-type BSE, sheep scrapie, 
and CJD brain homogenates to convert radioactively labelled PrPC expressed in 
transfected cells. They obtained limited conversion of human PrPC by CWD, C-type 
BSE and scrapie (Raymond et al., 2000). Using a more efficient  in vitro conversion 
system, Kurt and colleagues reported  failed  to support CWD amplification in 
human transgenic mouse substrate expressing both methionine and valine codon 129 
by PMCA(Kurt et al., 2009). However, extensive in vitro conditioning of a CWD 
isolate by PMCA in cervid substrate (or serial round in substrate from cervidised 
transgenic mice) was found to be sufficient to cross the species barrier and allow 
efficient in vitro amplification in humanized transgenic mouse substrate for this 
particular seed (Barria et al., 2011). The comparison of these studies is difficult due 
to (i) differences between in vivo vs. in vitro approaches, (ii) different transgenic 
constructs employed, and (iii) the technical details of the chosen conversion assay 
(summarised in Table 4.3). Another potential significant difference between these 
studies is the nature of the CWD isolate employed. Considering that CWD affects 
different deer species, that interspecies polymorphism in the prnp sequence has been 
detected, and that CWD also occurs in the form of different biological strains of 
agents (Angers et al., 2010, Perrott et al., 2012), it is reasonable to suggest that 
different strains of CWD may have a role in determining transmissibility and in vitro 




adaptation of a CWD isolate by serial PMCA, similar to that produced by in vivo 
sub-passage (Meyerett et al., 2008). 
Among in vivo studies, the most directly comparable study to the present research is 
the one performed by Wilson and colleagues (Wilson et al., 2012), in which a panel 
of atypical TSEs were used to inoculate transgenic animals expressing a single copy 
of human PrPC. C-type BSE, H-type BSE, L-type BSE CWD and atypical scrapie 
isolates, were unable to produce disease (or signs of infection) on first passage in 
these mouse model. Potential explanations for this discrepancy are the use of 
different animal prion disease isolates and the utilization of different cervid species 
and CWD strain. However, a more fundamental difference between studies may be 
that the in vivo and in vitro model systems assess different aspects of the agent and 
its replication. The in vitro cell-free conversion model relies in the molecular 
compatibility of PrPSc / PrPC (seed / substrate), evaluating the potential interaction 
above the sub-cellular level. Differences between these two models (in vivo v/s in 
vitro) are evidenced by the comparison of C-type BSE and vCJD.  As presented in 
this chapter C-type BSE and vCJD  seeds amplify efficiently  in PMCA using  
human PrPC derived from human post mortem tissue and humanized brain 
homogenate as a substrate, whereas intracranial inoculation of C-type BSE into 
humanized (129 MM) mice fails to produce disease (Bishop et al., 2006), unless first 
experimentally transmitted to sheep or goat (Plinston et al., 2011, Padilla et al., 2011, 
Wilson et al., 2013). 
A direct comparison between the two models (in vivo and in vitro) is difficult and 
complex. The in vitro conversion models offer an attractive opportunity to 




2014a, Castilla et al., 2008a, Jones et al., 2009). Complementary to this, the in vivo 
models have a closer relationship to prion disease in their natural hosts. An adequate 
interpretation of both models can provide important information for a better 
understanding of the basis of the transmission barrier to humans.     
In summary, this chapter evaluated the susceptibility of human prion protein to 
different animal prion diseases by PMCA. Human brain and humanized transgenic 
mouse brain homogenates of the PRNP codon 129 MM and VV genotypes, failed to 
support amplification when the PMCA reactions were seeded with L-BSE, H-type 
BSE, scrapie and atypical scrapie. In contrast C-type BSE, and vCJD PrPSc 
efficiently converted the human PrPC after PMCA, albeit in a codon 129 dependent 
manner. Surprisingly, a CWD isolate was able to effect the conversion of human 
PrPC, converting both the 129 MM and 129 VV PRNP polymorphic variants, but the 
conversion of 129 MM was found to be the more efficient. These findings suggest 
that, at least at the molecular level, atypical scrapie and atypical BSE present a lower 
level of risk of zoonotic disease than classical BSE. Data also suggest that there is no 
absolute barrier to the conversion of human PrPC by CWD prions in a protocol using 
96 cycles of PMCA. These results would seem to suggest that CWD does indeed 
have zoonotic potential, at least as judged by the compatibility of CWD prions and 
their human PrPC target.  
This study, using the in vitro prion conversion approach has some obvious 
limitations. First, it does not take account of factors operating above the sub-cellular 
level. Although the prion hypothesis locates the major determinants of prion disease 
pathogenesis in prion protein structure it is clear that addition factors affect the 




conducted with a single specimen of CWD in an elk. CWD affects several cervid 
species and in some of these species there exist prnp polymorphisms and different 
strains of CWD agent. Before generalizing too broadly from these results, it will be 
important to test a wide variety of CWD isolates from different cervid species, 
polymorphic genotypes and geographical locations, raising again the question of 








Spontaneous PrPSc formation using in vitro conversion systems as a 





5.1 Introduction  
5.1.1 Overview  
Sporadic CJD is the most common form of human TSEs, affecting approximately 1-2 
persons per one million people per year (Ironside and Head, 2008, Ironside et al., 
2005). However, important basic questions remain unanswered, such as the 
molecular mechanisms underlying prion pathology and whether sporadic CJD arises 
in individuals as a result of a spontaneous conversion of PrPC to PrPSc, which then 
self-propagates. The propagation of the diseases is due to the ability of the misfolded 
prion protein to convert normal PrP, acting then as a template for further conversions 
(Prusiner, 1982, Prusiner, 1998). As previously mentioned, structural differences 
between the two protein isoforms, particularly associated with a higher level of β-
sheet content, confer to the pathological isoform a new set of biochemical properties, 
including detergent insolubility and protease resistance (Baskakov et al., 2004, 
Legname, 2012, Legname et al., 2004, Prusiner, 1998). Currently, two possible 
mechanisms have been proposed to generate spontaneous conformational changes of 
the cellular prion protein: changes in the PRNP gene (e.g., mutations and insertions) 
and spontaneous non-covalent post transcriptional modifications of the expressed PrP 
(Aguzzi and Calella, 2009).  To gain a deeper understanding of this process, both in 
vivo and in vitro approaches have been used to assess some of the fundamental 





5.1.2 Spontaneous prion conversion, in vivo approaches 
Transgenic mouse models have confirmed that disease-associated mutations of the 
PRNP sequence induce clinical features associated with prion diseases (Hsiao et al., 
1990, Jackson et al., 2009, Torres et al., 2013).  In this sense, the use of transgenic 
animals has helped to evaluate the phenotypic-pathological effect of certain PRNP 
mutations. The mutation associated with the GSS syndrome – a substitution of 
proline for leucine at codon 102 of the PRNP gene – was modelled in overexpressing 
transgenic murine models. (The equivalent codon in the mouse prnp gene is 101) 
After 150 to 200 days P101L transgenic animals developed spontaneously vascular 
degradation, lethargy and ataxia (Hsiao et al., 1990). Serial transmission experiments 
using brain homogenate from symptomatic P101L transgenic animals, showed 
neurological features in a second in vivo passage, between 117 and 639 days post 
inoculation in Syrian hamster and also in the transgenic mouse line which express 
low levels of the mutated isoform. These results indicated that genetic modification 
of the prion protein gene can be modelled in experimental animals to evaluate the 
molecular and histological aspects of pathology, and also its infectivity (Hsiao et al., 
1994). A subsequent study using the same animal model indicated that the link 
between PrPSc formation, neurodegeneration, and infectivity was not totally clear, 
and suggested that the potential spontaneous generation might be rather due to 
acceleration of the disease by promoting the aggregation and accumulation of a pre-
existing misfolded PrP isoform (Nazor et al., 2005). Using a similar approach but 
generating transgenic animals carrying one or two copies of the mutated allele, 
Manson and colleagues reported lack of spontaneous neurodegeneration in a 




discrepancy could be due to the variation in the expression levels of the mutated gene 
(Manson et al., 1999).  
Jackson and colleagues created a knock-in mouse (Jackson et al., 2009) which 
express the human PrP carrying the mutation D178N - a change of  asparagine (N) 
instead of the normal aspartic acid (D) - coupled with methionine at the polymorphic 
codon 129 present in patients who develop FFI. The transgenic animals 
spontaneously develop clinical signs similar to those described in patients with this 
particular condition, presenting clinical signs such: ataxia, kyphosis (hunched back 
posture), pruritus, reduced body weight, and highly unusual paroxysmal hind limb 
tremors. Intracerebral inoculation of brain homogenate in transgenic animals 
carrying the wild-type PrP showed transmission of the disease. The authors conclude 
that a known disease-associated modification of the PRNP gene can cause a specific 
neurodegenerative disease, and be sufficient to create a distinct protein-based 
infectious element (Jackson et al., 2009). 
Also, several attempts to decipher the relationship between penetrance of TSE and 
the PrP structure have been conducted. Modifications of the prion protein at the 
octapeptide repeat region, globular domain, and glycosylphosphatidylinositol anchor 
have shown a variety of effects on the spontaneous generation of prion diseases and 
their potential transmissibility (Asante et al., 2009, Chiesa et al., 2000, Harris et al., 





5.1.3 Spontaneous prion conversion by using in vitro generated aggregates  
If the prion hypothesis is true, then it should be possible to make “synthetic prions” 
by refolding PrPC in vitro. Legname and colleagues, (Legname et al., 2004) 
evaluated the infectivity of amyloid fibrils produced from murine truncated 
recombinant PrP expressed in bacteria (amino acids 89 to 230). Fibrils were 
intracerebrally inoculated into transgenic animals overexpressing similar truncated 
murine prion protein 16-times higher than wild-type animals. The mice developed 
neurologic signs after 380 to 660 days post inoculation, and the brain extract showed 
spongiform change and deposition of the protease resistant PrPSc. Secondary 
transmission experiment in transgenic and wild-type animals revealed a reduction in 
the incubation time, with a mean incubation time of 90 and 154 days respectively 
(Legname et al., 2004). These results suggest that synthetic PrP fibrils-alone were 
sufficient to generate infectivity in transgenic animals, and even more importantly, 
structural modifications of the recombinant PrP protein were sufficient to produce a 
new synthetic strain that was able to propagate. Later, in order to evaluate 
conformational stability of PrP amyloids and its potential effect over the replication 
and propagation of prions, Colby and colleagues created several synthetic prion 
strains using truncated recombinant mouse PrP. They produced a spectrum of 
synthetic prions with different conformational stabilities, which subsequently were 
inoculated into transgenic animals. The most stable recPrP amyloid conformations 
exhibit the longest incubation periods, whereas the less stable PrP amyloids produce 
strain which generated a shorter survival time. Thereby direct correlation between 
stability and incubation time was proposed (Colby et al., 2009). More recently, the 




prions resulting from the polymerisation of recPrP (Colby et al., 2010). PrPSc is 
usually associated with resistance to protease; however PrPSc sensitive to the 
proteolytic treatment has been isolated and characterized in certain animal or human 
prion pathologies (Colby et al., 2010, Gambetti et al., 2008, Nazor et al., 2005). The 
recPrP protease sensitive preparations were inoculated into transgenic mice that 
overexpress N-terminally truncated PrP. Interestingly, only recPrP amyloid 
preparations, but not recPrP monomers or oligomers were able to generate a prion-
like disease phenotype to the transgenic animals. When prion isolates (from infected 
mice challenged with recPrP protease sensitive) were serially transmitted in the same 
transgenic mouse line, or when the synthetic PrP amyloid was inoculated in a 
transgenic model that overexpresses full-length PrP, both murine models exhibited 
accumulation of protease sensitive PrPSc and extensive neurodegeneration. The 
inoculation of new in vitro generated synthetic prions demonstrate that a 
conformational change of murine wild-type PrP was capable of producing abnormal 
prions, composed exclusively of sensitive PrPSc (Colby et al., 2010). 
Attempts to use the full-length recombinant hamster PrP to evaluate the spontaneous 
prion conversion and infectivity have also been conducted. Full-length hamster 
recombinant PrP, mixed with normal brain homogenate and bovine serum albumin 
(BSA), were used to yield β-sheet-rich aggregates. These synthetic hamster amyloid 
prion preparations were inoculated intracerebrally in golden Syrian hamsters, 
demonstrating a lack of infectivity in the first in vivo passage. Nevertheless, animals 
developed neurological signs after ~550 days, presenting higher levels of protease 
resistant PrP in the second transmission. Several conclusions can be drawn from this 




wild-type animals in consecutive transmission experiments. Second, the disease 
generated by the inoculation of recPrP amyloids seems to show a distinct clinical 
presentation, pathology and biochemistry compared to other rodent prions strains 
(Makarava et al., 2010). 
5.1.4 Cell free conversion systems and spontaneous prion generation 
The in vitro conversion assays considered thus far were developed to reproduce the 
seeded conversion process of the normal prion protein into its misfolded isoform. In 
the earliest attempts, large amounts of radioactively labelled PrPC incubated with 
brain-derived PrPSc were required to achieve only limited prion conversion (Kocisko 
et al., 1994). More recently, with the development of two different in vitro 
conversion assays, named protein misfolding cyclic amplification (PMCA) and real-
time quaking induced conversion (RT-QuIC), the detection of PrPSc has experienced 
dramatic increase in sensitivity, with these techniques being able to amplify and 
therefore detect minute amounts (around 1≥ femtogram) of PrPSc. Both technologies 
have proved to be suitable candidates for diagnostic test development (Atarashi et al., 
2011a, Atarashi et al., 2011b, Castilla et al., 2006, Chen et al., 2010, McGuire et al., 
2012, Morales et al., 2012, Peden et al., 2012). An important issue in the 
development of potential in vitro conversion tests for TSEs has been the detection of 
“unwanted” false positives in unseeded control reactions. This important issue has 
been utilized to explore basic questions concerning protein conversion and 
replication. Indeed, both systems have been used as experimental strategies to 
elucidate the spontaneous PrP misfolding (Barria et al., 2009, Deleault et al., 2007, 
Supattapone, 2013, Vieira et al., 2014, Wang et al., 2010). A central issue in the 




titres of infectivity, long incubation times, and lack of infectivity in wild-type 
animals (Colby and Prusiner, 2011). There are possible explanations for this: (i) 
during the in vitro synthetic prion amyloid preparation a heterogenous mixture of 
conformers is generated, in which only some have the appropriate folding to 
propagate successfully; (ii) maturation process: perhaps, some of the aggregates 
require a molecular adaptation to acquire the appropriate conformation to become 
fully infectious (Colby and Prusiner, 2011, Vanni et al., 2014).  
5.1.4.1 In vitro generation of prions by PMCA 
Apparently, PMCA through the continuous amplification cycles appears to select 
certain PrPSc conformations (Makarava et al., 2013, Vanni et al., 2014). The “new 
formed” PMCA products through the consecutive cycles of sonication / incubation 
and subsequently with serial amplification rounds, appear to select PrP conformers 
capable of propagating efficiently in vitro. Because of this, PMCA has been used by 
several laboratories to explore the generation of prions in vitro (Barria et al., 2009, 
Deleault et al., 2007, Kim et al., 2010, Wang et al., 2010, Zhang et al., 2013). Using 
purified native PrPC, co-purified lipids, and synthetic polyanions, Deleault and 
colleagues showed that these were the minimal components required to generate de 
novo infectious prions by PMCA. After serial rounds of amplification they were able 
to produce, apparently in a stochastic manner, PrPres fragments detectable by PK 
treatment and Western blot. This spontaneous PrPres PMCA material was able to 
infect wild-type hamsters, with incubations periods around 130 to 170 days, 
presenting typical signs of scrapie indistinguishable from two well characterized 




strains meant that the investigators were unable to entirely discard the effect of a 
potential contamination (Deleault et al., 2007).  
In order to evaluate whether murine amyloid, generated spontaneously in the absence 
of any additional cofactors, was able to produce TSE pathology in wild-type animals, 
Kim and colleagues (Kim et al., 2010) used a modified version of PMCA to 
propagate synthetic hamster prions, which were then inoculated into wild-type 
animals. The modified version of the PMCA used bacterially expressed recombinant 
PrP, instead of brain homogenate PrPC, as substrate. The inoculated PMCA products 
resulted in the development of clinical signs of scrapie in the inoculated Syrian 
hamsters, showing a long and varied incubation period in the first passage and a 
substantial decrease on serial passage (Kim et al., 2010).  
The susceptibility to generate de novo prion in murine brain derived tissue has also 
been evaluated (Barria et al., 2009). Brain extract from healthy hamster, wild-type 
mice, and transgenic mice that overexpress human PrPC were used in serial rounds of 
PMCA, under standard and prolonged sonication / incubation cycles. None of the 
specimens were able to produce PrPres under standard PMCA conditions. However, 
after extensive PMCA cycles, PrPres fragments were infrequently observed, but only 
in the samples incubated with rodent PrPC, with no evidence of spontaneous PrPres 
formation of  human PrP under the same conditions. After inoculation of the PMCA 
spontaneous generated material in wild-type hamster, a new TSE-disease phenotype 
was observed, suggesting the emergence of a new strain derived from the 
spontaneous conversion of the normal prion protein (Barria et al., 2009). These 
results suggest that different animal species have a differential propensity to initiate 




tool to investigate the spontaneous formation and propagation of de novo prions 
(Colby and Prusiner, 2011, Jones et al., 2011, Morales et al., 2012). 
Recently, Wang and colleagues (Wang et al., 2010, Zhang et al., 2013) have 
employed PMCA to generate spontaneously infectious prions using only a mixture of 
recombinant murine PrP, synthetic anionic phospholipids and RNA isolated from 
liver. After 17 serial PMCA rounds, proteinase K resistant recombinant PrP 
fragments were detected by Western blot and subsequently inoculated into CD-1 
wild-type mice. The in vitro generated material induced neurological signs in the 
animals after about 130 days, reaching the terminal phase of disease around 150 days 
post inoculation, with minimal variation in the incubation time between animals 
(Wang et al., 2010). Thus, for the first time it was possible to produce in vitro 
infectious prions, which in terms of infectivity behave similarly to a natural 
occurring strain.  
To further clarify the equation that represents the spontaneous in vitro prion 
propagation proposed by Wang (recPrP + lipids + RNA à prions), Deleault and 
colleagues, investigated the effect of the phospholipid phosphatidylethanolamine 
(PE) as a sole cofactor for prion propagation (Deleault et al., 2012, Supattapone, 
2013). This membrane phospholipid seemed to facilitate the propagation of recPrPres 
(protease resistant prion protein derived from recPrP) in PMCA of several prion 
strains in seeded reactions, acting as an endogenous factor in the propagation of 
infectious prions (Deleault et al., 2012).  
The large majority of studies that have investigated the spontaneous conversion of 




made using human prion protein, and with no success. As a result, currently, there is 
no information concerning the in vitro susceptibility and spontaneous formation of 
human prions.  
This chapter directly addresses the potential of human prion protein to generate 
spontaneously misfolded PrP using in vitro conversion models. RT-QuIC and PMCA 
were both used to model the spontaneous generation of human PrP.  
The aims of this chapter were (i) to establish a protocol for the spontaneous 
generation of the abnormal form of the human PrP in vitro, (ii) to determine whether 
the spontaneous in vitro generated human PrPres can propagate in vitro and (iii) to 
determine whether PrPC methionine or valine at the position 129 conferred greater 





5.2 Material and methods  
5.2.1 Methods 
5.2.1.1 Expression and purification of recombinant PrP 
The full-length human recombinant prion proteins used in this chapter (residues 23-
231), named recPrP 129 M or recPrP 129 V (with either methionine or valine at 
codon 129) were produced using the procedures described in Wilham and colleagues 
(Wilham et al., 2010) with minor modifications and were generously provided by Dr 
G Malinson (Bristol Institute of Transfusion Sciences, Bristol, UK). Briefly, the PCR 
amplification products of the human prion gene (GenBank accession number No. 
M13899) were ligated into the pRSET A vector (Cat. No. V351-20, Invitrogen). The 
ligation products were transfected into Escherichia coli Rosetta cells (Invitrogen). 
Protein expression was achieved by using Overnight Express Autoinduction system 
(Novagen- Merck Millipore). To isolate inclusion bodies, 0.5 litres of cells culture 
were centrifuged and subsequently lysed with BugBuster master mix (Cat. No. 
71456, Merck Millipore). The inclusion bodies were washed two times with 0.1X 
BugBuster and then recovered by centrifugation and frozen. Pellets were 
resuspended and denatured in 8M guanidine/HCl (pH 8.0). Protein extracts were 
recovered by centrifugation at 16,000 g for 5 minutes. Supernatant were bound to 20 
ml Ni-NTA Superflow resin (Qiagen) which was previously equilibrated in 
denaturing buffer (100mM sodium phosphate (pH 8.0), 10mM Tris/HCl, 6M 
guanidine/HCl). The Superflow resin coupled to the protein extract was loaded onto 
a column. The denatured protein was refolded using a linear gradient of refolding 




rate of 1 ml min-1. Protein was eluted with a linear gradient of sodium 
phosphate/imidazole buffer (100mM sodium phosphate (pH 5.8), 10 mM Tris/HCl, 
500mM Imidazole) at 1 ml min-1 over 60 min. Recovered protein was diluted 1/2 into 
dialysis buffer (10mM sodium phosphate (pH 5.8)) filtered with a 0.2 mm syringe 
filter and dialysed. Comassie blue staining of SDS gels revealed that both 
recombinant PrP proteins purity (methionine and valine at the codon 129) were 
greater than 90%. Finally, recPrP protein concentration was determined by 
bicinchoninic acid assay (Thermo Scientific) and aliquoted in a final concentration of 
0.2–0.5 mg/ml-1. Aliquots were stored at -80°C.  
 
5.2.1.2 RT-QuIC procedure 
Tubes containing frozen aliquots of bacterially expressed full-length human 
recombinant PrP, with either methionine or valine at codon 129, were allowed to 
thaw in water at room temperature for 10 minutes and then kept on ice. Prior to 
determination of the protein concentration, recPrP aliquots were filtered through 100 
kDa Nanosep centrifugal concentrators (VWR). Protein concentration was 
determined by absorbance spectroscopy. To avoid saturated measurements, three 
independent aliquot of the filtrated protein solution were diluted 1/10 in PBS, 
containing 0.1% SDS.  Protein concentration was determined by absorbance at 280 
nm in an Ultrospec 3000 spectrophotometer (GE Life Sciences). The final protein 
concentration was calculated by multiplying the dilution factor with the extinction 
coefficient of full-length recombinant PrP (2.6 l g-1 cm-1). A master mix reaction, 




concentrations: 10mM phosphate buffer (pH 7.4), 324mM NaCl, 1mM EDTA, 10µM 
ThT and 0.1mg/ml recPrP. Aliquots of RT-QuIC master mix reactions were added to 
a 96 wells clear-bottomed microplate in a final volume of 100 µl per reaction. The 
microplates were sealed with Adhesive PCR Film and incubated in the FLUOstar 
Omega at 42°C for 100 hours with 87 seconds of consecutive double orbital shaking 
at 900rpm followed by 33 seconds of rest. ThT fluorescence was measured every 15 
minutes at 480nm, after excitation at a wavelength of 450nm. The ThT activity was 
evaluated in real time by relative fluorescence units (RFU) with a maximum plateau 
at 260000 RFU. The protocol was that of Peden and colleagues, and McGuire and 
colleagues, with minor modifications (McGuire et al., 2012, Peden et al., 2012). All 
RT-QuIC reactions performed for this thesis chapter were unseeded. 
5.2.1.3 Preparation of brain PMCA substrates 
Transgenic mouse brain PMCA substrates were prepared exactly as described in 
General Material and Methods (Chapter 2) 
 
5.2.1.4 PMCA procedure 
PMCA reactions were prepared exactly as described in General Material and 
Methods (Chapter 2) 
 
5.2.1.5 Protease digestion and Western blot analysis  
Western blotting experiments were prepared exactly as described in General Material 






5.2.1.6 Image Analysis 
Image analyses were performed using, Image Lab software version 2.01, Bio Rad. 
 
5.2.1.7 RT-QuIC Fluorescence readings 
Fluorescence measurements were collected by BMG Omega Data Analysis software 
and further exported into Microsoft Excel 2010.  
 
5.2.1.8 Data analysis 
All statistical analysis, graphs and further analysis were completed using GraphPad 





5.3.1 Determination of cut-off criteria for the unseeded amyloid formation of 
recombinant PrP by RT-QuIC 
RT-QuIC involves the use of soluble recombinant prion protein (recPrP) as a 
substrate for the formation of amyloid. Thioflavin T is a dye that binds amyloid 
resulting in enhanced fluorescence. Consequently Thioflavin T it has been used in 
RT-QuIC as a reporter molecule to evaluate amyloid formations. In order to evaluate 
the unseeded amyloid formation using recombinant PrP, an in vitro conversion 
system (RT-QuIC) was used to mimic the spontaneous misfolding of bacterially 
expressed recombinant human PrP	   (recPrP). In order to establish a definition of 
positive and negative reactions, a cut-off point or exclusion value was first 
determined. Thioflavin T activity of each sample was measured in relative 
fluorescence units (RFU) every 15 minutes for a total time of 100 hours. Twelve 
replicates were tested for each experimental condition and the mean and standard 
deviation (SD) of the first readings were used to establish the baseline. The cut-off 
was calculated by the mean of the tested samples, plus 3 times the standard deviation 
(mean + 3 x SD) (Figure 5.1). All samples below the cut-off level were considered 
negative (Figure 5.2A). Samples that rose above the cut-off level were considered 
positive (Figure 5.2B). Positive samples had a fluorescence level between 15,000 to 







Figure 5.1 Determination of cut-off value for the unseeded amyloid formation of 
recombinant PrP by RT-QuIC. Formation of PrP amyloid was monitored by 
detection of ThT fluorescence. The (“Y”) axis represents the ThT fluorescence 
(relative fluorescence units, RFU) and the (“X”) axis represents time. The mean and 
standard deviation (SD) of 12 replicates (colour lines) were calculated. A cut-off 
level (solid red line) was chosen based on the mean of the total number of samples 










Figure 5.2 RT-QuIC response generated by recombiant PrP in unseeded 
reactions. The detection of recombinant PrP amyloid formation was monitored  by 
ThT activity  every 15 minutes for 100 hours. The (“Y”) axes represents the ThT 
activity in relatives flouresence units (RFU). The (“X”) axes represent time. (A) An 
example of  a typical negative trace (blue line). (B) A typical sigmoidal positive trace 
(green line). (C) Overlaying of a positive (green line) and negative curves (blue line). 





5.3.2 Unseeded amyloid formation in recombinant human prion protein with 
either methionine or valine at the codon 129 
RT-QuIC is an amyloid seeding assay, currently under development for use as a 
diagnostic assay for sCJD, which aims to detect prions in human or animal tissues. 
Based on features of agitation and ThT reporter activity, RT-QuIC technology was 
used to evaluate the unseeded amyloid formation of full-length recombinant human 
prion methionine or valine at position 129 of the PRNP gene (recPrP 129 M or 
recPrP 129 V). Eight independent experiments were performed in which twelve 
replicates were performed for each assay. The number of positive samples was 
expressed as a percentage for each experimental group (n=12). By 100 hours, 
unseeded amyloid formation was observed in a subset of samples of both groups (M 
or V at the codon 129). A higher percentage of positive samples were found in 
samples that had valine at the codon 129, within a range of 58 to 100% of samples 
becoming positive. In contrast, the samples that had methionine at codon 129 showed 
lower levels of amyloid formation, with the percentage of positives less than or equal 
to 50% (Figure 5.3). The unseeded conversion of recPrP (129 M or V) by RT-QuIC 
showed a degree of consistency: in eight independent experiments, the unseeded 
human recPrP 129 M amyloid formation samples never exceeded the 50% rate. In 
contrast, human recPrP 129 V samples were always over 58%. In general, the time 
required for samples to reach the cut-off level (to be considered positive) was 






Figure 5.3 Determination of unseeded amyloid formation in full length human 
recombinant prion protein (methionine or valine at the codon 129) by RT-
QuIC. Eight independent experiments were performed in which twelve replicates 
were conducted for each experiment (coloured symbols correspond to the mean of 12 
replicates). The number of samples with unseeded amyloid formation was calculated 
in each experiment, and the final percentages of positive samples were plotted (“Y” 
axis). Full-length recombinant human prion [methionine (blue dots) or valine (red 
squares) at position 129 of the PRNP gene] was used in the RT-QuIC reactions. The 





5.3.3 Effect of protein concentration and batch-to-batch variation on the 
unseeded recombinant human PrP conversion 
It is possible that recombinant human PrP concentration or batch-to-batch variability 
may affect unseeded amyloid formation in RT-QuIC assays. In order to evaluate (i) 
the effect of protein concentration and (ii) batch-to-batch variability on unseeded PrP 
conversion, two protein concentrations and two different full length recombinant 
human prion protein batches were tested. The standard RT-QuIC procedures 
recommend an optimal recombinant PrP final concentration of 100µg/ml. To assess 
whether the protein concentration has an effect on the unseeded conversion of the 
recombinant PrP, 100 and 200µg/ml of recPrP substrate were added to twelve 
technical replicates that encode methionine or valine at codon 129. After 100 hours 
of incubation and shaking, RT-QuIC reactions showed variations in the percentage of 
positive samples associated to the two polymorphic variants. Similar to the previous 
findings, in which under standard conditions the recombinant PrP methionine 
substrate showed a rate of spontaneous formation under 50% (Figure 5.3 and 5.4), a 
new set of samples carrying the same amino acid at the position 129  had a positive 
signal for around 10% of the samples. The recombinant PrP valine substrate 
presented consistency with the previous data (Figure 5.3), showing a higher number 
(90%) of positive reactions (Figure 5.4).  
Using a double concentration of recombinant PrP substrate (200µg/ml of recPrP), 
from twelve samples that had methionine at codon 129, five had positive reactions 
(41% of the samples). The other polymorphic substrate (recPrP 129 V) had a positive 




In order to evaluate consistency of the results, two recombinant PrP batches, 
designated batch “A” and “B” were utilized. Two independent set of experiments 
were carried out. Similar to the control reactions the samples prepared with the batch 
B showed 0 and 25% of positive samples in the reactions incubated with recPrP 129 
M in two independent experiments. The recPrP 129 V reactions were 91 and 100% 
positive. Reactions using recombinant PrP carrying valine at the position 129 had a 
higher predisposition to form PrP amyloids compared with reactions using 
recombinant PrP methionine at the same position (Figure 5.4). Given the limited 
number of batches available, only two sets of recombinant PrP substrates carrying 
codon 129 M and V were tested. Further experiments must be performed using a 
larger number of batches in order to evaluate the variability between batches. 
Nevertheless, the results presented in this chapter suggest that the protein 
concentration and batch-to-batch variability had no effect on the trend shown by 
recPrP 129 M or recPrP 129 V to form amyloids. 





Figure 5.4 The effect of protein concentration and batch-to-batch variability on 
the unseeded conversion of rec PrP methionine or valine at the codon 129. Two 
recombinant PrP batches, designated batch “A” and “B, were used to test for the 
unseeded recPrP amyloid formation. The concentration of rec human PrP were 
100µg/ml and 200µg/ml of recPrP. recPrP M (red square, triangle, diamond and 
circle) or recPrP V (blue square, triangle, diamond and circle) at codon 129 were 
utilized.  The proportion of samples with unseeded amyloid formation was calculated 
in each experiment and the final percentages of positive samples were plotted. The Y 
axis indicates percentage of positive samples. X axis indicates recPrP protein 
concentration and the two recombinant PrP batches utilized, named batch A and B. 
Results obtained in previous trials were imported into the chart for comparative 






5.3.4 Determination of the effect of phosphatidylethanolamine on the unseeded 
PrPC conversion of recombinant PrP methionine or valine at the codon 129 by 
RT-QuIC 
To investigate conditions which may promote or inhibit the unseeded amyloid 
formation of recombinant PrP (methionine or valine at PRNP codon 129), different 
concentrations of phosphatidylethanolamine (PE) were incorporated to the RT-QuIC 
reactions. PE is one of the most abundant phospholipids present in the cell 
membrane, frequently found in nervous and other tissues. In the brain, PE accounts 
for around 45% of the total phospholipid content. Recently, PE has been described as 
an endogenous cofactor for the in vitro prion propagation (Deleault et al., 2012). In 
order to evaluate the effect of PE on unseeded recPrP conversion, concentrations of 
0, 1, 10 and 100µM PE were introduced into the RT-QuIC reactions. 
RT-QuIC reactions were performed with recombinant PrP substrate with either 
methionine or valine at the codon 129. Recombinant PrP amyloid formation was not 
observed when the two polymorphic substrates were incubated with PE at 100 and 
10µM. In contrast, comparable levels of unseeded amyloid formation were observed 
over the samples incubated with 0 and 1µM of PE. Samples incubated with recPrP 
129 M substrate showed 4 and 3 reactions with amyloid formation in the samples 
containing 1µM or no PE respectively. The reactions incubated with recPrP 129 V 
containing 1µM or no PE had 6 and 8 positive reactions.  
These results suggest that higher levels of PE (100 and 10µM) inhibit the PrP in vitro 
amyloid formation. Nevertheless, a concentration of 1µM does not have an obvious 





Figure 5.5 Effect of phosphatidylethanolamine on the unseeded human recPrP 
amyloid formations by RT-QuIC. Concentrations of 100, 10, 1µM or non PE were 
used in RT-QuIC unseeded reactions. The amyloidogenic activity was monitored by 
detection of ThT fluorescence in relative fluorescence units (“Y”) axis. The 
measurements were taken every 15 minutes for a total of 100 hours. Recombinant 
PrP 129 M or V were used as a source of PrPC. (“X”) axis indicates PE concentration 





5.3.5 Effect of heparin on the unseeded amyloid formation of recombinant PrP 
methionine or valine at the codon 129 by RT-QuIC 
Heparin is a glycosaminoglycan that has been reported to be associated with varied 
types of amyloids. Several lines of evidence have shown that heparin can act as a 
ligand for the prion protein inhibiting or enhancing the prion conversion / replication 
(Vieira et al., 2014, Yokoyama et al., 2011). Heparin, particularly low molecular 
weight heparin (LMWH), has been reported to act as an enhancer of in vitro vCJD 
PrPSc conversion in PMCA, with an effective concentration of 100µg/ml (Yokoyama 
et al., 2011). To evaluate the effect of LMWH on the in vitro unseeded amyloid 
formation, 100µg/ml of LMWH was added to recombinant PrP, either methionine or 
valine at codon 129, for 100 hours. Amyloid formation was measured by ThT 
fluorescence every 15 minutes. Twelve technical replicates were performed for each 
experimental condition. The levels of ThT fluorescence were evaluated for the two 
substrates (recPrP 129 M or V), both in presence or absence of LMWH. Samples 
incubated with heparin and recPrP 129 M showed 11/12 positive reactions, compared 
with 5/12 samples in the absence of heparin. This 50% increase in positive samples 
was found to be significant using a one way ANOVA-Tukey test (P = 0.0200). The 
recPrP 129 V substrate showed 11/12 positive replicates whether or not heparin was 
in the reaction. Statistical analyses showed significant differences in the level of 
fluorescence among the two experimental conditions (P = 0.0001).  
Considering the number of positive samples observed in the reactions incubated with 
recPrP V, it seems that the statistical differences was not a reflection of the number 
of samples above the cut-off, but rather, it was a reflection of the ThT fluorescence 




Heparin seems to enhance the spontaneous amyloid formation in samples carrying 
methionine at the position 129 of the recombinant prion protein. However, the 
recombinant PrP valine substrate did not show a clear effect on the number of 
positive samples, although a significant difference in the level of fluorescence was 
observed. The potential impact of heparin on the in vitro spontaneous prion 







Figure 5.6 Effect of heparin on the unseeded human recPrP amyloid formations 
in RT-QuIC. Unseeded RT-QuIC reactions without heparin and with heparin at 
100µg/ml reactions were used to evaluate the unseeded amyloid formation of recPrP. 
The amyloidogenic PrP activity was monitored by detection of ThT fluorescence in 
relative fluorescence units (“Y” axis). The measurements were taken every 
15minutes over 100 hours. Statistical analysis was performed by a one-way ANOVA 
Tukey test. recPrP M or V were used as a source of PrPC. Asterisk (*) indicate 





5.3.6 Can unseeded amyloid RT-QuIC reaction products be amplified in 
PMCA? 
The results presented so far have shown that RT-QuIC was able to produce recPrP 
amyloid spontaneously after 100 hours of continuous incubation and shaking. 
Additional components such as PE or heparin were able to inhibit and promote the 
unseeded formation of prion protein amyloid. recPrP amyloid derived from several 
RT-QuIC reactions were selected to seed serial PMCA reactions. To analyse the 
potential capacities of RT-QuIC unseeded amyloid products to further propagate 
conversion in vitro, several unseeded recPrP amyloid RT-QuIC products were used 
to seed PMCA reactions. recPrP amyloids with either methionine or valine at codon 
129 were used in serial PMCA to maximise the chances of detecting amplification. 
Seed and substrate matching of the polymorphism at codon 129 was made between 
the PMCA and RT-QuIC. The PMCA substrates used were humanized transgenic 
mouse brain homozygous for PrP with methionine or valine at codon 129 (Tg-MM or 
Tg-VV).  Several conditions that promote the recPrP amyloid formation were 
selected for PMCA analysis as follows:   
1) Condition “A”: recPrP amyloid product derived from standards RT-QuIC 
protocol (see Material and Methods Chapter 5). For this condition, two 
samples were selected: a negative sample (under the RT-QuIC cut-off level), 
and a positive sample (above the cut-off level) (Figure 5.7, lanes 1 and 2 
respectively). 
2) Condition “B”: recPrP amyloid product derived from RT-QuIC in presence of 
heparin (100µg/ml). Both selected samples presented amyloid formation 




3) Condition “C”: recPrP amyloid product derived from RT-QuIC reactions in 
which humanized transgenic mouse brain was present. In order to promote 
the amyloid formation from wild-type human PrPC (rather than recombinant 
human PrP), a dilution 1/1000 (regarding the 10% homogenate) of humanized 
transgenic mouse brain homogenate (Tg-MM or Tg-VV) was incorporated to 
the RT-QuIC reactions. Both selected samples showed amyloid formation 
(Figure 5.7, lanes 5 and 6). 
4) Condition “D”: Rec-PrP amyloid product derived from RT-QuIC in the 
presence of PE (1µM). Both selected samples showed amyloid formation 
(Figure 5.7, lanes 7 and 8). 
5) Condition “E”: PMCA reactions performed in absence of any recPrP seed 
(Figure 5.7, lanes 9 and 10) 
6) Condition “F”: PMCA reactions performed in absence of any recPrP seed and 
without heparin added. The standard PMCA protocol (used in this thesis) 
employed heparin at 100µg/ml. In order to evaluate the effect of heparin over 
unseeded PMCA reactions, two samples without heparin were serial 
amplified (Figure 5.7, lanes 11 and 12) 
Amplification reactions incorporated five consecutive rounds of PMCA. After each 
PMCA round, a 1/10 dilution of the previous PMCA product was diluted in fresh 
substrate in order to perform the subsequent round of PMCA. All PMCA reactions 
were performed in presence of heparin 100µg/ml, except the samples that correspond 





After five rounds of PMCA higher levels of PrPres formation were detected for the 
samples seeded with recPrP 129 M amyloids (Figure 5.7, Tg-MM; conditions A, B, 
C, and D). One of the unseeded samples showed PrPres at the fifth rounds of PMCA 
(Figure 5.7, Tg-MM; condition E). The detection of PrPres in one unseeded control 
may be due to several factors, including a specific effect of heparin on the PrP 
amplification in substrate carrying methionine at the codon 129 or cross-
contamination between samples. Further amplification experiments utilizing a larger 
number of unseeded controls (carrying the two possible polymorphisms) and 
incorporating molecular cofactors such as heparin may help to discriminate at least 
one of these possible scenarios.  
The other two unseeded samples did not show PrPres formation (Figure 5.7, Tg-MM; 
condition F). No amplification was detected in samples seeded with recPrP 129 V 






Figure 5.7 PMCA reactions seeded with RT-QuIC unseeded amyloid products. 
Four different RT-QuIC conditions that promoted the recPrP amyloid formation, 
were diluted (1/10) to seed serial rounds of PMCA using transgenic mouse brain 
homogenate substrate methionine (tg-MM) or valine (tg-VV) at the codon 129 of the 
PRNP (Conditions A, B, C and D). Two groups, of two samples each, were used as 
unseeded control (Conditions E and F). The condition “E” corresponds to PMCA 
following the standard amplification procedure. The condition “F” uses the same 
PMCA procedure, but in absence of low molecular weight heparin. The amplification 
procedure was performed using 5 rounds of PMCA, each corresponding to 96 PMCA 
cycles. All samples were digested with PK (under standard conditions at a 
concentration of 50µg/ml) before Western blotting. M: Molecular Marker. 






The autocatalytic PrPSc conversion, which is generated at the expense of the normal 
prion protein, is considered a key event in the prion replication process. However, 
the mechanism behind the prion spontaneous conversion remains unknown. Different 
technical approaches have been used to address these questions: cell-free conversion 
systems, cell culture models or genetic modifications of the prion protein gene 
(Benetti et al., 2010, Benetti and Legname, 2009, Colby and Prusiner, 2011, Morales 
et al., 2012). The use of recombinant prion protein and purified wild-type brain 
derived PrPC has been important in the study of this phenomenon. Using cell-free 
conversion systems Supattapone and colleagues explored the minimal components 
for spontaneous PrPSc generation. Lipids and nucleic acids were found to be essential 
in the formation and propagation of new prions (Supattapone, 2013). Using cell 
culture models Edgeworth and colleagues showed that the incubation of metal wires 
with susceptible cells was sufficient to generate PrPSc spontaneously and to produce 
a new disease phenotype in recipient wild-type mice (Edgeworth et al., 2010). 
Recently, Wang and colleagues have reported spontaneous generation of infectious 
prion by PMCA using a mixture of recombinant PrP, purified RNA from mice liver 
and synthetic lipids (Wang et al., 2010, Zhang et al., 2013). Thus far, the vast 
majority of groups that investigate the in vitro generation of prions in the absence of 
a PrPSc seed have used either mouse or hamster prion protein. In the cases in which 
human prion protein has been used, the spontaneous in vitro conversion of PrPSc has 
been unsuccessful (Barria et al., 2009, Colby and Prusiner, 2011). In this thesis, RT-
QuIC technology combined with PMCA reactions were used to establish conditions 




were (i) to establish a protocol for the spontaneous generation of the abnormal form 
of the human PrP protein in vitro, (ii) to determine whether the spontaneous and in 
vitro generated human PrPres can propagate in vitro and (iii) to determine whether 
PrPC with methionine or valine at the position 129 conferred greater susceptibility to 
the spontaneous conversion. 
The process of amyloid formation is associated with several human 
neurodegenerative diseases including Alzheimer disease, Parkinson diseases and 
Creutzfeldt-Jakob disease, among others. Amyloid formation has been described to 
be dependent on several factors including protein concentration, pH, temperature and 
sometimes the effect of cofactors (Eisenberg and Jucker, 2012). The kinetic of 
amyloid formations may be influenced by physical conditions, such as shaking or 
sonication. These mechanical processes can lead the acceleration and formation of 
different fibril morphologies (Buttstedt et al., 2013). Considering the amyloidogenic 
property of the misfolded isoform of the human prion protein, and the enhancing 
effect of agitation on  fibril formation, RT-QuIC amplification technology was used 
to evaluate the spontaneous recombinant PrP conversion, using full-length 
recombinant human prion protein with either methionine or valine at position 129.  
RT-QuIC is a relatively new recPrP conversion assay, in which nucleation and 
polymerisation occur to convert synthetic recombinant prion protein. It also 
incorporates real time monitoring of the formation of recPrP amyloid using ThT. RT-
QuIC has been developed as a potential diagnostic test for the detection of PrPSc in 
different human and non-human tissues and biological fluids. In order to discriminate 
between positive and negative samples in RT-QuIC, clear criteria are needed. 




clinical human CSF samples from sporadic CJD patients and controls in which all 
three 129 codon genotypes were represented. Eighty to 100% sensitivity was 
obtained for the different genotypic groups (Atarashi et al., 2011a, Atarashi et al., 
2011b, Capellari et al., 2011, McGuire et al., 2012). The samples were considered 
positive if the average of the two highest readings were greater than 10000rfu 
(relative fluorescence unit). This cut-off value (10000rfu) was chosen based on the 
mean reading of the first 20 CSF non-CJD RT-QuIC reactions performed, added to 
three times the value of the standard deviation of the mean (McGuire et al., 2012).  
Considering that in this study only unseeded RT-QuIC reactions were utilized to 
investigate the spontaneous conversion of the recombinant human PrP, a similar cut-
off criteria was chosen as follows: the mean value of the initial RFU readings in all 
samples (for each condition) plus three times the standard deviation. Using this 
criteria, spontaneous amyloid formation was observed for human recombinant prion 
protein, either M or V at codon 129, by RT-QuIC. 
By comparing a total of eight separate experiments, spontaneous amyloid formation 
of recPrP 129 M was found to have a lower frequency of spontaneous conversion 
compared to its recPrP 129 V counterpart. This was a surprising outcome. 
Previously, it has been reported that the polymorphism at the codon 129 may affect 
β-sheet-rich oligomer formation, with a higher propensity of the 129 M protein to 
form oligomers (Tahiri-Alaoui et al., 2004). All these analyses were performed using 
low pH and high protein concentration. In contrast, the kinetics of amyloid formation 
(not oligomer formation) seems to show a different pathway compared to the initial 
folding states of the PrP. The polymerisation of recPrP into amyloid forms (fibrils) 




amyloid formation in partially folded human PrP carrying methionine or valine at the 
position 129, and under continuous shaking, showed that recombinant PrP (valine at 
codon 129) exhibits a considerable shorter lag phase, with a rapid acquisition of β-
sheet conformation compared with recombinant PrP methionine under both 
spontaneous and seeded conditions (Baskakov et al., 2005). 
Considering the methodology employed throughout this thesis, being able to 
distinguish the different stages and pathways associated with PrP aggregation is 
fairly complex. However, the in vitro conversion systems used here (RT-QuIC) 
seems to show that both polymorphic forms of the prion protein are able to generate 
spontaneous PrP amyloids. Moreover, PrP carrying valine at position 129 appears to 
have a higher predisposition to form PrP aggregates compared with PrP carrying 
methionine at this position. This observation is consistent with the work reported by 
Baskakov and colleagues (Baskakov et al., 2005) in which the presence of valine at 
the position 129 accelerates the formation of amyloids under spontaneous and seeded 
conditions.  
It has been reported that the aggregation of several amyloidogenic proteins is 
affected by the protein concentration and shaking (Atarashi et al., 2011a). 
Commonly, agitation is considered to cause aggregation of proteins by increasing the 
air-water interaction. However, under specific circumstances in which the protein 
concentration is elevated, the aggregation rate seems to have an inverse correlation 
with the protein concentration (Atarashi et al., 2011a). Atarashi and colleagues tested 
the effects of recombinant PrP protein concentration on the amyloid formation using 
RT-QuIC. They found an inverse correlation between the rate of PrP amyloid 




Moreover, others studies using cell-free conversion have shown that the rate of PrPSc 
conversion and the amyloid formation is directly proportional to the concentration of 
PrPC (Baskakov et al., 2000, Caughey et al., 1995, Stohr et al., 2008). In order to 
evaluate if the amount of recombinant human prion protein has an effect on the 
spontaneous in vitro amyloid formation, two concentrations of recombinant PrP 
methionine or valine at the codon 129 were utilized in unseeded RT-QuIC reactions. 
The proportion of samples that showed spontaneous PrP amyloid formation did not 
change, either in the controls or in the samples with double protein concentration. A 
greater predisposition to amyloid formation (over 70% of the samples) was detected 
for the recPrP 129 V, whereas the samples with the methionine at the codon 129 
remained with a spontaneous amyloid formation below that at 50%. In order to test 
consistency and reproducibility of the previous results (batch-to-batch variability), a 
second batch of full-length recombinant PrP methionine or valine at the 129 codon 
was used. Two independent experiments, performed at different times, showed that 
the percentage of spontaneous amyloid formation maintained the same trend, 
showing a highest percentage of positive samples for recPrP 129 V compared to 
recPrP 129 M. These results confirm the potential for human recPrP to form 
spontaneous amyloid under the experimental in vitro procedure used here. 
Furthermore, valine at the position 129 of the PRNP appears to confer a greater 
susceptibility to spontaneous amyloid formation. 
The mechanism by which the normal prion acquires a β-sheet-rich conformation 
remains unclear. Similarly, whether the conversion or the propagation of PrPC / PrPSc 
requires a cofactor remains as an open question. The use of simplified in vitro 




process. Nucleic acids, other polyanions and lipids have been proposed as 
fundamental cofactors required for in vitro propagation and for the production of 
infectivity. Recently, Supattapone and colleagues isolated and identified a 
phospholipid cofactor involved in the in vitro prion conversion (Deleault et al., 
2012). In a seeded reaction phosphatidylethanolamine (PE) facilitates the conversion 
of recombinant PrP into infectious PrPSc (Deleault et al., 2012).To investigate the 
effect of this membrane phospholipid on in vitro human PrP amyliod formation by 
RT-QuIC, a range of concentrations of synthetic PE were incubated with recPrP 
(methionine and valine) for 100 hours. Inhibition of amyloid formation was observed 
for concentration higher that 1µM of PE. However, the reactions incubated with 
1µM of PE showed similar number of positive samples that the samples without PE. 
A predominant spontaneous amyloid formation was observed in the recPrP 129 V 
samples, thereby retaining the original trend of the recPrP 129 V.  In serial rounds of 
PMCA, PE successfully propagated recPrP (into the misfolded form) in seeded 
reactions with optimal concentrations ≥ 100µM.  Here, using the same concentration 
or 10 times less, PE exhibits an apparent inhibition on the spontaneous human recPrP 
amyloid formation. Many factors can be attributed to this discrepancy, (i) the use of 
different in vitro conversion systems, which are based on two different physical 
properties (sonication for the PMCA or shaking for RT-QuIC), (ii) the use of seeded 
or unseeded reactions, (iii) the use of different substrates, etc. It seems that cofactors 
appear to have a degree of specificity in their action, with a predisposition to 
propagate certain type of seed / substrates conventions depending on whether the 





Glycosaminoglycans (GAGs) are a group of polysaccharide commonly associated 
with β-sheet-rich aggregates, including prions (Vieira et al., 2014). GAGs have been 
show to act as potential physiological ligands of PrPC, sometimes promoting or 
inhibiting the PrP conversion / propagation (Gonzalez-Iglesias et al., 2002, Vieira et 
al., 2014). Heparin is a highly sulphated glycosaminoglycan, widely investigated in 
several amyloidoses with some contradictory effects. For example, in order to 
develop a highly sensitive in vitro screening tests for vCJD, low molecular weight 
heparin (LMWH) can be added to PMCA; PMCA in conjunction with heparin 
achieved an increase of 100-fold of vCJD PrPSc detection, using human PRNP 
transfected cell lysate substrate. On the other hand, incubation of heparin with 
recombinant murine prion protein decreased the polymerisation of recPrP. 
Additionally, RT-QuIC reactions seeded with RML and 263K prion strains incubated 
with  LMWH, have shown a delay on the fibrillation of recPrP in reactions seeded 
with RML, whereas 263K showed delay and also a decrease in fibril formation, 
suggesting a potential  species-specific effect in its action (Vieira et al., 2014). As 
shown here unseeded RT-QuIC reactions using recombinant human PrP, appear to 
have an inherent tendency to amyloid formation. Heparin seems to increase the 
formation of amyloid in samples with methionine at codon 129 of PRNP. This 
difference was not evident in samples with valine at codon 129, perhaps because the 
rates of spontaneous amyloid formation were already elevated. However, differences 
in the level the ThT fluorescence were observed. The cause of this difference may be 
due to a specific target effect of heparin on human prion protein, particularly 
associated to the presence of methionine or valine at the codon 129. It is well known 




prion diseases, therefore differences in the effect of heparin on these two human 
polymorphic substrates, is not completely surprising and might be biologically 
relevant. 
To assess whether the recPrP amyloids generated by RT-QuIC have the property to 
convert full-length wild-type PrPC, serial PMCA round were performed. Previously, 
Soto and colleagues reported that as a result of many round of PMCA, minimal 
amounts of PrPSc can convert “fresh” wild-type PrPC found in brain homogenate 
(Castilla et al., 2005, Castilla et al., 2006). recPrPres amyloids generated by RT-QuIC, 
were diluted 1/10 in substrate derived from transgenic animals that express 
physiological levels of the human PrPC.  It was decided to match seed and substrate 
the codon 129 genotype to maximise the chances of amplification. Hence, amyloid 
generated by RT-QuIC from recPrP carrying methionine at the codon 129 was 
propagated using transgenic brain homogenate homozygous for methionine at codon 
129. Similar considerations were made for samples possessing valine at the same 
codon. After five consecutive rounds of PMCA, samples seeded with RT-QuIC 
amyloid products, with methionine at the position 129, produced PrPres in all seeded 
amplified reactions, in addition to one of the unseeded reactions prepared in presence 
of heparin. Furthermore, the samples seeded with a RT-QuIC product (which showed 
ThT fluorescence levels below the cut-off) did not exhibit PrPres formation), in 
addition to the unseeded reactions prepared in absence of heparin, which also failed 
to propagate PrPres. No amplification was detected for the samples incubated with 
RT-QuIC amyloid products carrying valine at the codon 129.  
The results appear to show that the PMCA reactions seeded with recPrP 129 M 




seeded with recPrP 129V. This contrasts with the higher levels of spontaneous 
amyloid formation shown by recPrP 129 V compared with recPrP 129 M, by RT-
QuIC. The absence of amplification of recPrP 129 V seeded PMCA reactions may be 
due to several factors, including inhibition or incompatibility between seed and 
substrate. However, this is unlikely, because the volume of “seed” were apparently 
the same over the reactions incubated with recPrP M or V. One possible 
interpretation is that heparin can act as a specific cofactor for spontaneous prion 
formation in PMCA, being specific for recPrP codon 129 M. This could be the 
reason why one unseeded samples (prepared in presence of heparin) formed PrPres 
after five rounds of PMCA. Several lines of evidences have shown that cofactors can 
act specifically on the amplification of one particular strain. RNA for example has 
been described to be critical cofactor for hamster prion formation in vitro, whereas 
heparin has a profound effect on the amplification of vCJD, but limited on the 
amplification of sCJD (Yokoyama et al., 2011). Given that the amplification and the 
spontaneous formations of prions have the potential selection of cofactors according 
to the structure of the prion protein, is not so unreasonable to think that the human 
prion protein, and its different polymorphic variations, has the ability to behave 













6.1 Introduction  
Many neurodegenerative diseases share common features and molecular patterns. 
Diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s 
disease (HD), amyotrophic lateral sclerosis (ALS) and prion diseases share features 
including specific protein aggregation and inclusion body formation in the brain. 
Although the proteins characteristic of the above mentioned diseases lack significant 
primary sequence homology, they share similarities in their ability to undergo 
conformational changes and form fibrillar aggregates, alongside with comparable 
pathways of aggregation (Oliveira et al., 2013, Trzesniewska et al., 2004, Zanuy et 
al., 2004). One particular example of a neurodegenerative disease associated with 
protein aggregation is CJD, a lethal and infectious disease associated with the 
misfolding and accumulation of abnormal prion protein in brain regions (Head and 
Ironside, 2012b). The underlying pathogenesis is thought to be by the conformational 
change of a normal brain protein that changes its native conformation to a misfolded 
isoform. This misfolding process can result in the malfunction of the normal protein, 
toxicity, cell death and inflammation, all of which are also common aspects of AD, 
PD and motor neurone disease (Prusiner, 2013).  
The heat shock response is a set of conserved reactions of cells and organisms to 
stress. It was one of the first examples of inducible gene expression amenable to 
study and has allowed the identification of a series of protein families with 
constitutive and stress-regulated functions. The response to stress is represented at 
the molecular level by the induced expression of heat shock proteins (HSPs), of 
which many are chaperones. The function of molecular chaperones is to mediate the 




during stress stimulus (Lindquist and Kelly, 2011, Morimoto, 2011). The members of 
the small heat shock protein/ α-crystallin gene family (e.g., HSP27, αA-crystallin and 
αB-crystallin) are of particular interest because of their evolution and versatile 
functions (Wistow, 2012) . α-crystallin is a protein composed of two subunits “A” 
and “B”, and is a major soluble protein (up to 40%) of the vertebrate eye lens 
(Horwitz, 2003), although it can also be found at intermediate levels in various 
tissues and cell types (e.g., in oligodendrocytes in the brain). α-crystallin protein 
expression is upregulated in neurological disease states and physiological stress 
models (Head et al., 1994, Iwaki et al., 1993, Kato et al., 1993). At present it is 
unclear whether α-crystallin accumulation is part of a particular (perhaps adaptive) 
response to misfolded proteins, or whether this feature is part of a more generalised 
response to the neurodegenerative process (i.e., neuronal dysfunction and gliosis) or 
stress.  
In order to test whether the chaperone activity of α-crystallin affect the conversion 
and propagation of a neurological disease-specific protein, two well characterised 
cell-free conversion models were used to evaluate the in vitro propagation of vCJD 
and the spontaneous formation of recombinant human β-rich-sheet aggregates. 
Although both conversion systems appear similar, it has been suggested that protein 
misfolding cyclic amplification (PMCA) and real-time quaking induced conversion 
(RT-QuIC) may differ in their relationship to prion protein conversion in situ (Jones 
et al., 2011, Peden et al., 2012). PMCA generally uses brain homogenate as a source 
of PrPC and ultrasound to fragment the PrPSc aggregates. In contrast, RT-QuIC 
utilizes recombinant PrP derived from bacterially expressed and shear forces. The 




PMCA reaction, and (ii) evaluate if there is any effect on the formation of 





6.2 Material and methods  
6.2.1 vCJD brain tissue  
Human brain tissues (frontal cortex) were sampled from a frozen half brain collected 
at autopsy with the appropriate consent for tissue retention and research use. 
Selection criteria and ethical approval are described in General Material and 
Methods, section 2.1.2.1. The vCJD specimen was from a patient (PRNP codon 129 
MM) with definite variant CJD as defined by established criteria (General Material 
and Methods, section 2.1.2.1) 
 
6.2.2 Transgenic mouse brain tissue 
The entire brain from inbred humanized transgenic mouse lines expressing human 
PrPC of the PRNP codon 129 methionine (HuMM) was used for substrate preparation 
and PMCA reactions (Bishop et al., 2006).  
 
6.2.3 PMCA procedure  
6.2.3.1 Preparation of brain PMCA substrates 
Human brain and transgenic mouse brain PMCA substrates were prepared exactly as 






6.2.3.2 Preparation of prion disease brain PMCA seeds 
Homogenates (10% w/v) vCJD brain was prepared exactly as described in General 
Material and Methods (Chapter 2) 
 
6.2.3.3 PMCA procedure 
PMCA reactions were prepared exactly as described in General Material and 
Methods (Chapter 2) 
 
6.2.4 Protease digestion and Western blot analysis  
6.2.4.1 Western blot analysis 
Western blotting experiments were prepared exactly as described in General Material 
and Methods (Chapter 2).  
 
6.2.4.2 Western blot image analysis 
Western blot image analyses were performed using, Image Lab software version 








6.2.5 RT-QuIC procedure 
6.2.5.1 Expression and purification of recombinant PrP 
Expression and purification of recombinant PrP was exactly as described in Material 
and Methods Chapter 5, section 5.2.1.1. 
 
6.2.5.2 RT-QuIC procedure 
RT-QuIC procedure was performed as exactly as described in Material and Methods 
Chapter 5, section 5.2.1.2.  
 
6.2.5.3 RT-QuIC Fluorescence readings 
Fluorescence readings measurements were collected by BMG Omega Data Analysis 
software and further exported into Microsoft Excel 2010.  
 
6.2.5.4 Data analysis 
All statistical analysis, graphs and further analysis were completed using GraphPad 






6.3.1 Effect of α-crystallin on PMCA seeded with variant CJD brain 
PMCA was conducted using humanized transgenic mouse brain homogenate (codon 
129 MM) as substrate, and variant CJD brain homogenate as the PrPSc (seeds). The 
PMCA reactions resulted in a robust amplification detected by Western blots in 
which PrPres appears in sonicated lanes (marked S) compared to frozen lanes (marked 
F) (Figure 6.1A, B, C and D). In order to evaluate the effect of α-crystallin on 
PMCA, amplification reactions were seeded with a relatively low dilution of PrPSc 
(1/1000) and different concentration of α-crystallin were added: 10µg/ml, 1µg/ml, 
0.1µg/ml and 0.01µg/ml (Figure 6.1A). Amplification products derived from the 
amplification of vCJD (detected after proteinase K digestion and Western blots) 
suggested a partial inhibitory effect of α-crystallin at 10µg/ml (Figure 6.1A, lane 2), 
but an enhancing effect at the lower concentrations, 0.1µg/ml and 0.01µg/ml (Figure 
6.1A, lanes 4, 6 and 8), compared to the control reaction (without α-crystallin) 
(Figure 6.1A, lane 10). To further test whether this enhancing effect was 
reproducible, a second experiment was performed using lower concentration of 
variant CJD brain homogenate (1/100000), but maintaining the α-crystallin 
concentration range (Figure 6.1B). At this high dilution factor, PrPres was 
undetectable after PMCA (Figure 6.1B, lane 10). The addition of α-crystallin resulted 
in detectable PrPres after PMCA at the concentrations 1, 0.1, and 0.001 (Figure 6.1B, 
lanes 4, 6 and 8), suggesting that the addition of α-crystallin increases the limit of 
detection (sensitivity) of vCJD brain PrPres greater than 10 fold, with an optimal 
enhancing effects at a concentration of around 0.1µg/ml (Figure 6.1B, lane 6). In 




homogenate, an alternative substrate, non-CJD human brain homogenate, was used 
to perform the PMCA assay. The human post mortem brain homogenate was able to 
support vCJD brain homogenate PrPSc amplification, but is consistently less potent 
than the transgenic mouse brain substrate. Consequently, lower vCJD brain 
homogenate seed dilutions (1/1000 and 1/5000) were used. Similar enhancing effects 
were observed, but higher concentrations of compound were required (10µg/ml, 
100µg/ml and 1000µg/ml) (Figure 6.1C and D). The inclusion of α-crystallin in the 
PMCA reaction did not appear to modify the typical mobility and glycoform ratio of 











Figure 6.1 Effect of α-crystallin on PMCA seeded with variant CJD brain. 
Bovine lens α-crystallin was added to PMCA reactions at the concentrations shown 
using PRNP humanised transgenic mouse brain (PRNP 129 MM) as substrate (A and 
B) or using non-CJD human brain homogenate (PRNP 129 MM) as substrate (C and 
D). The seed was variant CJD (vCJD) brain homogenate added at 1/1000 (A) and 
1/100000 (B) in the reactions using humanised transgenic mouse brain, and added at 
1/1000 (C) and 1/5000 (D) in the non-CJD human brain homogenate. The samples 
were subjected to a single round of PMCA. Control PMCA reactions (C and D) were 
blotted from the same gel and given equivalent exposures; however they were not 
consecutive lanes. All samples were digested with proteinase K digestion and PrPres 
detected by Western blotting.	   F: Frozen samples; S: Sonicated samples; M: 





6.3.2 Effect of α-crystallin on unseeded RT-QuiC reactions 
In Chapter 5, RT-QuIC reactions using recombinant human prion protein were 
shown to display spontaneous amyloid formation as monitored by thioflavin T 
fluorescence. Therefore unseeded RT-QuIC reactions were utilized to evaluate the 
effect of α-crystallin on the spontaneous recPrP amyloid formation. The unseeded 
RT-QuIC reactions were performed using the full length human recombinant PrP, 
with either methionine (M) or valine (V) at the position of codon 129. A total of 
twelve replicates were used for each genotype, and the assay was run for 100 hours. 
Under these experimental conditions spontaneous amyloid formation was observed 
in both 129 M and 129 V, with a greater number of events occurring in the unseeded 
129 V genotype (11/12) versus 2/12 in 129 M (Figure 6.2). Considering the results 
presented in the previous chapter, and the results presented here, the general 
observation is that spontaneous amyloid formation occurs more frequently in 
unseeded 129 V than 129 M recPrP RT-QuIC reactions. To determine whether 
unseeded PrP amyloid formation was affected by the presence of α-crystallin in the 
reaction, unseeded RT-QuIC reactions were performed in presence or absence of α-
crystallin. The addition of α-crystallin at 10µg/ml completely suppressed 
spontaneous PrP amyloid formation in both unseeded 129-M and 129-V recombinant 






Figure 6.2 Effect of α-crystallin on unseeded RT-QuIC reactions. Twelve 
unseeded replicate reactions using full length recombinant human prion protein with 
either methionine (PrP 129M) or valine (PrP 129V) at codon 129 were run for 100 
hours by RT-QuiC. Amyloid formation was monitored by thioflavin T fluorescence. 
Fluorescence traces for individual PrP 129M and PrP 129V reactions are shown in 
red and blue respectively. Bovine lens α-crystallin was added at 10µg/ml to 12 
replicates for each genotype. The (“Y”) axis represents the ThT fluorescence 
(relative fluorescence units, RFU). The (“X”) axis indicates α-crystallin 





6.4 Discussion  
Although the two methods tested here are superficially similar, PMCA and RT-QuIC 
differ in a number if relevant aspects, including their response to seeding with brain 
homogenates from different forms of CJD (Atarashi et al., 2011b, Jones et al., 2007, 
Jones et al., 2008, McGuire et al., 2012, Peden et al., 2012). On one hand, RT-QuIC 
provides a sensitive and rapid method for the detection of seeding activity in sporadic 
CJD brain homogenates independent of the disease subtype and substrate genotype, 
but performs very poorly with variant CJD (Peden et al., 2012). On the other hand, 
PMCA displays a strong amplification of PrPSc from vCJD brain homogenates 
(Chapter 3 and 6). These distinctive features placed constraints on the design of the 
experiments presented here, in which the effects of α-crystallin on PMCA reactions 
seeded with variant CJD brain homogenate, and the spontaneous amyloid formation 
in unseeded reactions by RT-QuIC was evaluated.  
As examples of molecular chaperones, members of the α-crystallin / small heat shock 
protein family are known assist in protein folding and maintenance of the proteome, 
it is therefore not surprising that they would have an effect in cell-free conversion 
systems such as PMCA and RT-QuIC. The propensity to produce dysfunctional 
amyloidogenic conformations can be considered as an intrinsic weakness of protein 
structure. However, the exact molecular mechanism involved in this process is 
unclear.  
The data presented in this chapter seems to suggest that a molecular chaperone, α-
crystallin, may be a useful additive to increase sensitivity of detection of vCJD PrPSc 




spontaneous amyloid formation by RT-QuIC. Given that a single concentration of α-
crystallin was considered to perform the RT-QuIC experiments, higher and lower 
concentrations than 10µg/ml of the molecular chaperone should be used to assess the 
inhibitory in vitro effect on unseeded RT-QuIC reactions. The inhibitory effect on 
spontaneous PrP amyloid formation in RT-QuIC is consistent with the reports that 
αB-crystallin inhibits both α-synuclein and Aβ fibril growth in solution (Shammas et 
al., 2011, Waudby et al., 2010). 
In principle there are three different mechanisms that could explain the promotion of 
vCJD amplification by in PMCA by a molecular chaperone, (i) α-crystallin might 
preserve PrPC availability and its ability to be converted in the misfolded isoform, (ii) 
α-crystallin might interact with PrPSc to enhance the in vitro conversion, or (iii) α-
crystallin may interact with a third factor to influence, directly or indirectly, the PrP 
in vitro conversion.  
In the context of prion disorders, a basic requirement to link α-crystallin chaperone 
function to prion pathology in situ is that both molecules co-occur in the same 
cellular compartment. It has been previously reported that αB-crystallin and HPS27 
can accumulate in astrocytes and neurons in prion diseases (including CJD), 
however, within the cell αB-crystallin and PrP show a disjunct distribution. αB-
crystallin and HPS27 are cytoplasmatic proteins, which can translocate to the 
nucleus. Whereas PrP is a GPI anchored protein, secreted through the ER and Golgi 
apparatus, located in lipid raft membrane microdomains and usually excluded from 
the cytoplasm (Aguzzi and Calella, 2009, Horwitz, 2003). Nevertheless, 
cytoplasmatic localization of PrP has been observed in different species and cell 




Hegde, 2009). Under this scenario interaction between αB-crystallin and PrPSc is 
possible, however, to analyse whether this interaction is hypothetical or not, further 
experimental investigations are needed. Evaluating for instance a larger number of 
concentrations of α-crystallin in RT-QuIC and, the effect of seed and chaperone 
specificity by using sCJD seeds in both in vitro conversion systems will offer 
insights into the molecular mechanism involved in prion conversion, which in turn 
could be used as a practical outcome to improve the sensitivity and specificity of 













A key molecular event in the transmissible spongiform encephalopathies (TSEs) or 
prion diseases is the conformational change of the cellular prion protein PrPC into the 
misfolded and pathogenic isoform, PrPSc. This simple but still cryptic phenomenon 
triggers a series of concatenated events associated with protein aggregation, neuronal 
loss, toxicity, generation of infectivity and death.  
Over the course of this thesis, I have addressed several aspects linked with human 
prion replication, in particular those associated with the genetic compatibility, 
molecular susceptibility, spontaneous formation, and the enhancing or inhibitory 
effect of other molecules on prion protein (PrP) conversion. The topics were 
investigated in order to obtain a better understanding of the molecular mechanisms 
that form the basis of prion replication. To approach these questions, PrP conversion 
assays (protein misfolding cyclic amplification and real time quaking-induced 
conversion) were used to model in vitro the replication and the spontaneous 
conversion of the normal prion protein into the disease associated isoform.  
Human prion diseases are classified according to their aetiology into sporadic, 
inherited and acquired forms, which show clinical, genetic and neuropathological 
variation within each group. To model the human PrP protein-protein interaction 
associated with the genetic compatibility of the PRNP codon 129 genotypes by 
PMCA, normal human prion protein incubated with disease associated seeds (sCJD, 
VPSPr, FFI, GSS, GSS with 8kDa PrPres fragment and vCJD PrPSc) were used to 
seed in vitro conversions in order to analyse the molecular compatibility of the PrPC / 




7.2 Homologous (human:human) amplification of PrPSc from different human 
prion diseases (Chapter 3)  
The results obtained in this chapter confirmed the competence of human prion 
protein to act as a substrate for the amplification of vCJD and sCJD PrPSc seeds in a 
cell-free conversion system. They showed also that among the six sCJD subtypes 
analysed (MM/MV1, MM2 thalamic, MM2 cortical, MV2, VV1 and VV2), only 
three were able to convert the human prion protein after a single round of PMCA 
(MM1/MV1, MV2 and VV2). These observations suggest that the PrPSc types, found 
in the most prevalent sCJD subtypes, have a greater ability to convert PrPC in vitro, 
whereas the subtypes with a lower prevalence have poorer amplification potential. 
Differences in the ability to convert the normal prion protein in vitro have been 
reported previously in synthetic and natural prion strains by PMCA (Makarava et al., 
2013, Yokoyama et al., 2011). The explanation for this is not clear, however the 
presence of several PrPSc structural conformations  - or intermediate PrPSc 
conformers - in sCJD subtypes (MM2 thalamic, MM2 cortical, and VV1) might be 
considered as one of the reasons (Safar, 2012). Perhaps PrPSc samples derived from 
MM2 thalamic, MM2 cortical and VV1 cases require a step of molecular maturation 
or adaption before converting in an efficient manner, however, this hypothesis 
remains to be tested in future studies. Another possibility relates to the molecular 
environment in which the PrP conversion occurs. Prion conversion in mammals has 
been proposed to take place at the cell surface or at intracellular loci (endocytic 
vesicles), suggesting that the PrPC / PrPSc interaction may occur in different micro-
environments. Considering that the identities of the cofactors involved in the 




is an appropriate molecular environment that is necessary for in vitro PrPC 
misfolding. If so, the investigation of different cofactors such as lipids, RNA, 
polymers, or molecules with biological activity are necessary to understand the 
relatively poor in vitro conversion of the human prion subtypes. 
 
PrPSc from samples of brain from sCJD MV1 and MV2 cases was able to amplify in 
vitro. Furthermore, the efficiency of amplification of both subtypes was dependant 
on the codon 129 genotype of the substrate. In PMCA, MV1 PrPSc seeds amplified 
most efficiently in MM substrates, whereas MV2 seeds displayed a preference for 
VV substrate. These observations are similar to those reported by Jones and 
colleagues. However, the results obtained here show that the ability of the PrPSc seed 
to convert a particular allelic substrate exhibits variation between case samples. 
Several questions arise from these observations. For example: (i) Considering that 
there may be differential expression of the two PrP alleles in heterozygous 
individuals, are the allelic contributions of both PRNP codon 129 genotypes the same 
in the formation of PrPSc? (ii) Also, considering that an optimization process of the in 
vitro prion conversion is needed to amplify all subtypes that show a lack of 
amplification - are these modifications informative about the conversion of PrPSc in 
vivo? These are questions that should be addressed in future research. 
 
To evaluate in vitro conversion properties of non-standard PrPSc types, such as those 
found in GSS, FFI and VPSPr cases, PMCA experiments were performed. Low 
amplification was observed in the samples seeded with GSS brain homogenate. 




homogenates. Both GSS and FFI are associated with mutations in the prion protein 
gene. GSS is linked to a substitution of proline for leucine at codon 102, whereas FFI 
is linked to a substitution of aspartic acid for asparagine at codon 178, and in these 
genetic forms both mutations are in cis with methionine at polymorphic 129. 
Polymorphisms and specific mutations in PRNP are major determinants of 
phenotype variability in human prion diseases. The same PRNP mutation (e.g. 
D178N) coupled with methionine or valine at the position 129 can drive the prion 
pathology to two different conditions (FFI, if physically coupled to 129 MM and 
gCJD if physically coupled to 129 VV). Chen and colleagues evaluated the allelic 
contribution to PrPSc in the brain of FFI cases. They observed that the majority of 
PrPres produced in FFI cases derived from the mutated allele, with only a small 
contribution from the wild-type allelic product (Chen et al., 1997). In GSS cases, the 
contribution of wild-type PrPSc has been detected using a monoclonal antibody that 
recognizes wild-type PrP, but not PrP with the mutation (Wadsworth et al., 2006). 
Nearly all cases of genetic prion disease, such GSS and FFI, are heterozygous for the 
gene associated with the pathogenic mutation, and are therefore likely to express 
both the mutated and the wild-type form of the prion protein. The contributions of 
the different allelic forms of PrP into the prion conversion are not clear. However, as 
presented in this thesis, the participation of the wild-type PrPC appears to be 
important factor in forming PrPres. Whether the formation of FFI PrPres derived from 
the amplification of PrPSc with or without the D178N mutation is unclear, and 





It is noteworthy that - for the first time - VPSPr samples derived from two different 
brain regions can seed the conversion of PrPC to PrPSc in PMCA. Both frontal cortex 
and cerebellum amplified PrPSc in vitro, albeit with differences amplification 
efficiencies, and there was a notable increase in the formation of diglycosylated 
PrPres. Interestingly, no amplification was observed for the 8 kDa fragment 
characteristic of VPSPr cases, similar to the reaction seeded with GSS with the 8 kDa 
fragment. Whether the conversion of the different PrPSc conformations has 
distinctive conversion properties, kinetics, or competence to propagate in vivo or in 
vitro is unclear and remains to be investigated. What is clear is that the heterogeneity 
of prion conformations derived from the mutations or the polymorphisms in the prion 
protein gene or the spontaneous conversion of the PrPC is unpredictable and difficult 
to estimate. Molecular adaptation, selection and evolution of prions, could at least 
partially explain the in vitro different amplification efficiencies, and seed / substrate 





 Seed source (PrPSc) PMCA substrate (PrPC codon 129) 
 MM MV VV 
Idiopathic    
sCJD    
MM1 PP P P 
MV1 P P P 
VV1 nt nt O 
VV2 PP P PPP 
MV2 P P PP 
MM2 thalamic O nt nt 
MM2 cortical O nt nt 
    
VPSPr nt nt P 
Genetic    
GSS O nt nt 
GSS with 8kDa 
fragment  
O nt nt 
FFI P nt  nt 
Acquired    
vCJD PPP PP P 
Table 7.1 Summary of PMCA reactions conducted using brain homogenates 
from different human prion diseases as a source of PrPSc and humanised 
transgenic mouse brain homogenate containing PrPC as a substrate.  
(PPP) Correspond to a robust amplification (over 10 fold of conversion) 
(PP)     Correspond to a moderate amplification (between 4 – 10 fold of conversion) 
(P)       Correspond to a low amplification (between 1 – 4 fold of conversion) 
(O)       Corresponds to an absence of conversion 




7.3 Heterologous (animal:human) amplification of PrPSc from different animal 
prion diseases (Chapter 4) 
In order to study the molecular basis of transmission barriers, a panel of animal prion 
diseases were used to assess the susceptibility of conversion of the human prion 
protein by the in vitro conversion assay, PMCA. Amplification of the human PrPC, 
derived from different biological sources (normal human brain, humanized 
transgenic mouse brain or cell cultures), incubated with BSEs (C-type BSE, L-type 
BSE, H-type BSE), classical and atypical scrapie, and chronic wasting disease 
(CWD), showed that the known susceptibility of humans to BSE infection and the 
presumed resistance to scrapie infection are reflected in the susceptibility of human 
PrPC to be converted in PMCA by BSE and scrapie brain homogenates. Furthermore, 
the atypical forms of BSE and scrapie failed to produce human PrP conversion; 
nonetheless, the CWD isolate did convert human PrPC independent of the origin of 
the substrate (human brain, transgenic mouse brain or human cells) and in a codon 
129 dependent manner, showing a more efficient amplification for the methionine 
substrate than the valine. Comparing the CWD amplification efficiency alongside C-
type BSE and vCJD, a robust amplification was seen with vCJD, followed by C-type 
BSE and lastly CWD. These findings suggest that, at least at the molecular level, 
atypical scrapie and atypical BSE present a lower level of risk of zoonotic disease 
than classical BSE. They also suggest that there is no absolute barrier to the 
conversion of human PrPC by CWD prions in a single round of PMCA. 
It has been previously reported that mule deer CWD require an in vitro conditioning 
before to convert humanized transgenic mouse substrate (Barria et al., 2011). 




specimen was sufficient to convert the human prion protein. The reason behind this 
difference is unclear; nonetheless based on the available knowledge of prion 
transmission, adaptation, and stabilization – in vivo and in vitro - it is likely that 
molecular prion protein diversity it can lead to the selection of a prion strain, able to 
propagate efficiently in the same, or in a different species (Castilla et al., 2008a, 
Meyerett et al., 2008). Before outlining a more definitive conclusion, it will be 
important to test a wide variety of CWD isolates from different cervid species, 
polymorphic genotypes and geographical locations. The results presented here, raise 





7.4 Spontaneous PrPSc formation using in vitro conversion systems as a model 
for sporadic CJD (Chapter 5) 
This chapter focussed on the use of the cell-free conversion systems protein 
misfolding cyclic amplification and real time quaking-induced conversion to model 
the spontaneous misfolding of the human prion protein in vitro. A key event 
associated with all amyloidogenic diseases is the molecular conversion of wild-type 
cellular proteins into disease associated isoform. In this respect, the misfolded PrP, or 
PrPSc, is perhaps the prime example. Currently, two possible mechanisms have been 
proposed to generate spontaneous conformational changes of the cellular prion 
protein: somatic mutation of the PRNP gene sequence and spontaneous post-
transcriptional conversion of the cellular PrP conformation. To gain a deeper 
understanding of the second mechanism, a combination of two in vitro conversion 
assays were used to model the spontaneous misfolding of the human prion protein. 
The ultimate goal was evaluating the propensity of the human prion protein to 
spontaneous acquire a β-sheet-rich conformation in vitro. Using RT-QuIC 
spontaneous amyloid formation was detected in unseeded samples incubated with 
bacterially expressed recombinant human protein, with either methionine or valine at 
the codon 129. Human recombinant PrP carrying the amino acid valine at the 
position 129 showed a greater predisposition to spontaneously form amyloid in 
comparison to its allelic counterpart with methionine at the same position. The 
presence of methionine or valine at the codon 129 of the PRNP is the most important 
polymorphism associated with CJD. Considering that 70% of the sCJD cases have 
methionine homozygosity at the codon 129, the finding presented in this thesis that 




seems surprising. However, if we take into consideration one of the four different 
hypothesised PrP folding pathways; this observation is not so unreasonable. Four 
major folding pathways of recombinant human PrP have been proposed (Baskakov et 
al., 2005). In one of them, the transformation of partially unfolded PrP to multimeric 
β-sheet-rich amyloid forms is hypothesised (Figure 7.1A). Aggregation studies using 
recombinant prion protein have shown that allelic variation at the codon 129 of 
PRNP impacts on the formation of misfolded PrP amyloids. The presence of valine 
at the residue 129 accelerates the PrP amyloid formation in spontaneous and seeded 
reactions showing a considerable reduction on the lag phase to produce amyloid as 
compared with the methionine 129 allelomorph under the same condition (Baskakov 
et al., 2005). This observation provides an explanation of the difference in the 
susceptibility to spontaneous generation of PrP aggregates by the two recombinant 
PrP polymorphic substrates in this study.  
It is widely accepted that one of the possible pathways to the conversion of PrPC to 
the β-sheet-rich isoform requires a certain degree of unfolding of PrPC (Baskakov et 
al., 2005). It is also well accepted that the air / water interphase - through a 
denaturation boundary that exists between the hydrophilic water environment and the 
hydrophobic air environment - could induce unfolding of recombinant PrPC 
(Reviewed by Atarashi R, 2011) (Atarashi et al., 2011a). Such ‘boundary-induced-
unfolded’ condition can be increased due the mechanical agitation characteristic of 
RT-QuIC (Atarashi et al., 2011b). The combination of these two phenomena: the 
partial denaturation of the recombinant PrP by the exposition to the air / water 




produce spontaneous PrP amyloids could explain, at least partially the results 















Figure 7.1 Hypothetical model of the folding and the spontaneous conversion of 
PrP in vitro. (A) Four routes of PrP folding from denatured recombinant human PrP 
have been proposed by Baskakov and Tahiri-Alaoui and colleagues (Baskakov et al., 
2005, Tahiri-Alaoui and James, 2005). The first pathways produce α-helix-rich, 
soluble and monomeric PrP from PrP in a denatured state (1). The second pathway 
results in the formation of soluble, β-sheet-rich and PK resistant PrP oligomeric 
forms (2). The third pathways produce β-sheet-rich-PrP amyloids from PrP α-helix-
rich isoform (3) and the last pathway produce PrP β-sheet-rich amyloids, from 
partially unfolded PrP (4). (B) Homogeneous folded recombinant PrPC in a denatured 
free condition. (C) Exposure of folded recombinant PrPC to the air-water interfaces 
and shearing forces can induce unfolding of the recombinant PrPC. (D) Increased 
levels of unfolded (or partially unfolded) recombinant PrP , induced by the condition 
(C), can be redirected to the pathway (1) by molecular actions of the chaperones in 
vitro (α-crystallin). Low levels of unfolded or partial unfolded PrP α-helix-rich, can 
lead to a decrease of β-sheet-rich PrP oligomeric and amyloids formations. Arrows 





Serial rounds of PMCA seeded with spontaneous recombinant PrP amyloid 
aggregates - created by RT-QuIC, either methionine or valine at the codon 129 - 
showed an efficient in vitro amplification when PrP homozygous for methionine at 
codon 129 was used as a substrate. In contrast, there was a lack of conversion in 
similarly seeded PMCA reactions using PrP homozygous for valine at codon 129. 
Multiple factors might explain this finding, including inhibition or incompatibility 
PrP seed / substrate, enhancing or blocking effect of cofactors (such lipids, RNA or 
glycosaminoglycans), among others. It has been proposed that the amplification and 
spontaneous formation of prions in vitro may involve the potential selection of 
specific cofactors according to the architecture of the amplified products 
(Supattapone, 2013, Yokoyama et al., 2011), and that cell-free conversion systems 
can model the spontaneous prion formation. The combined progress in the 
development of new strategies to understand the molecular structure of the prion 
protein along the systematic investigation of the in vitro prion replication are 
essential to establish a mechanistic model to explore the spontaneous formation and 






7.5 A possible role for molecular chaperones in prion protein conversion 
(Chapter 6) 
Protein folding defines the three-dimensional structures of polypeptides and how 
they acquire their functional shape. In prion diseases, the conformational change of 
the normal folded PrPC is thought to trigger a series of events associated with 
accumulation of the abnormal prion protein in the brain, toxicity, and cell death. Heat 
shock proteins (HSP) are synthetized in response to heat shock or other kinds of 
physiological stress. Many HSPs are molecular chaperones that mediate the proper 
folding and translocation of proteins under normal physiological conditions and 
preserve native conformation during physiological stress and disease states. In order 
to test whether the chaperone activity of α-crystallin affects prion protein conversion, 
PMCA and RT-QuIC were used to evaluate the in vitro amplification of vCJD, and 
the spontaneous formation of recombinant human β-rich-sheet aggregates 
respectively.  
The inclusion of α-crystallin in the PMCA reaction enhanced the vCJD amplification 
greater than 10 fold compared to the control reaction, showing an optimal effect at 
concentration around 0.1µg/ml. Conversely, the incorporation α-crystallin on 
unseeded RT-QuIC reactions suppressed the spontaneous PrP amyloid formation in 
reactions carrying the amino acid methionine or valine at the position 129 of the 
prion protein gene. Taken together these data suggest that α-crystallin may have both 
direct and indirect effects on the conversion of the prion protein. Assuming that shear 
forces and air-water interfaces induce unfolding or partially unfolding of PrP in RT-
QuIC (Figure 7.1C), one possible explanation is that α-crystallin interacts with 




7.1D). On the other hand, the PrPC able to be converted into the misfolded isoform in 
PMCA is usually derived from tissue homogenate; therefore the complexity arising 
from the heterogeneity of protein interactions is higher than in RT-QuIC. In this 
situation, α-crystallin can be interacting with PrPC promoting the substrate 
availability (or competence), or interacting with third factors that influence the prion 
conversion. Considering that α-crystallin increases the amplification efficiency in a 
seeded reaction, it is also conceivable that the interaction of the α-crystallin protein 
might be through the interaction with the PrPSc, promoting the seed competence. 
Whether these properties are shared among others members of the α-crystallin / small 
heat shock proteins family, or others molecular chaperons, is an open question. The 
role of the molecular chaperones on the prion conversion in mammalian cells is 
unknown, but using cell-free conversion systems it might possible to gain a deeper 
understanding of the role of these molecules over the folding and misfolding of the 
prion protein (Meehan et al., 2007, Narayan et al., 2012, Shammas et al., 2011). 
Finally, the information obtained in the chapter 6, could be used in the optimization 






7.6 General conclusion 
 In vitro conversion assays can recapitulate and model fundamental aspects of the 
human prion phenomena. Through the research performed in this thesis it has been 
possible to (i) evaluate the combined effects of different PrP type and genotypes, (ii) 
replicate aspects of cross-species transmission potential and provide new information 
about molecular barrier to zoonotic transmission, (iii) model the spontaneous PrPSc 
formation, and (iv) assess the potential impact of chaperones on conversion of the 
human prion protein. In summary, this work provides molecular evidence about the 






Data generated form this thesis was published in two scientific manuscripts listed 
below. Full permission has been granted form the publishing journals. Both are 
included in this Appendix. 
 
Barria, M. A., Balachandran, A., Morita, M., Kitamoto, T., Barron, R., Manson, J., 
Knight, R., Ironside, J. W. & Head, M. W. (2014a). Molecular barriers to zoonotic 
transmission of prions. Emerg Infect Dis, 20, 88-97. 
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